<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth - Dodd, JM - 2013 | Cochrane Library</title> <meta content="Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth - Dodd, JM - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004947.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth - Dodd, JM - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004947.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004947.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth" name="citation_title"/> <meta content="Jodie M Dodd" name="citation_author"/> <meta content="The University of Adelaide, Women's and Children's Hospital" name="citation_author_institution"/> <meta content="jodie.dodd@adelaide.edu.au" name="citation_author_email"/> <meta content="Leanne Jones" name="citation_author"/> <meta content="The University of Liverpool" name="citation_author_institution"/> <meta content="Vicki Flenady" name="citation_author"/> <meta content="Mater Research Institute ‐ The University of Queensland (MRI‐UQ)" name="citation_author_institution"/> <meta content="Robert Cincotta" name="citation_author"/> <meta content="Mater Mothers' Hospital" name="citation_author_institution"/> <meta content="Caroline A Crowther" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD004947.pub3" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/07/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004947.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004947.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004947.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="17‐alpha‐Hydroxyprogesterone [administration &amp; dosage, adverse effects]; Pregnancy, High‐Risk; Premature Birth [*prevention &amp; control]; Prenatal Care [methods]; Progesterone [*administration &amp; dosage, adverse effects]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004947.pub3&amp;doi=10.1002/14651858.CD004947.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ZDBB8PHY";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004947\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004947\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004947\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004947\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","pt","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004947.pub3",title:"Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth",firstPublishedDate:"Jul 31, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pregnancy and Childbirth Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004947.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004947.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004947.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004947.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004947.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004947.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004947.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004947.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004947.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004947.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>9803 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004947.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/full#CD004947-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/full#CD004947-sec-0139"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/full#CD004947-sec-0029"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/full#CD004947-sec-0034"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/full#CD004947-sec-0035"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/full#CD004947-sec-0074"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/full#CD004947-sec-0128"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/appendices#CD004947-sec-0150"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/table_n/CD004947StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/table_n/CD004947StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/information#CD004947-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Jodie M Dodd</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/information#CD004947-cr-0003">Leanne Jones</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/information#CD004947-cr-0004">Vicki Flenady</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/information#CD004947-cr-0005">Robert Cincotta</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004947.pub3/information#CD004947-cr-0006">Caroline A Crowther</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/information/en#CD004947-sec-0167">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 July 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004947.pub3">https://doi.org/10.1002/14651858.CD004947.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004947-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004947-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004947-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004947-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004947-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD004947-abs-0002">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004947-abs-0001" lang="en"> <section id="CD004947-sec-0001"> <h3 class="title" id="CD004947-sec-0001">Background</h3> <p>Preterm birth is a major complication of pregnancy associated with perinatal mortality and morbidity. Progesterone for the prevention of preterm labour has been advocated. </p> </section> <section id="CD004947-sec-0002"> <h3 class="title" id="CD004947-sec-0002">Objectives</h3> <p>To assess the benefits and harms of progesterone for the prevention of preterm birth for women considered to be at increased risk of preterm birth and their infants. </p> </section> <section id="CD004947-sec-0003"> <h3 class="title" id="CD004947-sec-0003">Search methods</h3> <p>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (14 January 2013) and reviewed the reference list of all articles. </p> </section> <section id="CD004947-sec-0004"> <h3 class="title" id="CD004947-sec-0004">Selection criteria</h3> <p>Randomised controlled trials, in which progesterone was given for preventing preterm birth. </p> </section> <section id="CD004947-sec-0005"> <h3 class="title" id="CD004947-sec-0005">Data collection and analysis</h3> <p>Two review authors independently evaluated trials for methodological quality and extracted data. </p> </section> <section id="CD004947-sec-0006"> <h3 class="title" id="CD004947-sec-0006">Main results</h3> <p>Thirty‐six randomised controlled trials (8523 women and 12,515 infants) were included.</p> <p><b>Progesterone versus placebo for women with a past history of spontaneous preterm birth</b> <br/> Progesterone was associated with a statistically significant reduction in the risk of perinatal mortality (six studies; 1453 women; risk ratio (RR) 0.50, 95% confidence interval (CI) 0.33 to 0.75), preterm birth less than 34 weeks (five studies; 602 women; average RR 0.31, 95% CI 0.14 to 0.69), infant birthweight less than 2500 g (four studies; 692 infants; RR 0.58, 95% CI 0.42 to 0.79), use of assisted ventilation (three studies; 633 women; RR 0.40, 95% CI 0.18 to 0.90), necrotising enterocolitis (three studies; 1170 women; RR 0.30, 95% CI 0.10 to 0.89), neonatal death (six studies; 1453 women; RR 0.45, 95% CI 0.27 to 0.76), admission to neonatal intensive care unit (three studies; 389 women; RR 0.24, 95% CI 0.14 to 0.40), preterm birth less than 37 weeks (10 studies; 1750 women; average RR 0.55, 95% CI 0.42 to 0.74) and a statistically significant increase in pregnancy prolongation in weeks (one study; 148 women; mean difference (MD) 4.47, 95% CI 2.15 to 6.79). No differential effects in terms of route of administration, time of commencing therapy and dose of progesterone were observed for the majority of outcomes examined. </p> <p><b>Progesterone versus placebo for women with a short cervix identified on ultrasound</b> <br/> Progesterone was associated with a statistically significant reduction in the risk of preterm birth less than 34 weeks (two studies; 438 women; RR 0.64, 95% CI 0.45 to 0.90), preterm birth at less than 28 weeks' gestation (two studies; 1115 women; RR 0.59, 95% CI 0.37 to 0.93) and increased risk of urticaria in women when compared with placebo (one study; 654 women; RR 5.03, 95% CI 1.11 to 22.78). It was not possible to assess the effect of route of progesterone administration, gestational age at commencing therapy, or total cumulative dose of medication. </p> <p><b>Progesterone versus placebo for women with a multiple pregnancy</b><br/> Progesterone was associated with no statistically significant differences for the reported outcomes. </p> <p><b>Progesterone versus no treatment/placebo for women following presentation with threatened preterm labour</b><br/> Progesterone, was associated with a statistically significant reduction in the risk of infant birthweight less than 2500 g (one study; 70 infants; RR 0.52, 95% CI 0.28 to 0.98). </p> <p><b>Progesterone versus placebo for women with 'other' risk factors for preterm birth</b><br/> Progesterone, was associated with a statistically significant reduction in the risk of infant birthweight less than 2500 g (three studies; 482 infants; RR 0.48, 95% CI 0.25 to 0.91). </p> </section> <section id="CD004947-sec-0007"> <h3 class="title" id="CD004947-sec-0007">Authors' conclusions</h3> <p>The use of progesterone is associated with benefits in infant health following administration in women considered to be at increased risk of preterm birth due either to a prior preterm birth or where a short cervix has been identified on ultrasound examination. However, there is limited information available relating to longer‐term infant and childhood outcomes, the assessment of which remains a priority. </p> <p>Further trials are required to assess the optimal timing, mode of administration and dose of administration of progesterone therapy when given to women considered to be at increased risk of early birth. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004947-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004947-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004947-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004947-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004947-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD004947-abs-0006">Português</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004947-abs-0005" lang="en"> <h3>Prenatal administration of progesterone to prevent preterm birth in women considered to be at risk of having their baby early </h3> <p>Babies who are born before 37 weeks, and particularly those born before 34 weeks, are at greater risk of having problems at birth and complications in infancy. Infants who are born preterm are at greater risk of dying in their first year of life, and of those infants who survive, there is an increased risk of repeated admission to hospital and adverse outcomes including cerebral palsy and long‐term disability. Progesterone is a hormone that reduces contractions of the uterus and has an important role in maintaining pregnancy and is suggested for the prevention of preterm labour. Maternal side‐effects from progesterone therapy include headache, breast tenderness, nausea, cough and local irritation if administered intramuscularly. At present, there is little information available regarding the optimal dose of progesterone, mode of administration, gestation to commence therapy, or duration of therapy. </p> <p>The review of 36 randomised controlled trials, involving a total of 8523 women considered to be at increased risk of preterm birth, and 12,515 infants, found that where progesterone was given (by injection into the muscle in some studies and as a pessary into the vagina in others), it had beneficial effects, including reducing the risk of the baby dying after birth, suffering complications such as requiring assisted ventilation, necrotising enterocolitis or requiring admission to neonatal intensive care, prolonging the pregnancy, and reducing the chance of neonatal intensive care admission. </p> <p>Information related to longer‐term infant and childhood outcomes was limited. Overall, the trials included in this review were considered to be of good to fair quality. Further trials are required to assess the optimal timing, mode of administration and dose of administration of progesterone therapy.   </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004947-sec-0139" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004947-sec-0139"></div> <h3 class="title" id="CD004947-sec-0140">Implications for practice</h3> <section id="CD004947-sec-0140"> <section id="CD004947-sec-0141"> <h5 class="title">Summary of the available information</h5> <section id="CD004947-sec-0142"> <h6 class="title">Progesterone for women with a past history of spontaneous preterm birth</h6> <p>The use of progesterone in this group of women is associated with a reduction in the risk of perinatal death, preterm birth before 34 weeks' and 37 weeks' gestation, infant birthweight less than 2500 g, use of assisted ventilation, necrotising enterocolitis, neonatal death, admission to neonatal intensive care unit, and prolongation of pregnancy. There is limited information about longer‐term childhood health. In addition, further information is required as to the optimal route of administration of progesterone, the optimal dose to be administered, and the best time to commence therapy. </p> </section> <section id="CD004947-sec-0143"> <h6 class="title">Progesterone for women with a short cervix identified on ultrasound</h6> <p>The use of progesterone in this group of women is associated with a reduction in the risk of preterm birth less than 34 and 28 weeks' gestation, and a significant increase in the risk urticaria in women receiving progesterone. Further information is required about other maternal, infant and childhood health outcomes. Of particular note, there are no comparative data reported on longer‐term childhood health from trials conducted to date. In addition, further information is required as to the optimal route of administration of progesterone, the optimal dose to be administered, and the best time to commence therapy. </p> </section> <section id="CD004947-sec-0144"> <h6 class="title">Progesterone for women with a multiple pregnancy</h6> <p>The use of progesterone in this group of women is not associated with any statistically significant differences in perinatal death, preterm birth and other maternal, infant, and childhood health outcomes. </p> </section> <section id="CD004947-sec-0145"> <h6 class="title">Progesterone for women following presentation with threatened preterm labour</h6> <p>The use of progesterone in this group of women was associated with a statistically significant reduction in the risk of infant birthweight less than 2500 g. However, for all other outcomes, the role of progesterone for women presenting following symptoms or signs of threatened preterm labour is uncertain. </p> </section> <section id="CD004947-sec-0146"> <h6 class="title">Progesterone for women with 'other' risk factors for preterm birth</h6> <p>The use of progesterone in this group of women was associated with a statistically significant reduction in the risk of infant birthweight less than 2500 g. However, for all other outcomes, the role of progesterone in women considered to be at risk of preterm birth for 'other reasons' is uncertain. </p> </section> </section> </section> <h3 class="title" id="CD004947-sec-0147">Implications for research</h3> <section id="CD004947-sec-0147"> <p>Further well‐designed randomised controlled trials are required to assess the optimal timing, mode of administration and dose of administration of progesterone when given to women considered to be at increased risk of early birth, by virtue of previous history of spontaneous preterm birth, short cervix identified by transvaginal ultrasound, following arrest of symptoms or signs of threatened preterm labour, or on the basis of 'other' risk factors. Assessment of longer‐term infant and childhood outcomes remains a priority. </p> <p>There are several randomised trials that are currently addressing the use of progesterone for preterm birth which will contribute data in the future ‐ <i>see</i><a href="./references#CD004947-sec-0176" title="">Characteristics of ongoing studies</a> for details. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004947-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004947-sec-0029"></div> <section id="CD004947-sec-0030"> <h3 class="title" id="CD004947-sec-0030">Description of the condition</h3> <p>Preterm birth before 37 weeks' gestation is a common problem in obstetric care, with estimates ranging from 5% in several European countries to 18% in some African countries (<a href="./references#CD004947-bbs2-0071" title="BlencoweH , CousensS , OestergaardMZ , ChouD , MollerAB , NarwalR , et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet2012;379(9832):2162‐72. [PUBMED: 22682464] ">Blencowe 2012</a>). In Australia, approximately 8% of all infants were born preterm in 2000, with 2.7% of these births occurring prior to 34 weeks' gestation (<a href="./references#CD004947-bbs2-0066" title="Australian Institute of Health and Welfare. Australia's Mothers and Babies 2000. National Perinatal Statistics Unit, 2003. ">AIHW 2003</a>). Figures are similar for the United States, with a preterm birth rate of 12.0% (<a href="./references#CD004947-bbs2-0071" title="BlencoweH , CousensS , OestergaardMZ , ChouD , MollerAB , NarwalR , et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet2012;379(9832):2162‐72. [PUBMED: 22682464] ">Blencowe 2012</a>). While less than 2% of these infants were born prior to 32 weeks' gestation (<a href="./references#CD004947-bbs2-0095" title="MartinJA , HamiltonBE , SuttonPD , VenturaSJ , MenackerF , MunsonML . Births: final data for 2002. National Vital Statistics Report2003;52(10):1‐113. ">Martin 2003</a>), they are at increased risk of complications in infancy, and contribute in excess of 50% of the overall perinatal mortality (<a href="./references#CD004947-bbs2-0066" title="Australian Institute of Health and Welfare. Australia's Mothers and Babies 2000. National Perinatal Statistics Unit, 2003. ">AIHW 2003</a>). Infants who are born preterm are at greater risk of dying in their first year of life (<a href="./references#CD004947-bbs2-0095" title="MartinJA , HamiltonBE , SuttonPD , VenturaSJ , MenackerF , MunsonML . Births: final data for 2002. National Vital Statistics Report2003;52(10):1‐113. ">Martin 2003</a>), and of those infants who survive, there is an increased risk of repeated admission to hospital (<a href="./references#CD004947-bbs2-0077" title="ElderDE , HagaR , EvansSF , BenningerHR , FrenchNP . Hospital admissions in the first year of life in very preterm infants. Journal of Paediatrics and Child Health1999;35(2):145‐50. ">Elder 1999</a>) and adverse outcomes including cerebral palsy and long‐term disability (<a href="./references#CD004947-bbs2-0083" title="HackM . Consideration of the use of health status, functional outcome, and quality‐of‐life to monitor neonatal intensive care practice. Pediatrics1999;103(1 Suppl E):319‐28. ">Hack 1999</a>; <a href="./references#CD004947-bbs2-0112" title="StanleyF . Survival and cerebral palsy in low birthweight infants: implications for perinatal care. Paediatric and Perinatal Epidemiology1992;6(2):298‐310. ">Stanley 1992</a>), creating a significant burden upon the community (<a href="./references#CD004947-bbs2-0093" title="KramerM , DemissieK , YangH , PlattRW , SauveR , ListonR . The contribution of mild and moderate preterm birth to infant mortality. JAMA2000;284:843‐9. ">Kramer 2000</a>). </p> <p>The 'cause' of preterm labour is multifactorial in origin, and it is important to consider the role of any identifiable risk factors in a woman's pregnancy. </p> <p>The most significant and consistently identified risk factor for preterm birth, is a woman's history of previous preterm birth (<a href="./references#CD004947-bbs2-0065" title="AdamsMM , Elam‐EvansLD , WilsonHG , GilbertzDA . Rates and factors associated with recurrence of preterm delivery. JAMA2000;283(12):1591‐6. ">Adams 2000</a>; <a href="./references#CD004947-bbs2-0069" title="BakketeigLS , HoffmanHJ , HarleyEE . The tendency to repeat gestational age and birth weight in successive births. American Journal of Obstetrics and Gynecology1979;135(8):1086‐103. ">Bakketeig 1979</a>; <a href="./references#CD004947-bbs2-0070" title="BerkowitzG , PapiernikE . Epidemiology of preterm birth. Epidemiologic Reviews1993;88:233‐8. ">Berkowitz 1993</a>; <a href="./references#CD004947-bbs2-0073" title="BloomSL , YostNP , McIntireDD , LevenoKJ . Recurrence of preterm birth in singleton and twin pregnancies. Obstetrics &amp; Gynecology2001;98:379‐85. ">Bloom 2001</a>; <a href="./references#CD004947-bbs2-0079" title="GoldenbergRL , RouseDJ . Prevention of premature birth. New England Journal of Medicine1998;339:313‐20. ">Goldenberg 1998</a>; <a href="./references#CD004947-bbs2-0091" title="KaminskiM , GoujardJ , Rumeau‐RouquetteC . Prediction of low birthweight and prematurity by a multiple regression analysis with maternal characteristics known since the beginning of the pregnancy. International Journal of Epidemiology1973;2:195‐204. ">Kaminski 1973</a>; <a href="./references#CD004947-bbs2-0092" title="KistkaZA , PalomarL , LeeKA . Racial disparity in the frequency of recurrence of preterm birth. American Journal of Obstetrics and Gynecology2007;196:131.e1‐131.e6. ">Kistka 2007</a>; <a href="./references#CD004947-bbs2-0100" title="PapiernikE , KaminskiM . Multifactorial study of the risk of prematurity at 32 weeks of gestation: a study of the frequency of 30 predictive characteristics. Journal of Perinatal Medicine1974;2:30‐6. ">Papiernik 1974</a>; <a href="./references#CD004947-bbs2-0102" title="PetriniJ , CallaghanW , KlebanoffM . Estimated effect of 17 alpha hydroxyprogesterone caproate on preterm birth in the United States. Obstetrics &amp; Gynecology2005;105:267‐72. ">Petrini 2005</a>; <a href="./references#CD004947-bbs2-0107" title="RobinsonJN , ReganJA , NorwitzER . The epidemiology of preterm labour. Seminars in Perinatology2001;25:204‐14. ">Robinson 2001</a>). Estimates suggest the rate of recurrent preterm birth in this group of women to be 22.5% (<a href="./references#CD004947-bbs2-0102" title="PetriniJ , CallaghanW , KlebanoffM . Estimated effect of 17 alpha hydroxyprogesterone caproate on preterm birth in the United States. Obstetrics &amp; Gynecology2005;105:267‐72. ">Petrini 2005</a>), a 2.5 times increased risk ratio when compared with women with no previous spontaneous preterm birth (<a href="./references#CD004947-bbs2-0098" title="MercerBM , GoldenbergRL , MoawadAH . The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcomes. American Journal of Obstetrics and Gynecology1999;181(5 Pt 1):1216‐21. ">Mercer 1999</a>). For women with a history of a single preterm birth, the recurrence risk in a subsequent pregnancy is approximately 15%, increasing to 32% where there have been two previous preterm births (<a href="./references#CD004947-bbs2-0074" title="Carr‐HillRA , HallMH . The repetition of spontaneous preterm labour. BJOG:an international journal of obstetrics and gynaecology1985;92(9):921‐8. ">Carr‐Hill 1985</a>). Information derived from population‐based cohort data suggests that for women who give birth between 20 and 31 weeks' gestation in one pregnancy, 29.3% will give birth prior to 37 weeks in a subsequent pregnancy (<a href="./references#CD004947-bbs2-0065" title="AdamsMM , Elam‐EvansLD , WilsonHG , GilbertzDA . Rates and factors associated with recurrence of preterm delivery. JAMA2000;283(12):1591‐6. ">Adams 2000</a>). For approximately 10% of these women, the preterm birth will occur at a similar gestational age (<a href="./references#CD004947-bbs2-0065" title="AdamsMM , Elam‐EvansLD , WilsonHG , GilbertzDA . Rates and factors associated with recurrence of preterm delivery. JAMA2000;283(12):1591‐6. ">Adams 2000</a>; <a href="./references#CD004947-bbs2-0092" title="KistkaZA , PalomarL , LeeKA . Racial disparity in the frequency of recurrence of preterm birth. American Journal of Obstetrics and Gynecology2007;196:131.e1‐131.e6. ">Kistka 2007</a>). In up to 50% of cases of preterm birth, the cause is spontaneous onset of labour or preterm premature rupture of membranes (PPROM) (<a href="./references#CD004947-bbs2-0086" title="HewittBC , NewnhamJP . A review of the obstetric and medical complications leading to the delivery of very low birth weight infants. Medical Journal of Australia1988;149:234‐7. ">Hewitt 1988</a>; <a href="./references#CD004947-bbs2-0096" title="MattisonDR , DamusK , FioreE , PetriniJ , AlterC . Preterm delivery: a public health perspective. Paediatric and Perinatal Epidemiology2001;15(Suppl. 2):7‐16. ">Mattison 2001</a>; <a href="./references#CD004947-bbs2-0097" title="McLaughlinKJ , CrowtherCA , VigneswaranP , HancockE , WillsonK . Who remains undelivered more than seven days after a single course of prenatal corticosteroids and gives birth at less than 34 weeks?. Australian and New Zealand Journal of Obstetrics and Gynaecology2002;42(4):353‐7. ">McLaughlin 2002</a>). </p> <p>Other characteristics in a woman's current pregnancy may place her at increased risk of preterm birth, including women with a short cervix identified by ultrasound assessment, the presence of fetal fibronectin in the vaginal secretions, and presentation with symptoms or signs of threatened preterm labour. </p> <p>The identification of a short cervix (considered to be less than 2.5cm) on ultrasound examination has been associated with an increased likelihood of preterm birth before 34 weeks’ gestation (<a href="./references#CD004947-bbs2-0111" title="SmithV , DevaneD , BegleyCM , ClarkeM , HigginsS . A systematic review and quality assessment of systematic reviews of fetal fibronectin and transvaginal length for predicting preterm birth. European Journal of Obstetrics, Gynecology, and Reproductive Biology2007;133(2):134‐42. ">Smith 2007</a>). Identification of fetal fibronectin present in cervico‐vaginal secretions has also been proposed as a means of identifying women at risk of preterm birth. Overall, the value of fetal fibronectin in women presenting with symptoms of threatened preterm labour, is a negative test, where women are unlikely to proceed to preterm birth before 34 weeks’ gestation or within seven days of testing (<a href="./references#CD004947-bbs2-0111" title="SmithV , DevaneD , BegleyCM , ClarkeM , HigginsS . A systematic review and quality assessment of systematic reviews of fetal fibronectin and transvaginal length for predicting preterm birth. European Journal of Obstetrics, Gynecology, and Reproductive Biology2007;133(2):134‐42. ">Smith 2007</a>). </p> <p>Multiple pregnancy is a strong risk factor for preterm birth though the mechanisms may be different to those operating in women with a singleton pregnancy. Up to 50% of women with a twin pregnancy will give birth prior to 37 weeks' gestation (<a href="./references#CD004947-bbs2-0066" title="Australian Institute of Health and Welfare. Australia's Mothers and Babies 2000. National Perinatal Statistics Unit, 2003. ">AIHW 2003</a>). The preterm birth risk of early birth before 37 weeks for women with a singleton pregnancy is 6.3% compared with 97% for women with a triplet pregnancy (<a href="./references#CD004947-bbs2-0066" title="Australian Institute of Health and Welfare. Australia's Mothers and Babies 2000. National Perinatal Statistics Unit, 2003. ">AIHW 2003</a>). </p> </section> <section id="CD004947-sec-0031"> <h3 class="title" id="CD004947-sec-0031">Description of the intervention</h3> <p>Progesterone may be administered in various forms and by various routes. These different formulations and modes of administration will have different absorption patterns and potentially have differing bio effects. Whilst no teratogenic effects have been described with most progesterones, there is little in the way of long‐term safety data. Maternal side‐effects from progesterone therapy include headache, breast tenderness, nausea, cough and local irritation if administered intramuscularly. At present, there is little information available regarding the optimal dose of progesterone, mode of administration, gestation to commence therapy, or duration of therapy (<a href="./references#CD004947-bbs2-0081" title="GreeneMF . Progesterone and preterm delivery ‐ deja vu all over again. New England Medical Journal2003;348:2453‐5. ">Greene 2003</a>; <a href="./references#CD004947-bbs2-0090" title="IamsJD . Supplemental progesterone to prevent preterm birth. American Journal Obstetrics and Gynecology2003;188(2):303. ">Iams 2003</a>). </p> </section> <section id="CD004947-sec-0032"> <h3 class="title" id="CD004947-sec-0032">How the intervention might work</h3> <p>Progesterone has a role in maintaining pregnancy (<a href="./references#CD004947-bbs2-0084" title="HaluskaGJ , CookMJ , NovyMJ . Inhibition and augmentation of progesterone production during pregnancy: effects on parturition in rhesus monkeys. American Journal of Obstetrics and Gynecology1997;176(3):682‐91. ">Haluska 1997</a>; <a href="./references#CD004947-bbs2-0101" title="PepeGJ , AlbrechtED . Actions of placental and fetal adrenal steroid hormones in primate pregnancy. Endocrine Review1995;16(5):608‐48. ">Pepe 1995</a>; <a href="./references#CD004947-bbs2-0103" title="PeiberD , AllportVC , HillsF , JohnsonM , BennettPR . Interactions between progesterone receptor isoforms in myometrial cells in human labour. Molecular Human Reproduction2001;7(9):875‐9. ">Pieber 2001</a>) and is thought to act by suppressing smooth muscle activity in the uterus (<a href="./references#CD004947-bbs2-0068" title="AstleS , SlaterDM , ThorntonS . The involvement of progesterone in the onset of human labour. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2003;108(2):177‐81. ">Astle 2003</a>; <a href="./references#CD004947-bbs2-0080" title="GrazziniE , GuillonG , MouillacB , ZinggHH . Inhibition of oxytocin receptor function by direct binding of progesterone. Nature1998;392(6675):509‐12. ">Grazzini 1998</a>). In many animal species, there is a reduction in the amount of circulating progesterone before the onset of labour. While these changes have not been shown to occur in women (<a href="./references#CD004947-bbs2-0068" title="AstleS , SlaterDM , ThorntonS . The involvement of progesterone in the onset of human labour. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2003;108(2):177‐81. ">Astle 2003</a>; <a href="./references#CD004947-bbs2-0072" title="BlockBS , LigginsGC , CreasyRK . Preterm delivery is not predicted by serial plasma estradiol or progesterone concentration measurements. American Journal of Obstetrics and Gynecology1984;150(6):716‐22. ">Block 1984</a>; <a href="./references#CD004947-bbs2-0094" title="Lopez‐BernalA . Mechanism of labour ‐ biochemical aspects. BJOG: an international journal of obstetrics and gynaecology2003;110(Suppl 20):39‐45. ">Lopez‐Bernal 2003</a>; <a href="./references#CD004947-bbs2-0103" title="PeiberD , AllportVC , HillsF , JohnsonM , BennettPR . Interactions between progesterone receptor isoforms in myometrial cells in human labour. Molecular Human Reproduction2001;7(9):875‐9. ">Pieber 2001</a>; <a href="./references#CD004947-bbs2-0110" title="SmitDA , EssedGG , deHaanJ . Predictive value of uterine contractility and the serum levels of progesterone and oestrogens with regard to preterm labour. Gynecologic and Obstetric Investigation1984;18(5):252‐63. ">Smit 1984</a>), it has been suggested that there is a 'functional' withdrawal of progesterone related to changes in the expression of progesterone receptors in the uterus (<a href="./references#CD004947-bbs2-0068" title="AstleS , SlaterDM , ThorntonS . The involvement of progesterone in the onset of human labour. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2003;108(2):177‐81. ">Astle 2003</a>; <a href="./references#CD004947-bbs2-0076" title="CondonJC , JeyasuriaP , FaustJM , WilsonJW , MendelsonCR . A decline in the levels of progesterone receptor coactivators in the pregnant uterus at term may antagonize progesterone receptor function and contribute to the initiation of parturition. Proceedings of the National Academy of Sciences of the United States of America2003;100(16):9518‐23. ">Condon 2003</a>; <a href="./references#CD004947-bbs2-0085" title="HaluskaGJ , WellsTR , HirstJJ , BrennerRM , SadowskyDW , NovyMJ . Progesterone receptor localisation and isoforms in myometrium, decidua, and fetal membranes from rhesus macaques: evidence for functional progesterone withdrawal at parturition. Journal of the Society for Gynecological Investigation2002;9(3):125‐36. ">Haluska 2002</a>; <a href="./references#CD004947-bbs2-0103" title="PeiberD , AllportVC , HillsF , JohnsonM , BennettPR . Interactions between progesterone receptor isoforms in myometrial cells in human labour. Molecular Human Reproduction2001;7(9):875‐9. ">Pieber 2001</a>). There have been recent reports in the literature advocating the use of progesterone to reduce the risk of preterm birth (<a href="./references#CD004947-bbs2-0010" title="daFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics &amp; Gynecology2003;188(2):419‐24. daFonsecaEB , BittarRE , CarvalhoMHB , MartinelliS , ZugaibM . Uterine contraction monitoring in pregnant women using vaginal natural progesterone. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):525. ">da Fonseca 2003</a>; <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>), rekindling interest that dates back to the 1960s (<a href="./references#CD004947-bbs2-0047" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgical Obstetrics and Gynecology1964;72:30‐6. ">Le Vine 1964</a>). </p> <p>This review was modified in 2006, from the original protocol published in <i>The Cochrane Library</i> in Issue 4, 2004, in order to clarify the scope of the review. The title and objectives changed, and the description of participants expanded to include the reason the women were considered to be at increased risk of preterm birth. The primary outcome measure of preterm birth less than 32 weeks' gestation has been changed to preterm birth less than 34 weeks' gestation to be consistent with World Health Organization definitions of preterm birth. Secondary outcome measures reflecting childhood developmental assessment have been added, reflecting the need for ongoing evaluation of children participating in randomised trials. </p> </section> <section id="CD004947-sec-0033"> <h3 class="title" id="CD004947-sec-0033">Why it is important to do this review</h3> <p>Preterm birth and its consequences for women and their babies is a significant health problem in pregnancy and childbirth. While the suppression or prevention of preterm labour should lead to improved survival through a lower incidence of premature delivery, there are theoretical reasons why a fetus may not survive without disability. It is possible that an intrauterine mechanism that would trigger preterm labour could also cause neurological injury to the fetus and that progesterone may prevent labour but not fetal injury. The purpose of this review is to assess the benefits and harms of progesterone administration for the prevention of preterm birth for both women and their infants, when considering the risk factors present for preterm birth. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004947-sec-0034" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004947-sec-0034"></div> <p>To assess the benefits and harms of progesterone administration for the prevention of preterm birth in women and their infants. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004947-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004947-sec-0035"></div> <section id="CD004947-sec-0036"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004947-sec-0037"> <h4 class="title">Types of studies</h4> <p>All published and unpublished randomised controlled trials, in which progesterone was administered for the prevention of preterm birth, subdivided by the reason women were considered to be at risk for preterm birth. </p> <p>Trials were excluded if:</p> <p> <ul id="CD004947-list-0001"> <li> <p>they utilised quasi‐randomised methodology; cross‐over design;</p> </li> <li> <p>progesterone was administered for the acute treatment of actual or threatened preterm labour (that is, where progesterone was administered as an acute tocolytic medication); or </p> </li> <li> <p>progesterone was administered in the first trimester only for preventing miscarriage.</p> </li> </ul> </p> </section> <section id="CD004947-sec-0038"> <h4 class="title">Types of participants</h4> <p>Pregnant women considered to be at increased risk of preterm birth. These reasons include: </p> <p> <ul id="CD004947-list-0002"> <li> <p>past history of spontaneous preterm birth (including preterm prelabour rupture of membranes); </p> </li> <li> <p>multiple pregnancy;</p> </li> <li> <p>ultrasound identified short cervical length;</p> </li> <li> <p>fetal fibronectin testing;</p> </li> <li> <p>following acute presentation with symptoms or signs of threatened preterm labour (where a tocolytic medication may have been administered); </p> </li> <li> <p>other reason considered to be at increased risk of preterm birth.</p> </li> </ul> </p> </section> <section id="CD004947-sec-0039"> <h4 class="title">Types of interventions</h4> <p>Administration of progesterone by any route for the prevention of preterm birth.</p> </section> <section id="CD004947-sec-0040"> <h4 class="title">Types of outcome measures</h4> <section id="CD004947-sec-0041"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD004947-list-0003"> <li> <p>Perinatal mortality</p> </li> <li> <p>Preterm birth (less than 34 weeks' gestation)</p> </li> <li> <p>Major neurodevelopmental handicap at childhood follow‐up</p> </li> </ol> </p> </section> <section id="CD004947-sec-0042"> <h5 class="title">Secondary outcomes</h5> <section id="CD004947-sec-0043"> <h6 class="title">Maternal</h6> <p> <ol id="CD004947-list-0004"> <li> <p>Threatened preterm labour (as defined by trial authors)</p> </li> <li> <p>Prelabour spontaneous rupture of membranes</p> </li> <li> <p>Adverse drug reaction</p> </li> <li> <p>Pregnancy prolongation (interval between randomisation and birth)</p> </li> <li> <p>Mode of birth</p> </li> <li> <p>Number of antenatal hospital admissions</p> </li> <li> <p>Satisfaction with the therapy</p> </li> <li> <p>Use of tocolysis</p> </li> <li> <p>Antenatal corticosteroids (not a prespecified outcome)</p> </li> <li> <p>Maternal quality of life (not a prespecified outcome)</p> </li> </ol> </p> </section> <section id="CD004947-sec-0044"> <h6 class="title">Infant</h6> <p> <ol id="CD004947-list-0005"> <li> <p>Birth before 37 completed weeks</p> </li> <li> <p>Birth before 28 completed weeks</p> </li> <li> <p>Birthweight less than the third centile for gestational age</p> </li> <li> <p>Birthweight less than 2500 g</p> </li> <li> <p>Apgar score of less than seven at five minutes</p> </li> <li> <p>Respiratory distress syndrome</p> </li> <li> <p>Use of mechanical ventilation</p> </li> <li> <p>Duration of mechanical ventilation</p> </li> <li> <p>Intraventricular haemorrhage ‐ grades III or IV</p> </li> <li> <p>Periventricular leucomalacia</p> </li> <li> <p>Retinopathy of prematurity</p> </li> <li> <p>Retinopathy of prematurity ‐ grades III or IV</p> </li> <li> <p>Chronic lung disease</p> </li> <li> <p>Necrotising enterocolitis</p> </li> <li> <p>Neonatal sepsis</p> </li> <li> <p>Fetal death</p> </li> <li> <p>Neonatal death</p> </li> <li> <p>Admission to neonatal intensive care unit</p> </li> <li> <p>Neonatal length of hospital stay</p> </li> <li> <p>Teratogenic effects (including virilisation in female infants)</p> </li> <li> <p>Patent ductus arteriosis (not a prespecified outcome)</p> </li> </ol> </p> </section> <section id="CD004947-sec-0045"> <h6 class="title">Child</h6> <p> <ol id="CD004947-list-0006"> <li> <p>Major sensorineural disability (defined as any of legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy, or developmental delay or intellectual impairment (defined as developmental quotient or intelligence quotient less than ‐2 standard deviations below mean)) </p> </li> <li> <p>Developmental delay (however defined by the authors)</p> </li> <li> <p>Intellectual impairment</p> </li> <li> <p>Motor impairment</p> </li> <li> <p>Visual impairment</p> </li> <li> <p>Blindness</p> </li> <li> <p>Deafness</p> </li> <li> <p>Hearing impairment</p> </li> <li> <p>Cerebral palsy</p> </li> <li> <p>Child behaviour</p> </li> <li> <p>Child temperament</p> </li> <li> <p>Learning difficulties</p> </li> <li> <p>Growth assessments at childhood follow‐up (weight, head circumference, length, skin fold thickness) </p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD004947-sec-0046"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004947-sec-0047"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register by contacting the Trials Search Co‐ordinator (14 January 2013). </p> <p>The Cochrane Pregnancy and Childbirth Group’s Trials Register is maintained by the Trials Search Co‐ordinator and contains trials identified from: </p> <p> <ol id="CD004947-list-0007"> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>weekly searches of MEDLINE;</p> </li> <li> <p>weekly searches of Embase;</p> </li> <li> <p>handsearches of 30 journals and the proceedings of major conferences;</p> </li> <li> <p>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. </p> </li> </ol> </p> <p>Details of the search strategies for CENTRAL, MEDLINE and Embase, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the ‘Specialized Register’ section within the editorial information about the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/preg/frame.html" target="_blank">Cochrane Pregnancy and Childbirth Group</a>. </p> <p>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co‐ordinator searches the register for each review using the topic list rather than keywords.  </p> <p>For details of searching carried out for the initial version of the review, please see <a href="./appendices#CD004947-sec-0151">Appendix 1</a>. </p> </section> <section id="CD004947-sec-0048"> <h4 class="title">Searching other resources</h4> <p>We also manually cross‐referenced key publications.</p> <p>We did not apply any language restrictions.</p> </section> </section> <section id="CD004947-sec-0049"> <h3 class="title" id="CD004947-sec-0049">Data collection and analysis</h3> <p>For the methods used when assessing the trials identified in the previous version of this review, see <a href="./appendices#CD004947-sec-0154">Appendix 2</a>. </p> <p>For this update we used the following methods when assessing the reports identified by the updated search. </p> <section id="CD004947-sec-0050"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently assessed for inclusion all the potential studies identified as a result of the search strategy. We resolved any disagreement through discussion or, if required, we consulted a third author. </p> </section> <section id="CD004947-sec-0051"> <h4 class="title">Data extraction and management</h4> <p>We designed a form to extract data. For eligible studies, two review authors extracted the data using the agreed form. We resolved discrepancies through discussion or, if required, we consulted third author. We entered data into Review Manager software (<a href="./references#CD004947-bbs2-0106" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>) and checked for accuracy. When information regarding any of the above was unclear, we contacted authors of the original reports to provide further details. </p> </section> <section id="CD004947-sec-0052"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004947-bbs2-0089" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Disagreement was resolved by discussion or by involving the third author. </p> <section id="CD004947-sec-0053"> <h5 class="title">(1) Sequence generation (checking for possible selection bias)</h5> <p>We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p>We assessed the method as:</p> <p> <ul id="CD004947-list-0008"> <li> <p>low risk of bias (any truly random process, e.g. random number table; computer random number generator); </p> </li> <li> <p>high risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004947-sec-0054"> <h5 class="title">(2) Allocation concealment (checking for possible selection bias)</h5> <p>We described for each included study the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. </p> <p>We assessed the methods as:</p> <p> <ul id="CD004947-list-0009"> <li> <p>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); </p> </li> <li> <p>high risk of bias (open random allocation; unsealed or non‐opaque envelopes, alternation; date of birth); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004947-sec-0055"> <h5 class="title">(3.1) Blinding of participants and personnel (checking for possible performance bias)</h5> <p>We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding would be unlikely to affect results. We planned to assess blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed the methods as:</p> <p> <ul id="CD004947-list-0010"> <li> <p>low, high or unclear risk of bias for participants;</p> </li> <li> <p>low, high or unclear risk of bias for personnel.</p> </li> </ul> </p> </section> <section id="CD004947-sec-0056"> <h5 class="title">(3.2) Blinding of outcome assessment (checking for possible detection bias)</h5> <p>We described for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We planned to assess blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed methods used to blind outcome assessment as:</p> <p> <ul id="CD004947-list-0011"> <li> <p>low, high or unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004947-sec-0057"> <h5 class="title">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data) </h5> <p>We described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the trial authors, we planned to re‐include missing data in the analyses which we undertook. </p> <p>We assessed methods as:</p> <p> <ul id="CD004947-list-0012"> <li> <p>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups; or less than 20% losses to follow‐up); </p> </li> <li> <p>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as treated’ analysis done with substantial departure of intervention received from that assigned at randomisation); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004947-sec-0058"> <h5 class="title">(5) Selective reporting bias</h5> <p>We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found. We assessed the methods as: </p> <p> <ul id="CD004947-list-0013"> <li> <p>low risk of bias (where it is clear that all of the study’s pre‐specified outcomes and all expected outcomes of interest to the review have been reported); </p> </li> <li> <p>high risk of bias (where not all the study’s pre‐specified outcomes have been reported; one or more reported primary outcomes were not prespecified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD004947-sec-0059"> <h5 class="title">(6) Other sources of bias (checking for bias due to problems not covered by (1) to (5) above) </h5> <p>We described for each included study any important concerns we had about other possible sources of bias. </p> <p>We assessed whether studies that included multiple pregnancies accounted appropriately for non‐independence of babies from the same pregnancy in the analysis.  There are several ways this can be done, and these studies should present something like an odds ratio adjusted for non‐independence. If adjustment was not done, we assessed the potential for bias i.e. if multiples only made up a small proportion of the total then there is probably not much potential for bias. </p> <p>We assessed whether each study was free of other problems that could put it at risk of bias: </p> <p> <ul id="CD004947-list-0014"> <li> <p>low risk of other bias;</p> </li> <li> <p>high risk of other bias;</p> </li> <li> <p>unclear whether there is risk of other bias.</p> </li> </ul> </p> </section> <section id="CD004947-sec-0060"> <h5 class="title">(7) Overall risk of bias</h5> <p>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <i>Cochrane Handbook</i> (<a href="./references#CD004947-bbs2-0089" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it likely to impact on the findings. We planned to explore the impact of the level of bias through undertaking sensitivity analyses ‐ <i>see</i><a href="#CD004947-sec-0073">Sensitivity analysis</a>.  </p> </section> </section> <section id="CD004947-sec-0061"> <h4 class="title">Measures of treatment effect</h4> <section id="CD004947-sec-0062"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous data, we presented results as summary risk ratio with 95% confidence intervals. </p> </section> <section id="CD004947-sec-0063"> <h5 class="title">Continuous data</h5> <p>For continuous data, we used the mean difference if outcomes were measured in the same way between trials. We planned to use the standardised mean difference to combine trials that measured the same outcome, but used different methods, if required. </p> </section> </section> <section id="CD004947-sec-0064"> <h4 class="title">Unit of analysis issues</h4> <section id="CD004947-sec-0065"> <h5 class="title">Cluster‐randomised trials</h5> <p>We did not identify any cluster‐randomised trials for inclusion in this review, but we may include trials of this type in future updates. If we do, we plan to include cluster‐randomised trials in the analyses along with individually‐randomised trials. Their sample sizes will be adjusted using the methods described in the <i>Cochrane Handbook</i> (<a href="./references#CD004947-bbs2-0089" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) using an estimate of the intracluster correlation co‐efficient (ICC) derived from the trial (if possible), or from another source. If ICCs from other sources are used, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster‐randomised trials and individually‐randomised trials, we planned to synthesise the relevant information. We consider it reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit is considered to be unlikely. We also planned to acknowledge heterogeneity in the randomisation unit and perform a sensitivity analysis to investigate the effects of the randomisation unit. </p> </section> <section id="CD004947-sec-0066"> <h5 class="title">Cross‐over trials</h5> <p>Cross‐over trials were not included.</p> </section> <section id="CD004947-sec-0067"> <h5 class="title">Other unit of analysis issues</h5> <p>The analysis in this review involves multiple pregnancies, therefore, wherever possible, analyses should be adjusted for clustering to take into account the non‐independence of babies from the same pregnancy (<a href="./references#CD004947-bbs2-0078" title="GatesS , BrocklehurstP . How should randomised trial including multiple pregnancies be analysed?. BJOG: an international journal of obstetrics and gynaecology2004;111:213‐9. ">Gates 2004</a>). Treating babies from multiple pregnancies as if they are independent, when they are more likely to have similar outcomes than babies from different pregnancies, will overestimate the sample size and give confidence intervals that are too narrow. Each woman can be considered a cluster in multiple pregnancy, with the number of individuals in the cluster being equal to the number of fetuses in her pregnancy. Analysis using cluster trial methods allows calculation of relative risk and adjustment of confidence intervals. Usually this will mean that the confidence intervals get wider. Although this may make little difference to the conclusion of a trial, it avoids misleading results in those trials where the difference may be substantial. </p> <p>We planned to adjust for clustering in the analyses, wherever possible, and to use the inverse variance method for adjusted analyses, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004947-bbs2-0089" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). However, due to insufficient information in the included trials, we were not able to adjust our analyses. In future updates, if possible, we will adjust for clustering in the analyses. </p> </section> </section> <section id="CD004947-sec-0068"> <h4 class="title">Dealing with missing data</h4> <p>For included studies, we noted levels of attrition. We explored the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis. For all outcomes, we carried out analyses, as far as possible, on an intention‐to‐treat basis, i.e. we attempted to include all participants randomised to each group in the analyses, and all participants were analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing. </p> </section> <section id="CD004947-sec-0069"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity in each meta‐analysis using the T², I² and Chi² statistics. We regarded heterogeneity as substantial if an I² was greater than 30% and either the T² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity. </p> </section> <section id="CD004947-sec-0070"> <h4 class="title">Assessment of reporting biases</h4> <p>If 10 or more studies contributed data to meta‐analysis for any particular outcome, we investigated reporting biases (such as publication bias) using funnel plots. We assessed possible asymmetry visually. If asymmetry was suggested by a visual assessment, we planned to perform exploratory analyses to investigate it. In this version of the review insufficient data were available to allow us to carry out this planned analysis. </p> </section> <section id="CD004947-sec-0071"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using the RevMan software (<a href="./references#CD004947-bbs2-0106" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). We used fixed‐effect meta‐analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e. where trials examined the same intervention, and where we judged the trials’ populations and methods to be sufficiently similar. If we suspected clinical heterogeneity sufficient to expect the underlying treatment effects to differ between trials, or if substantial statistical heterogeneity was detected, we used random‐effects meta‐analysis to produce an overall summary provided that we considered an average treatment effect across trials was clinically meaningful. The random‐effects summary was treated as the average of the range of possible treatment effects and the clinical implications of treatment effects differing between trials is discussed. If the average treatment effect was not clinically meaningful we did not combine trials. </p> <p>Where we used random‐effects analyses, the results were presented as the average treatment effect with 95% confidence intervals, and the estimates of T² and I². </p> <p>Results were analysed according to the reason women were considered to be at risk of preterm birth, including: </p> <p> <ul id="CD004947-list-0015"> <li> <p>past history of spontaneous preterm birth (including preterm prelabour rupture of membranes); </p> </li> <li> <p>multiple pregnancy;</p> </li> <li> <p>ultrasound identified short cervical length;</p> </li> <li> <p>fetal fibronectin testing;</p> </li> <li> <p>presentation with symptoms or signs of threatened preterm labour;</p> </li> <li> <p>other reason for risk of preterm birth.</p> </li> </ul> </p> <p>For analyses where there are high levels of heterogeneity we have provided an estimate of the 95% range of underlying intervention effects (prediction interval). </p> </section> <section id="CD004947-sec-0072"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If we identified substantial heterogeneity, we investigated it using subgroup analyses and sensitivity analyses. We considered whether an overall summary was meaningful, and if it was, we used random‐effects analysis to produce it.<br/> <br/> We planned, where possible, to carry out the following subgroup analyses: </p> <p> <ol id="CD004947-list-0016"> <li> <p>time of treatment commencing (before 20 weeks' gestation versus after 20 weeks' gestation);</p> </li> <li> <p>route of administration (intramuscular, intravaginal, oral, intravenous);</p> </li> <li> <p>different dosage regimens (divided arbitrarily into a cumulative dose of less than 500 mg per week and a dose of greater than or equal to 500 mg per week). </p> </li> </ol> </p> <p>All outcomes were considered in subgroup analyses.</p> <p>We assessed subgroup differences by interaction tests available within RevMan (<a href="./references#CD004947-bbs2-0106" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). </p> </section> <section id="CD004947-sec-0073"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out sensitivity analyses to explore the effect of trial quality assessed by concealment of allocation, high attrition rates (greater than 20%), or both, with poor‐quality studies being excluded from the analyses in order to assess whether this made any difference to the overall result. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004947-sec-0074" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004947-sec-0074"></div> <section id="CD004947-sec-0075"> <h3 class="title">Description of studies</h3> <section id="CD004947-sec-0076"> <h4 class="title">Results of the search</h4> <p>In the 2006 update, our search strategy identified 22 studies for consideration. Eleven studies met the inclusion criteria stated (<a href="./references#CD004947-bbs2-0003" title="BornaS , SahabiN . Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2008;48(1):58‐63. BornaS , ShakoieS , BornaH . Progesterone for maintenance tocolytic therapy after threatened preterm labor. Randomized controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:151‐2. ">Borna 2008</a>; <a href="./references#CD004947-bbs2-0010" title="daFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics &amp; Gynecology2003;188(2):419‐24. daFonsecaEB , BittarRE , CarvalhoMHB , MartinelliS , ZugaibM . Uterine contraction monitoring in pregnant women using vaginal natural progesterone. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):525. ">da Fonseca 2003</a>; <a href="./references#CD004947-bbs2-0012" title="FacchinettiF , DanteG , VenturiniP , PaganelliS , VolpeA . 17alpha‐hydroxy‐progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery. American Journal of Perinatology2008;25(8):503‐6. FacchinettiF , PaganelliS , ComitinitG , DanteG , VolpeA . Cervical length changes during preterm cervical ripening: effects of 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2007;196:453e1‐453e4. FacchinettiF , PaganelliS , VenturiniP , DanteG . 17 alpha hydroxy‐progesterone caproate (17P) treatment reduced cervical shortening inhibiting cervical interleukin‐1 secretion. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S5. ">Facchinetti 2007</a>; <a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>; <a href="./references#CD004947-bbs2-0016" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56(6):692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen 1980</a>; <a href="./references#CD004947-bbs2-0018" title="HauthJC , GilstrapLC , BrekkenAL , HauthJM . The effect of 17 alpha‐hydroxyprogesterone caproate on pregnancy outcome in an active‐duty military population. American Journal of Obstetrics and Gynecology1983;146(2):187‐90. ">Hauth 1983</a>; <a href="./references#CD004947-bbs2-0020" title="JohnsonJWC , AustinKL , JonesGS , DavisGH , KingTM . Efficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine1975;293(14):675‐80. KlebanoffM , for the NICHD MFMU Network. Impact of 17alpha hydroxyprogesterone caproate administration on salivary progesterone and estriol [abstract]. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S140. ">Johnson 1975</a>; <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>; <a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>; <a href="./references#CD004947-bbs2-0028" title="Papiernik‐BerkhauerE . Double blind study of an agent to prevent preterm delivery among women at increased risk [Etude en double aveugle d'un medicament prevenant la survenue prematuree de l'accouchement chez les femmes a risque eleve d'accouchement premature]. Edition Schering Serie IV1970; Vol. 3:65‐8. ">Papiernik 1970</a>; <a href="./references#CD004947-bbs2-0031" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S197. ManuckT , for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha‐hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S18. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 Alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357:454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>) involving a total of 2714 women and 3452 infants. The study by Northern (<a href="./references#CD004947-bbs2-0099" title="NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. ">Northen 2007</a>) reports the follow‐up of children involved in the Meis study (<a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>). </p> <p>Sixty‐four reports from an updated search in January 2013 have been assessed for this update. Of these 64 reports, an additional 25 studies (33 reports) to the original 11 studies, were included (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD004947-bbs2-0002" title="AkbariS , BirjandiM , MohtashamN . Evaluation of the effect of progesterone on prevention of preterm delivery and its complications. Scientific Journal of Kurdistan University of Medical Sciences2009;14(3):11‐9. ">Akbari 2009</a>; <a href="./references#CD004947-bbs2-0004" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. BrieryCM , VeillonEW , KlauserCK , MartinRW , MagannEF , ChauhanSP , et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. American Journal of Obstetrics and Gynecology2011;204(1):54.e1‐5. ">Briery 2011</a>; <a href="./references#CD004947-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>; <a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>; <a href="./references#CD004947-bbs2-0009" title="CombsCA , GariteTJ , MaurelK , MalloryK , EdwardsRK , LuG , et al. 17‐Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double‐blind, randomized clinical trial. BMC Research Notes2011;4(1):568. ">Combs 2011a</a>; <a href="./references#CD004947-bbs2-0011" title="ElsheikhahAZ , DahabS , NegmS , EbrashyA . Effect of prophylactic progesterone on incidence of preterm labour in spontaneous twin pregnancy, randomized controlled study. Ultrasound in Obstetrics and Gynecology2010;36(Suppl 1):108. ">Elsheikhah 2010</a>; <a href="./references#CD004947-bbs2-0014" title="GloverM , CroomCS , SonekJD , KovacC , McKennaD . A randomized placebo controlled trial of oral micronized progesterone to prevent recurrent preterm birth. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S172. GloverMM , McKennaDS , DowningCM , SmithDB , CroomCS , SonekJD . A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. American Journal of Perinatology2011;28(5):377‐81. ">Glover 2011</a>; <a href="./references#CD004947-bbs2-0015" title="GrobmanW . RCT of progesterone to prevent preterm birth in nulliparous women with a short cervix. http://controlledtrials.com(accessed 2007). GrobmanW . Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S367. GrobmanWA , ThomEA , SpongCY , IamsJD , SaadeGR , MercerBM , et al. 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;207(5):390.e1‐8. ">Grobman 2012</a>; <a href="./references#CD004947-bbs2-0017" title="HassanSS , RomeroR , VidyadhariD , FuseyS , BaxterJK , KhandelwalM , et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(1):18‐31. ">Hassan 2011</a>; <a href="./references#CD004947-bbs2-0019" title="IbrahimM , Mohamed RamyAR , YounisMA‐F . Progesterone supplementation for prevention of preterm labor: a randomized controlled trial. Middle East Fertility Society Journal2010;15(1):39‐41. ">Ibrahim 2010</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0022" title="MajhiP , BaggaR , KalraJ , SharmaM . Intravaginal use of natural micronised progesterone to prevent pre‐term birth: a randomised trial in India. Journal of Obstetrics and Gynaecology2009;29(6):493‐8. ">Majhi 2009</a>; <a href="./references#CD004947-bbs2-0024" title="MoghtadaeiP , SardariF , LatifiM . Progesterone for prevention of preterm birth and improvement in pregnancy outcomes among primiparae of advanced maternal age. Archives of Disease in Childhood. Fetal and Neonatal Edition2008; Vol. 93, issue Suppl 1:Fa71. MoghtadeiP , SardariF , LatifiM . Progesterone for prevention of preterm birth and improvement pregnancy outcomes among primiparae of advanced maternal age. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:122. ">Moghtadaei 2008</a>; <a href="./references#CD004947-bbs2-0025" title="NdoniE , BimbashiA , DokleA , KallfaE . Treatment with different types of progesterone in prevention of preterm delivery. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):305. ">Ndoni 2010</a>; <a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD004947-bbs2-0029" title="RaiP , RajaramS , GoelN , Ayalur GopalakrishnanR , AgarwalR , MehtaS . Oral micronized progesterone for prevention of preterm birth. International Journal of Gynecology &amp; Obstetrics2009;104(1):40‐3. ">Rai 2009</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>; <a href="./references#CD004947-bbs2-0032" title="RozenbergP . Efficacy of 17 alpha‐hydroxyprogesterone caproate for the prevention of preterm delivery. http://controlledtrials.com(accessed 2007). RozenbergP , ChauveaudA , DeruelleP , CapelleM , WinerN ,  DesbriereR , et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. American Journal of Obstetrics &amp; Gynecology2012;206(3):206.e1‐9. RozenbergP , DeruelleP , ChauveaudA , CapelleM , WinerN , PorcherR , et al. Prevention of preterm delivery after successful tocolysis in preterm labour by 17 alpha‐hydroxyprogesterone caproate: a randomised controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S2‐S3. ">Rozenberg 2012</a>; <a href="./references#CD004947-bbs2-0033" title="SaghafiN , KhademN , MohajeriT , ShakeriMT . Efficacy of 17alpha‐hydroxyprogesterone caproate in prevention of preterm delivery. Journal of Obstetrics and Gynaecology Research2011;37(10):1342‐5. SaghafiN , KhademN , MohajeriT , ShakeriMT , AminiM . Efficacy of 17alpha‐hydroxyprogesterone caproate in preterm delivery prevention. Iranian Journal of Obstetrics, Gynecology and Infertility2011;14(2):28‐33. ">Saghafi 2011a</a>; <a href="./references#CD004947-bbs2-0034" title="SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: A randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2012</a>; <a href="./references#CD004947-bbs2-0035" title="SerraV . Natural progesterone and preterm birth in twins. http://controlledtrials.com(accessed 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>; <a href="./references#CD004947-bbs2-0036" title="SharamiSH , ZahiriZ , ShakibaM , MilaniF . Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: a randomized placebo‐controlled double‐blind trial. International Journal of Fertility and Sterility2010;4(2):45‐50. ">Sharami 2010</a>); seven studies (seven reports) were excluded (<a href="./references#CD004947-bbs2-0037" title="AbbottD . Relationship between cervical‐vaginal fluid elafin concentrations and subsequent cervical shortening in women at high risk of spontaneous preterm birth. Reproductive Sciences2012;19(3Suppl):73A. ">Abbott 2012</a>; <a href="./references#CD004947-bbs2-0038" title="ArikanI , BarutA , HarmaM , HarmaIM . Effect of progesterone as a tocolytic and in maintenance therapy during preterm labor. Gynecologic and Obstetric Investigation2011;72(4):269‐73. ">Arikan 2011</a>; <a href="./references#CD004947-bbs2-0039" title="BerghellaV , FigueroaD , SzychowskiJM , OwenJ , HankinsGD , IamsJD , et al. 17‐alpha‐hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. American Journal of Obstetrics and Gynecology2010;202(4):351.e1‐6. ">Berghella 2010</a>; <a href="./references#CD004947-bbs2-0042" title="ChandiramaniM . Serum progesterone concentrations in women with a previous preterm birth treated with vaginal progesterone supplementation. Reproductive Sciences2012;19(3Suppl):189A. ">Chandiramani 2012</a>; <a href="./references#CD004947-bbs2-0045" title="IonescuAC , GheorghiuD , PacuI , DavitoiuB , DimitriuM , HaradjaH . Randomized trial of cerclage and progesterone to prevent spontaneous preterm brith in high‐risk women with a short cervix. Journal of Perinatal Medicine2012;39 Suppl:Abstract no. 008. ">Ionescu 2012</a>; <a href="./references#CD004947-bbs2-0046" title="KeelerSM , KieferD , RochonM , QuinonesJN , NovetskyAP , RustO . A randomized trial of cerclage vs. 17 alpha‐hydroxyprogesterone caproate for treatment of short cervix. Journal of Perinatal Medicine2009;37(5):473‐9. ">Keeler 2009</a>; <a href="./references#CD004947-bbs2-0048" title="RustO , LarkinR , RobertsW , QuinonesJ , RochonM , ReedJ , et al. A randomized trial of cerclage versus 17 hydroxyprogesterone for the treatment of short cervix. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S112. ">Rust 2006</a>); two studies (two reports) are ongoing studies (<a href="./references#CD004947-bbs2-0053" title="CoomarasamyA . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). http://www.controlled‐trials.com/ISRCTN92644181/ISRCTN92644181 (accessed 11.01.2012). ">Coomarasamy 2012</a>; <a href="./references#CD004947-bbs2-0062" title="vanOsMA , van derVenJA , KleinrouwelerCE , PajkrtE , deMirandaE , vanWassenaerA , et al. Preventing preterm birth with progesterone: Costs and effects of screening low risk women with a singleton pregnancy for short cervical length, the Triple P study. BMC Pregnancy and Childbirth2011;11:77. ">van Os 2011</a>); one is an additional report of an ongoing study (<a href="./references#CD004947-bbs2-0055" title="ArmsonBA , DoddJ , for the POPPI Collaborative Trial Group. POPPI: prevention of problems of preterm birth with progesterone in women at increased risk: a multicentre randomised controlled trial [abstract]. Journal of Paediatrics and Child Health2007;43:A29. AshwoodP . Progesterone after previous preterm birth for the prevention of neonatal respiratory distress syndrome. WOMBAT Collaboration (www.wombatcollaboration.net/trials) (accessed 4 October 2006). CrowtherCA , DoddJM , McPheeAJ , FlenadyV . Australasian Collaborative Trial of Vaginal Progesterone Therapy (The PROGRESS Trial). http://controlledtrials.com(accessed 2007). DoddJM , CrowtherCA , McPheeAJ , FlenadyV , RobinsonJS . Progesterone after previous preterm birth for prevention of neonatal respiratory distress syndrome (PROGRESS): a randomised controlled trial. BMC Pregnancy and Childbirth2009;9:6. ">Crowther 2007</a>); one additional report was added to each of the following included studies (<a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>; <a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>; <a href="./references#CD004947-bbs2-0012" title="FacchinettiF , DanteG , VenturiniP , PaganelliS , VolpeA . 17alpha‐hydroxy‐progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery. American Journal of Perinatology2008;25(8):503‐6. FacchinettiF , PaganelliS , ComitinitG , DanteG , VolpeA . Cervical length changes during preterm cervical ripening: effects of 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2007;196:453e1‐453e4. FacchinettiF , PaganelliS , VenturiniP , DanteG . 17 alpha hydroxy‐progesterone caproate (17P) treatment reduced cervical shortening inhibiting cervical interleukin‐1 secretion. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S5. ">Facchinetti 2007</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0057" title="NassarA . Prevention of preterm delivery in twin pregnancies by 17 alpha hydroxyprogesterone caproate. http://controlledtrials.com(accessed 2007). NassarA , AwwadJ , SuccarJ , SaassouhW , KhalifeT , HayekS , et al. Incidence of GDM in twin pregnancies of women receiving prophylactic 17‐A OH progesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):307‐8. ">Nassar 2007</a>). Two additional reports were identified for the <a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a> and <a href="./references#CD004947-bbs2-0031" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S197. ManuckT , for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha‐hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S18. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 Alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357:454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a> included studies. Three additional reports were identified for the <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a> included study. </p> <p>A total of 36 studies are included in this update.</p> </section> <section id="CD004947-sec-0077"> <h4 class="title">Included studies</h4> <p>Refer to table <a href="./references#CD004947-sec-0174" title="">Characteristics of included studies</a> for further details. </p> <section id="CD004947-sec-0078"> <h5 class="title">Use of progesterone in women with a history of prior spontaneous preterm birth</h5> <section id="CD004947-sec-0079"> <h6 class="title">Description of studies</h6> <p>Eleven studies were included involving a total of 1936 women with a past history of spontaneous preterm birth (<a href="./references#CD004947-bbs2-0002" title="AkbariS , BirjandiM , MohtashamN . Evaluation of the effect of progesterone on prevention of preterm delivery and its complications. Scientific Journal of Kurdistan University of Medical Sciences2009;14(3):11‐9. ">Akbari 2009</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0010" title="daFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics &amp; Gynecology2003;188(2):419‐24. daFonsecaEB , BittarRE , CarvalhoMHB , MartinelliS , ZugaibM . Uterine contraction monitoring in pregnant women using vaginal natural progesterone. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):525. ">da Fonseca 2003</a>; <a href="./references#CD004947-bbs2-0014" title="GloverM , CroomCS , SonekJD , KovacC , McKennaD . A randomized placebo controlled trial of oral micronized progesterone to prevent recurrent preterm birth. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S172. GloverMM , McKennaDS , DowningCM , SmithDB , CroomCS , SonekJD . A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. American Journal of Perinatology2011;28(5):377‐81. ">Glover 2011</a>; <a href="./references#CD004947-bbs2-0020" title="JohnsonJWC , AustinKL , JonesGS , DavisGH , KingTM . Efficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine1975;293(14):675‐80. KlebanoffM , for the NICHD MFMU Network. Impact of 17alpha hydroxyprogesterone caproate administration on salivary progesterone and estriol [abstract]. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S140. ">Johnson 1975</a>; <a href="./references#CD004947-bbs2-0019" title="IbrahimM , Mohamed RamyAR , YounisMA‐F . Progesterone supplementation for prevention of preterm labor: a randomized controlled trial. Middle East Fertility Society Journal2010;15(1):39‐41. ">Ibrahim 2010</a>; <a href="./references#CD004947-bbs2-0022" title="MajhiP , BaggaR , KalraJ , SharmaM . Intravaginal use of natural micronised progesterone to prevent pre‐term birth: a randomised trial in India. Journal of Obstetrics and Gynaecology2009;29(6):493‐8. ">Majhi 2009</a>; <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>; <a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>; <a href="./references#CD004947-bbs2-0029" title="RaiP , RajaramS , GoelN , Ayalur GopalakrishnanR , AgarwalR , MehtaS . Oral micronized progesterone for prevention of preterm birth. International Journal of Gynecology &amp; Obstetrics2009;104(1):40‐3. ">Rai 2009</a>; <a href="./references#CD004947-bbs2-0033" title="SaghafiN , KhademN , MohajeriT , ShakeriMT . Efficacy of 17alpha‐hydroxyprogesterone caproate in prevention of preterm delivery. Journal of Obstetrics and Gynaecology Research2011;37(10):1342‐5. SaghafiN , KhademN , MohajeriT , ShakeriMT , AminiM . Efficacy of 17alpha‐hydroxyprogesterone caproate in preterm delivery prevention. Iranian Journal of Obstetrics, Gynecology and Infertility2011;14(2):28‐33. ">Saghafi 2011a</a>). Four studies compared weekly intramuscular injection with placebo (<a href="./references#CD004947-bbs2-0019" title="IbrahimM , Mohamed RamyAR , YounisMA‐F . Progesterone supplementation for prevention of preterm labor: a randomized controlled trial. Middle East Fertility Society Journal2010;15(1):39‐41. ">Ibrahim 2010</a>; <a href="./references#CD004947-bbs2-0020" title="JohnsonJWC , AustinKL , JonesGS , DavisGH , KingTM . Efficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine1975;293(14):675‐80. KlebanoffM , for the NICHD MFMU Network. Impact of 17alpha hydroxyprogesterone caproate administration on salivary progesterone and estriol [abstract]. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S140. ">Johnson 1975</a>; <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>) or routine care (<a href="./references#CD004947-bbs2-0033" title="SaghafiN , KhademN , MohajeriT , ShakeriMT . Efficacy of 17alpha‐hydroxyprogesterone caproate in prevention of preterm delivery. Journal of Obstetrics and Gynaecology Research2011;37(10):1342‐5. SaghafiN , KhademN , MohajeriT , ShakeriMT , AminiM . Efficacy of 17alpha‐hydroxyprogesterone caproate in preterm delivery prevention. Iranian Journal of Obstetrics, Gynecology and Infertility2011;14(2):28‐33. ">Saghafi 2011a</a>); five studies compared daily vaginal progesterone, three with placebo (<a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0010" title="daFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics &amp; Gynecology2003;188(2):419‐24. daFonsecaEB , BittarRE , CarvalhoMHB , MartinelliS , ZugaibM . Uterine contraction monitoring in pregnant women using vaginal natural progesterone. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):525. ">da Fonseca 2003</a>; <a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>) and two with routine care (<a href="./references#CD004947-bbs2-0002" title="AkbariS , BirjandiM , MohtashamN . Evaluation of the effect of progesterone on prevention of preterm delivery and its complications. Scientific Journal of Kurdistan University of Medical Sciences2009;14(3):11‐9. ">Akbari 2009</a>; <a href="./references#CD004947-bbs2-0022" title="MajhiP , BaggaR , KalraJ , SharmaM . Intravaginal use of natural micronised progesterone to prevent pre‐term birth: a randomised trial in India. Journal of Obstetrics and Gynaecology2009;29(6):493‐8. ">Majhi 2009</a>); and two studies compared daily oral progesterone with placebo (<a href="./references#CD004947-bbs2-0014" title="GloverM , CroomCS , SonekJD , KovacC , McKennaD . A randomized placebo controlled trial of oral micronized progesterone to prevent recurrent preterm birth. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S172. GloverMM , McKennaDS , DowningCM , SmithDB , CroomCS , SonekJD . A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. American Journal of Perinatology2011;28(5):377‐81. ">Glover 2011</a>; <a href="./references#CD004947-bbs2-0029" title="RaiP , RajaramS , GoelN , Ayalur GopalakrishnanR , AgarwalR , MehtaS . Oral micronized progesterone for prevention of preterm birth. International Journal of Gynecology &amp; Obstetrics2009;104(1):40‐3. ">Rai 2009</a>). Dose of progesterone administered varied from 90 mg daily (<a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>), to 100 mg daily (<a href="./references#CD004947-bbs2-0002" title="AkbariS , BirjandiM , MohtashamN . Evaluation of the effect of progesterone on prevention of preterm delivery and its complications. Scientific Journal of Kurdistan University of Medical Sciences2009;14(3):11‐9. ">Akbari 2009</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0010" title="daFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics &amp; Gynecology2003;188(2):419‐24. daFonsecaEB , BittarRE , CarvalhoMHB , MartinelliS , ZugaibM . Uterine contraction monitoring in pregnant women using vaginal natural progesterone. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):525. ">da Fonseca 2003</a>; <a href="./references#CD004947-bbs2-0022" title="MajhiP , BaggaR , KalraJ , SharmaM . Intravaginal use of natural micronised progesterone to prevent pre‐term birth: a randomised trial in India. Journal of Obstetrics and Gynaecology2009;29(6):493‐8. ">Majhi 2009</a>), to 200 mg daily (<a href="./references#CD004947-bbs2-0029" title="RaiP , RajaramS , GoelN , Ayalur GopalakrishnanR , AgarwalR , MehtaS . Oral micronized progesterone for prevention of preterm birth. International Journal of Gynecology &amp; Obstetrics2009;104(1):40‐3. ">Rai 2009</a>), to 400 mg daily (<a href="./references#CD004947-bbs2-0014" title="GloverM , CroomCS , SonekJD , KovacC , McKennaD . A randomized placebo controlled trial of oral micronized progesterone to prevent recurrent preterm birth. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S172. GloverMM , McKennaDS , DowningCM , SmithDB , CroomCS , SonekJD . A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. American Journal of Perinatology2011;28(5):377‐81. ">Glover 2011</a>), to 200 mg weekly (<a href="./references#CD004947-bbs2-0029" title="RaiP , RajaramS , GoelN , Ayalur GopalakrishnanR , AgarwalR , MehtaS . Oral micronized progesterone for prevention of preterm birth. International Journal of Gynecology &amp; Obstetrics2009;104(1):40‐3. ">Rai 2009</a>), to 250 mg weekly (<a href="./references#CD004947-bbs2-0020" title="JohnsonJWC , AustinKL , JonesGS , DavisGH , KingTM . Efficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine1975;293(14):675‐80. KlebanoffM , for the NICHD MFMU Network. Impact of 17alpha hydroxyprogesterone caproate administration on salivary progesterone and estriol [abstract]. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S140. ">Johnson 1975</a>; <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>; <a href="./references#CD004947-bbs2-0033" title="SaghafiN , KhademN , MohajeriT , ShakeriMT . Efficacy of 17alpha‐hydroxyprogesterone caproate in prevention of preterm delivery. Journal of Obstetrics and Gynaecology Research2011;37(10):1342‐5. SaghafiN , KhademN , MohajeriT , ShakeriMT , AminiM . Efficacy of 17alpha‐hydroxyprogesterone caproate in preterm delivery prevention. Iranian Journal of Obstetrics, Gynecology and Infertility2011;14(2):28‐33. ">Saghafi 2011a</a>). Supplementation commenced prior to 20 weeks' gestation in four trials (<a href="./references#CD004947-bbs2-0014" title="GloverM , CroomCS , SonekJD , KovacC , McKennaD . A randomized placebo controlled trial of oral micronized progesterone to prevent recurrent preterm birth. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S172. GloverMM , McKennaDS , DowningCM , SmithDB , CroomCS , SonekJD . A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. American Journal of Perinatology2011;28(5):377‐81. ">Glover 2011</a>; <a href="./references#CD004947-bbs2-0020" title="JohnsonJWC , AustinKL , JonesGS , DavisGH , KingTM . Efficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine1975;293(14):675‐80. KlebanoffM , for the NICHD MFMU Network. Impact of 17alpha hydroxyprogesterone caproate administration on salivary progesterone and estriol [abstract]. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S140. ">Johnson 1975</a>; <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>; <a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>), and continued up to a gestational age varying from 24 weeks (<a href="./references#CD004947-bbs2-0020" title="JohnsonJWC , AustinKL , JonesGS , DavisGH , KingTM . Efficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine1975;293(14):675‐80. KlebanoffM , for the NICHD MFMU Network. Impact of 17alpha hydroxyprogesterone caproate administration on salivary progesterone and estriol [abstract]. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S140. ">Johnson 1975</a>; <a href="./references#CD004947-bbs2-0022" title="MajhiP , BaggaR , KalraJ , SharmaM . Intravaginal use of natural micronised progesterone to prevent pre‐term birth: a randomised trial in India. Journal of Obstetrics and Gynaecology2009;29(6):493‐8. ">Majhi 2009</a>; <a href="./references#CD004947-bbs2-0029" title="RaiP , RajaramS , GoelN , Ayalur GopalakrishnanR , AgarwalR , MehtaS . Oral micronized progesterone for prevention of preterm birth. International Journal of Gynecology &amp; Obstetrics2009;104(1):40‐3. ">Rai 2009</a>), to 28 weeks (<a href="./references#CD004947-bbs2-0010" title="daFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics &amp; Gynecology2003;188(2):419‐24. daFonsecaEB , BittarRE , CarvalhoMHB , MartinelliS , ZugaibM . Uterine contraction monitoring in pregnant women using vaginal natural progesterone. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):525. ">da Fonseca 2003</a>), to 34 weeks (<a href="./references#CD004947-bbs2-0002" title="AkbariS , BirjandiM , MohtashamN . Evaluation of the effect of progesterone on prevention of preterm delivery and its complications. Scientific Journal of Kurdistan University of Medical Sciences2009;14(3):11‐9. ">Akbari 2009</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>), to 36 weeks (<a href="./references#CD004947-bbs2-0019" title="IbrahimM , Mohamed RamyAR , YounisMA‐F . Progesterone supplementation for prevention of preterm labor: a randomized controlled trial. Middle East Fertility Society Journal2010;15(1):39‐41. ">Ibrahim 2010</a>; <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>), and to 37 weeks (<a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>; <a href="./references#CD004947-bbs2-0033" title="SaghafiN , KhademN , MohajeriT , ShakeriMT . Efficacy of 17alpha‐hydroxyprogesterone caproate in prevention of preterm delivery. Journal of Obstetrics and Gynaecology Research2011;37(10):1342‐5. SaghafiN , KhademN , MohajeriT , ShakeriMT , AminiM . Efficacy of 17alpha‐hydroxyprogesterone caproate in preterm delivery prevention. Iranian Journal of Obstetrics, Gynecology and Infertility2011;14(2):28‐33. ">Saghafi 2011a</a>) gestation. </p> <p>The primary outcomes reported by the trials related to the occurrence of preterm birth prior to 28 weeks' gestation (<a href="./references#CD004947-bbs2-0029" title="RaiP , RajaramS , GoelN , Ayalur GopalakrishnanR , AgarwalR , MehtaS . Oral micronized progesterone for prevention of preterm birth. International Journal of Gynecology &amp; Obstetrics2009;104(1):40‐3. ">Rai 2009</a>), 32 weeks' gestation (<a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>), 34 weeks' gestation (<a href="./references#CD004947-bbs2-0002" title="AkbariS , BirjandiM , MohtashamN . Evaluation of the effect of progesterone on prevention of preterm delivery and its complications. Scientific Journal of Kurdistan University of Medical Sciences2009;14(3):11‐9. ">Akbari 2009</a>; <a href="./references#CD004947-bbs2-0022" title="MajhiP , BaggaR , KalraJ , SharmaM . Intravaginal use of natural micronised progesterone to prevent pre‐term birth: a randomised trial in India. Journal of Obstetrics and Gynaecology2009;29(6):493‐8. ">Majhi 2009</a>), and 37 weeks' gestation (<a href="./references#CD004947-bbs2-0002" title="AkbariS , BirjandiM , MohtashamN . Evaluation of the effect of progesterone on prevention of preterm delivery and its complications. Scientific Journal of Kurdistan University of Medical Sciences2009;14(3):11‐9. ">Akbari 2009</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0010" title="daFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics &amp; Gynecology2003;188(2):419‐24. daFonsecaEB , BittarRE , CarvalhoMHB , MartinelliS , ZugaibM . Uterine contraction monitoring in pregnant women using vaginal natural progesterone. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):525. ">da Fonseca 2003</a>; <a href="./references#CD004947-bbs2-0019" title="IbrahimM , Mohamed RamyAR , YounisMA‐F . Progesterone supplementation for prevention of preterm labor: a randomized controlled trial. Middle East Fertility Society Journal2010;15(1):39‐41. ">Ibrahim 2010</a>; <a href="./references#CD004947-bbs2-0020" title="JohnsonJWC , AustinKL , JonesGS , DavisGH , KingTM . Efficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine1975;293(14):675‐80. KlebanoffM , for the NICHD MFMU Network. Impact of 17alpha hydroxyprogesterone caproate administration on salivary progesterone and estriol [abstract]. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S140. ">Johnson 1975</a>; <a href="./references#CD004947-bbs2-0022" title="MajhiP , BaggaR , KalraJ , SharmaM . Intravaginal use of natural micronised progesterone to prevent pre‐term birth: a randomised trial in India. Journal of Obstetrics and Gynaecology2009;29(6):493‐8. ">Majhi 2009</a>; <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>; <a href="./references#CD004947-bbs2-0033" title="SaghafiN , KhademN , MohajeriT , ShakeriMT . Efficacy of 17alpha‐hydroxyprogesterone caproate in prevention of preterm delivery. Journal of Obstetrics and Gynaecology Research2011;37(10):1342‐5. SaghafiN , KhademN , MohajeriT , ShakeriMT , AminiM . Efficacy of 17alpha‐hydroxyprogesterone caproate in preterm delivery prevention. Iranian Journal of Obstetrics, Gynecology and Infertility2011;14(2):28‐33. ">Saghafi 2011a</a>). Eight trials involved single centres (<a href="./references#CD004947-bbs2-0002" title="AkbariS , BirjandiM , MohtashamN . Evaluation of the effect of progesterone on prevention of preterm delivery and its complications. Scientific Journal of Kurdistan University of Medical Sciences2009;14(3):11‐9. ">Akbari 2009</a>; <a href="./references#CD004947-bbs2-0010" title="daFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics &amp; Gynecology2003;188(2):419‐24. daFonsecaEB , BittarRE , CarvalhoMHB , MartinelliS , ZugaibM . Uterine contraction monitoring in pregnant women using vaginal natural progesterone. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):525. ">da Fonseca 2003</a>; <a href="./references#CD004947-bbs2-0014" title="GloverM , CroomCS , SonekJD , KovacC , McKennaD . A randomized placebo controlled trial of oral micronized progesterone to prevent recurrent preterm birth. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S172. GloverMM , McKennaDS , DowningCM , SmithDB , CroomCS , SonekJD . A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. American Journal of Perinatology2011;28(5):377‐81. ">Glover 2011</a>; <a href="./references#CD004947-bbs2-0019" title="IbrahimM , Mohamed RamyAR , YounisMA‐F . Progesterone supplementation for prevention of preterm labor: a randomized controlled trial. Middle East Fertility Society Journal2010;15(1):39‐41. ">Ibrahim 2010</a>; <a href="./references#CD004947-bbs2-0020" title="JohnsonJWC , AustinKL , JonesGS , DavisGH , KingTM . Efficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine1975;293(14):675‐80. KlebanoffM , for the NICHD MFMU Network. Impact of 17alpha hydroxyprogesterone caproate administration on salivary progesterone and estriol [abstract]. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S140. ">Johnson 1975</a>; <a href="./references#CD004947-bbs2-0022" title="MajhiP , BaggaR , KalraJ , SharmaM . Intravaginal use of natural micronised progesterone to prevent pre‐term birth: a randomised trial in India. Journal of Obstetrics and Gynaecology2009;29(6):493‐8. ">Majhi 2009</a>; <a href="./references#CD004947-bbs2-0029" title="RaiP , RajaramS , GoelN , Ayalur GopalakrishnanR , AgarwalR , MehtaS . Oral micronized progesterone for prevention of preterm birth. International Journal of Gynecology &amp; Obstetrics2009;104(1):40‐3. ">Rai 2009</a>; <a href="./references#CD004947-bbs2-0033" title="SaghafiN , KhademN , MohajeriT , ShakeriMT . Efficacy of 17alpha‐hydroxyprogesterone caproate in prevention of preterm delivery. Journal of Obstetrics and Gynaecology Research2011;37(10):1342‐5. SaghafiN , KhademN , MohajeriT , ShakeriMT , AminiM . Efficacy of 17alpha‐hydroxyprogesterone caproate in preterm delivery prevention. Iranian Journal of Obstetrics, Gynecology and Infertility2011;14(2):28‐33. ">Saghafi 2011a</a>), and two were multicentre trials (<a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>; <a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>), conducted principally from the United States of America (<a href="./references#CD004947-bbs2-0014" title="GloverM , CroomCS , SonekJD , KovacC , McKennaD . A randomized placebo controlled trial of oral micronized progesterone to prevent recurrent preterm birth. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S172. GloverMM , McKennaDS , DowningCM , SmithDB , CroomCS , SonekJD . A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. American Journal of Perinatology2011;28(5):377‐81. ">Glover 2011</a>; <a href="./references#CD004947-bbs2-0020" title="JohnsonJWC , AustinKL , JonesGS , DavisGH , KingTM . Efficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine1975;293(14):675‐80. KlebanoffM , for the NICHD MFMU Network. Impact of 17alpha hydroxyprogesterone caproate administration on salivary progesterone and estriol [abstract]. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S140. ">Johnson 1975</a>; <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>; <a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>), India (<a href="./references#CD004947-bbs2-0022" title="MajhiP , BaggaR , KalraJ , SharmaM . Intravaginal use of natural micronised progesterone to prevent pre‐term birth: a randomised trial in India. Journal of Obstetrics and Gynaecology2009;29(6):493‐8. ">Majhi 2009</a>; <a href="./references#CD004947-bbs2-0029" title="RaiP , RajaramS , GoelN , Ayalur GopalakrishnanR , AgarwalR , MehtaS . Oral micronized progesterone for prevention of preterm birth. International Journal of Gynecology &amp; Obstetrics2009;104(1):40‐3. ">Rai 2009</a>), Iran (<a href="./references#CD004947-bbs2-0002" title="AkbariS , BirjandiM , MohtashamN . Evaluation of the effect of progesterone on prevention of preterm delivery and its complications. Scientific Journal of Kurdistan University of Medical Sciences2009;14(3):11‐9. ">Akbari 2009</a>; <a href="./references#CD004947-bbs2-0033" title="SaghafiN , KhademN , MohajeriT , ShakeriMT . Efficacy of 17alpha‐hydroxyprogesterone caproate in prevention of preterm delivery. Journal of Obstetrics and Gynaecology Research2011;37(10):1342‐5. SaghafiN , KhademN , MohajeriT , ShakeriMT , AminiM . Efficacy of 17alpha‐hydroxyprogesterone caproate in preterm delivery prevention. Iranian Journal of Obstetrics, Gynecology and Infertility2011;14(2):28‐33. ">Saghafi 2011a</a>), Egypt (<a href="./references#CD004947-bbs2-0019" title="IbrahimM , Mohamed RamyAR , YounisMA‐F . Progesterone supplementation for prevention of preterm labor: a randomized controlled trial. Middle East Fertility Society Journal2010;15(1):39‐41. ">Ibrahim 2010</a>), Istanbul (<a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>), and Brazil (<a href="./references#CD004947-bbs2-0010" title="daFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics &amp; Gynecology2003;188(2):419‐24. daFonsecaEB , BittarRE , CarvalhoMHB , MartinelliS , ZugaibM . Uterine contraction monitoring in pregnant women using vaginal natural progesterone. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):525. ">da Fonseca 2003</a>). The report by <a href="./references#CD004947-bbs2-0099" title="NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. ">Northen 2007</a> reports childhood follow‐up of 348 participants in the Meis randomised trial (<a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>). </p> <p>One study (<a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>) included a mix of women with a history of prior preterm birth (n = 71) and women with a multiple pregnancy (n = 67) and the results for this study have been analysed separately for the two risk groups. </p> </section> </section> <section id="CD004947-sec-0080"> <h5 class="title">Use of progesterone in women with a short cervix identified on transvaginal ultrasound examination </h5> <section id="CD004947-sec-0081"> <h6 class="title">Description of studies</h6> <p>Four studies were included involving 1560 women who were identified with a short cervix (various definitions: less than 15 mm (<a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>); less than 30 mm (<a href="./references#CD004947-bbs2-0015" title="GrobmanW . RCT of progesterone to prevent preterm birth in nulliparous women with a short cervix. http://controlledtrials.com(accessed 2007). GrobmanW . Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S367. GrobmanWA , ThomEA , SpongCY , IamsJD , SaadeGR , MercerBM , et al. 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;207(5):390.e1‐8. ">Grobman 2012</a>); between 10 and 20mm (<a href="./references#CD004947-bbs2-0017" title="HassanSS , RomeroR , VidyadhariD , FuseyS , BaxterJK , KhandelwalM , et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(1):18‐31. ">Hassan 2011</a>); and less than 25 mm (<a href="./references#CD004947-bbs2-0032" title="RozenbergP . Efficacy of 17 alpha‐hydroxyprogesterone caproate for the prevention of preterm delivery. http://controlledtrials.com(accessed 2007). RozenbergP , ChauveaudA , DeruelleP , CapelleM , WinerN ,  DesbriereR , et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. American Journal of Obstetrics &amp; Gynecology2012;206(3):206.e1‐9. RozenbergP , DeruelleP , ChauveaudA , CapelleM , WinerN , PorcherR , et al. Prevention of preterm delivery after successful tocolysis in preterm labour by 17 alpha‐hydroxyprogesterone caproate: a randomised controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S2‐S3. ">Rozenberg 2012</a>)) at the time of transvaginal ultrasound examination. One study compared weekly intramuscular injection with placebo (<a href="./references#CD004947-bbs2-0015" title="GrobmanW . RCT of progesterone to prevent preterm birth in nulliparous women with a short cervix. http://controlledtrials.com(accessed 2007). GrobmanW . Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S367. GrobmanWA , ThomEA , SpongCY , IamsJD , SaadeGR , MercerBM , et al. 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;207(5):390.e1‐8. ">Grobman 2012</a>); one study compared twice weekly intramuscular injection with no treatment (<a href="./references#CD004947-bbs2-0032" title="RozenbergP . Efficacy of 17 alpha‐hydroxyprogesterone caproate for the prevention of preterm delivery. http://controlledtrials.com(accessed 2007). RozenbergP , ChauveaudA , DeruelleP , CapelleM , WinerN ,  DesbriereR , et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. American Journal of Obstetrics &amp; Gynecology2012;206(3):206.e1‐9. RozenbergP , DeruelleP , ChauveaudA , CapelleM , WinerN , PorcherR , et al. Prevention of preterm delivery after successful tocolysis in preterm labour by 17 alpha‐hydroxyprogesterone caproate: a randomised controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S2‐S3. ">Rozenberg 2012</a>) and two studies compared daily intravaginal progesterone with placebo (<a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>; <a href="./references#CD004947-bbs2-0017" title="HassanSS , RomeroR , VidyadhariD , FuseyS , BaxterJK , KhandelwalM , et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(1):18‐31. ">Hassan 2011</a>). Dose of progesterone administered varied from 90 mg daily in the morning (<a href="./references#CD004947-bbs2-0017" title="HassanSS , RomeroR , VidyadhariD , FuseyS , BaxterJK , KhandelwalM , et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(1):18‐31. ">Hassan 2011</a>), to 200 mg nightly (<a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>), to 250 mg weekly (<a href="./references#CD004947-bbs2-0015" title="GrobmanW . RCT of progesterone to prevent preterm birth in nulliparous women with a short cervix. http://controlledtrials.com(accessed 2007). GrobmanW . Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S367. GrobmanWA , ThomEA , SpongCY , IamsJD , SaadeGR , MercerBM , et al. 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;207(5):390.e1‐8. ">Grobman 2012</a>), to 500 mg twice weekly (<a href="./references#CD004947-bbs2-0032" title="RozenbergP . Efficacy of 17 alpha‐hydroxyprogesterone caproate for the prevention of preterm delivery. http://controlledtrials.com(accessed 2007). RozenbergP , ChauveaudA , DeruelleP , CapelleM , WinerN ,  DesbriereR , et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. American Journal of Obstetrics &amp; Gynecology2012;206(3):206.e1‐9. RozenbergP , DeruelleP , ChauveaudA , CapelleM , WinerN , PorcherR , et al. Prevention of preterm delivery after successful tocolysis in preterm labour by 17 alpha‐hydroxyprogesterone caproate: a randomised controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S2‐S3. ">Rozenberg 2012</a>). Supplementation commenced from 16 to 22 weeks' gestation in one study (<a href="./references#CD004947-bbs2-0015" title="GrobmanW . RCT of progesterone to prevent preterm birth in nulliparous women with a short cervix. http://controlledtrials.com(accessed 2007). GrobmanW . Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S367. GrobmanWA , ThomEA , SpongCY , IamsJD , SaadeGR , MercerBM , et al. 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;207(5):390.e1‐8. ">Grobman 2012</a>), from 19 to 23 weeks in another study (<a href="./references#CD004947-bbs2-0017" title="HassanSS , RomeroR , VidyadhariD , FuseyS , BaxterJK , KhandelwalM , et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(1):18‐31. ">Hassan 2011</a>), from 24 to 31 weeks in another study (<a href="./references#CD004947-bbs2-0032" title="RozenbergP . Efficacy of 17 alpha‐hydroxyprogesterone caproate for the prevention of preterm delivery. http://controlledtrials.com(accessed 2007). RozenbergP , ChauveaudA , DeruelleP , CapelleM , WinerN ,  DesbriereR , et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. American Journal of Obstetrics &amp; Gynecology2012;206(3):206.e1‐9. RozenbergP , DeruelleP , ChauveaudA , CapelleM , WinerN , PorcherR , et al. Prevention of preterm delivery after successful tocolysis in preterm labour by 17 alpha‐hydroxyprogesterone caproate: a randomised controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S2‐S3. ">Rozenberg 2012</a>), and from 24 to 33 completed weeks of gestation in another study (<a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>). </p> <p>The primary outcomes reported by the trials related to the occurrence of preterm birth prior to 33 weeks' gestation (<a href="./references#CD004947-bbs2-0017" title="HassanSS , RomeroR , VidyadhariD , FuseyS , BaxterJK , KhandelwalM , et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(1):18‐31. ">Hassan 2011</a>), 34 weeks' gestation (<a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>), 35 weeks' gestation (<a href="./references#CD004947-bbs2-0015" title="GrobmanW . RCT of progesterone to prevent preterm birth in nulliparous women with a short cervix. http://controlledtrials.com(accessed 2007). GrobmanW . Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S367. GrobmanWA , ThomEA , SpongCY , IamsJD , SaadeGR , MercerBM , et al. 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;207(5):390.e1‐8. ">Grobman 2012</a>), or 37 weeks' gestation (<a href="./references#CD004947-bbs2-0015" title="GrobmanW . RCT of progesterone to prevent preterm birth in nulliparous women with a short cervix. http://controlledtrials.com(accessed 2007). GrobmanW . Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S367. GrobmanWA , ThomEA , SpongCY , IamsJD , SaadeGR , MercerBM , et al. 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;207(5):390.e1‐8. ">Grobman 2012</a>) and time from randomisation to delivery in one study (<a href="./references#CD004947-bbs2-0032" title="RozenbergP . Efficacy of 17 alpha‐hydroxyprogesterone caproate for the prevention of preterm delivery. http://controlledtrials.com(accessed 2007). RozenbergP , ChauveaudA , DeruelleP , CapelleM , WinerN ,  DesbriereR , et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. American Journal of Obstetrics &amp; Gynecology2012;206(3):206.e1‐9. RozenbergP , DeruelleP , ChauveaudA , CapelleM , WinerN , PorcherR , et al. Prevention of preterm delivery after successful tocolysis in preterm labour by 17 alpha‐hydroxyprogesterone caproate: a randomised controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S2‐S3. ">Rozenberg 2012</a>). All trials were multicentre conducted in centres worldwide, including the United Kingdom, USA, France, Greece, Chile and Brazil. </p> <p>One study (<a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>) included a mix of singleton and twin pregnancies (226 singleton and 24 twin pregnancies), but due to the small proportion of twin pregnancies in this study, we have analysed all of this data within the short cervix subgroup. </p> </section> </section> <section id="CD004947-sec-0082"> <h5 class="title">Use of progesterone in women with a multiple pregnancy</h5> <section id="CD004947-sec-0083"> <h6 class="title">Description of studies</h6> <p>Fourteen studies were included involving 3792 women; 11 trials with a twin pregnancy (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>; <a href="./references#CD004947-bbs2-0011" title="ElsheikhahAZ , DahabS , NegmS , EbrashyA . Effect of prophylactic progesterone on incidence of preterm labour in spontaneous twin pregnancy, randomized controlled study. Ultrasound in Obstetrics and Gynecology2010;36(Suppl 1):108. ">Elsheikhah 2010</a>; <a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>; <a href="./references#CD004947-bbs2-0016" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56(6):692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen 1980</a>; <a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>; <a href="./references#CD004947-bbs2-0031" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S197. ManuckT , for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha‐hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S18. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 Alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357:454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD004947-bbs2-0034" title="SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: A randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2012</a>; <a href="./references#CD004947-bbs2-0035" title="SerraV . Natural progesterone and preterm birth in twins. http://controlledtrials.com(accessed 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>), two trials with a triplet pregnancy (<a href="./references#CD004947-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>) or one trial with any multiple pregnancy, e.g. twins, triplets or quadruplets (<a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>). Six studies compared 250 mg weekly intramuscular progesterone injections with placebo (<a href="./references#CD004947-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>; <a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>; <a href="./references#CD004947-bbs2-0016" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56(6):692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen 1980</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0031" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S197. ManuckT , for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha‐hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S18. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 Alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357:454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>); one study compared 1000 mg weekly intramuscular progesterone injections with no treatment (<a href="./references#CD004947-bbs2-0034" title="SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: A randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2012</a>); three studies compared intravaginal progesterone with placebo (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0011" title="ElsheikhahAZ , DahabS , NegmS , EbrashyA . Effect of prophylactic progesterone on incidence of preterm labour in spontaneous twin pregnancy, randomized controlled study. Ultrasound in Obstetrics and Gynecology2010;36(Suppl 1):108. ">Elsheikhah 2010</a>), one at a daily dose of 100 mg (<a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>), one at a daily dose of 200 mg (<a href="./references#CD004947-bbs2-0011" title="ElsheikhahAZ , DahabS , NegmS , EbrashyA . Effect of prophylactic progesterone on incidence of preterm labour in spontaneous twin pregnancy, randomized controlled study. Ultrasound in Obstetrics and Gynecology2010;36(Suppl 1):108. ">Elsheikhah 2010</a>) and one at a daily dose of 400 mg <a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>); one study compared 90 mg daily intravaginal gel with placebo (<a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>); and one study compared 100 mg daily oral progesterone with placebo (<a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>). One trial (<a href="./references#CD004947-bbs2-0035" title="SerraV . Natural progesterone and preterm birth in twins. http://controlledtrials.com(accessed 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>) consisted of three groups and compared 200 mg daily intravaginal progesterone with 400 mg daily intravaginal progesterone with placebo. Supplementation commenced from 16 to 20 weeks' gestation in three studies (<a href="./references#CD004947-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0031" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S197. ManuckT , for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha‐hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S18. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 Alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357:454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>), from 16 to 22 weeks in one study (<a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>), from 16 to 24 weeks in one study (<a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>), from 18 to 24 weeks in one study (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>), from 24 to 34 weeks in two studies (<a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0011" title="ElsheikhahAZ , DahabS , NegmS , EbrashyA . Effect of prophylactic progesterone on incidence of preterm labour in spontaneous twin pregnancy, randomized controlled study. Ultrasound in Obstetrics and Gynecology2010;36(Suppl 1):108. ">Elsheikhah 2010</a>), from 24 weeks' gestation in one study (<a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>), and from 28 completed weeks' of gestation in one study (<a href="./references#CD004947-bbs2-0016" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56(6):692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen 1980</a>). </p> <p>The primary outcomes reported by the trials related to the occurrence of preterm birth prior to 34 weeks' gestation (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>; <a href="./references#CD004947-bbs2-0034" title="SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: A randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2012</a>) or 37 weeks' gestation (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0035" title="SerraV . Natural progesterone and preterm birth in twins. http://controlledtrials.com(accessed 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>), delivery or fetal loss before 34 weeks' gestation (<a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>), delivery or fetal loss before 35 weeks' gestation (<a href="./references#CD004947-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>), mean cervical length and mean gestational age at delivery (<a href="./references#CD004947-bbs2-0011" title="ElsheikhahAZ , DahabS , NegmS , EbrashyA . Effect of prophylactic progesterone on incidence of preterm labour in spontaneous twin pregnancy, randomized controlled study. Ultrasound in Obstetrics and Gynecology2010;36(Suppl 1):108. ">Elsheikhah 2010</a>), perinatal death (<a href="./references#CD004947-bbs2-0016" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56(6):692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen 1980</a>) or composite neonatal morbidity (<a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>; <a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0034" title="SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: A randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2012</a>). Five trials were multicentre conducted in centres worldwide, including the United Kingdom, USA, the Netherlands, Denmark, Austria and France (<a href="./references#CD004947-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>; <a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>; <a href="./references#CD004947-bbs2-0031" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S197. ManuckT , for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha‐hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S18. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 Alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357:454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>) and four were single‐centre trials conducted in Istanbul, Egypt and Finland (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0011" title="ElsheikhahAZ , DahabS , NegmS , EbrashyA . Effect of prophylactic progesterone on incidence of preterm labour in spontaneous twin pregnancy, randomized controlled study. Ultrasound in Obstetrics and Gynecology2010;36(Suppl 1):108. ">Elsheikhah 2010</a>; <a href="./references#CD004947-bbs2-0016" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56(6):692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen 1980</a>). </p> <p>Two studies included a mix of women with multiple and singleton pregnancies (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>). One study (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>) included a mix of women with singleton pregnancies (n = 215) and women with a multiple pregnancy (n = 91) all conceived by IVF/ICSI (in vitro fertilisation/intracytoplasmic sperm injection) and the results for this study have been analysed separately for the two risk groups: women at risk of preterm birth for 'other' reasons; and women with a multiple pregnancy. One study (<a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>) included a mix of women with a history of prior preterm birth (n = 71) and women with a multiple pregnancy (n = 67) and the results for this study have been analysed separately for the two risk groups. </p> </section> </section> <section id="CD004947-sec-0084"> <h5 class="title">Use of progesterone in women following symptoms or signs of threatened preterm labour</h5> <section id="CD004947-sec-0085"> <h6 class="title">Description of studies</h6> <p>Six small studies were included involving a total of 505 women presenting with symptoms or signs of threatened preterm labour (<a href="./references#CD004947-bbs2-0003" title="BornaS , SahabiN . Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2008;48(1):58‐63. BornaS , ShakoieS , BornaH . Progesterone for maintenance tocolytic therapy after threatened preterm labor. Randomized controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:151‐2. ">Borna 2008</a>; <a href="./references#CD004947-bbs2-0004" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. BrieryCM , VeillonEW , KlauserCK , MartinRW , MagannEF , ChauhanSP , et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. American Journal of Obstetrics and Gynecology2011;204(1):54.e1‐5. ">Briery 2011</a>; <a href="./references#CD004947-bbs2-0009" title="CombsCA , GariteTJ , MaurelK , MalloryK , EdwardsRK , LuG , et al. 17‐Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double‐blind, randomized clinical trial. BMC Research Notes2011;4(1):568. ">Combs 2011a</a>; <a href="./references#CD004947-bbs2-0012" title="FacchinettiF , DanteG , VenturiniP , PaganelliS , VolpeA . 17alpha‐hydroxy‐progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery. American Journal of Perinatology2008;25(8):503‐6. FacchinettiF , PaganelliS , ComitinitG , DanteG , VolpeA . Cervical length changes during preterm cervical ripening: effects of 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2007;196:453e1‐453e4. FacchinettiF , PaganelliS , VenturiniP , DanteG . 17 alpha hydroxy‐progesterone caproate (17P) treatment reduced cervical shortening inhibiting cervical interleukin‐1 secretion. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S5. ">Facchinetti 2007</a>; <a href="./references#CD004947-bbs2-0025" title="NdoniE , BimbashiA , DokleA , KallfaE . Treatment with different types of progesterone in prevention of preterm delivery. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):305. ">Ndoni 2010</a>; <a href="./references#CD004947-bbs2-0036" title="SharamiSH , ZahiriZ , ShakibaM , MilaniF . Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: a randomized placebo‐controlled double‐blind trial. International Journal of Fertility and Sterility2010;4(2):45‐50. ">Sharami 2010</a>). Two studies compared 250 mg weekly progesterone injections with placebo (<a href="./references#CD004947-bbs2-0004" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. BrieryCM , VeillonEW , KlauserCK , MartinRW , MagannEF , ChauhanSP , et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. American Journal of Obstetrics and Gynecology2011;204(1):54.e1‐5. ">Briery 2011</a>; <a href="./references#CD004947-bbs2-0009" title="CombsCA , GariteTJ , MaurelK , MalloryK , EdwardsRK , LuG , et al. 17‐Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double‐blind, randomized clinical trial. BMC Research Notes2011;4(1):568. ">Combs 2011a</a>), one study compared vaginal progesterone pessaries on a daily basis (400 mg) with no treatment (<a href="./references#CD004947-bbs2-0003" title="BornaS , SahabiN . Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2008;48(1):58‐63. BornaS , ShakoieS , BornaH . Progesterone for maintenance tocolytic therapy after threatened preterm labor. Randomized controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:151‐2. ">Borna 2008</a>), one study compared 341 mg intramuscular progesterone injection every four days with no treatment (<a href="./references#CD004947-bbs2-0012" title="FacchinettiF , DanteG , VenturiniP , PaganelliS , VolpeA . 17alpha‐hydroxy‐progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery. American Journal of Perinatology2008;25(8):503‐6. FacchinettiF , PaganelliS , ComitinitG , DanteG , VolpeA . Cervical length changes during preterm cervical ripening: effects of 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2007;196:453e1‐453e4. FacchinettiF , PaganelliS , VenturiniP , DanteG . 17 alpha hydroxy‐progesterone caproate (17P) treatment reduced cervical shortening inhibiting cervical interleukin‐1 secretion. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S5. ">Facchinetti 2007</a>), one study had three arms and compared intramuscular progesterone with oral progesterone with placebo (<a href="./references#CD004947-bbs2-0025" title="NdoniE , BimbashiA , DokleA , KallfaE . Treatment with different types of progesterone in prevention of preterm delivery. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):305. ">Ndoni 2010</a>) and one study compared vaginal pessaries on a daily basis (200 mg) with placebo pessaries (<a href="./references#CD004947-bbs2-0036" title="SharamiSH , ZahiriZ , ShakibaM , MilaniF . Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: a randomized placebo‐controlled double‐blind trial. International Journal of Fertility and Sterility2010;4(2):45‐50. ">Sharami 2010</a>). Women presented with symptoms and signs between 24 and 34 weeks' gestation (<a href="./references#CD004947-bbs2-0003" title="BornaS , SahabiN . Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2008;48(1):58‐63. BornaS , ShakoieS , BornaH . Progesterone for maintenance tocolytic therapy after threatened preterm labor. Randomized controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:151‐2. ">Borna 2008</a>), between 25 and 33 weeks' gestation (<a href="./references#CD004947-bbs2-0012" title="FacchinettiF , DanteG , VenturiniP , PaganelliS , VolpeA . 17alpha‐hydroxy‐progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery. American Journal of Perinatology2008;25(8):503‐6. FacchinettiF , PaganelliS , ComitinitG , DanteG , VolpeA . Cervical length changes during preterm cervical ripening: effects of 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2007;196:453e1‐453e4. FacchinettiF , PaganelliS , VenturiniP , DanteG . 17 alpha hydroxy‐progesterone caproate (17P) treatment reduced cervical shortening inhibiting cervical interleukin‐1 secretion. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S5. ">Facchinetti 2007</a>), between 20 and 30 weeks' gestation (<a href="./references#CD004947-bbs2-0004" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. BrieryCM , VeillonEW , KlauserCK , MartinRW , MagannEF , ChauhanSP , et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. American Journal of Obstetrics and Gynecology2011;204(1):54.e1‐5. ">Briery 2011</a>), between 23 and 31.9 weeks' gestation (<a href="./references#CD004947-bbs2-0009" title="CombsCA , GariteTJ , MaurelK , MalloryK , EdwardsRK , LuG , et al. 17‐Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double‐blind, randomized clinical trial. BMC Research Notes2011;4(1):568. ">Combs 2011a</a>), between 15 and 22 weeks' gestation (<a href="./references#CD004947-bbs2-0025" title="NdoniE , BimbashiA , DokleA , KallfaE . Treatment with different types of progesterone in prevention of preterm delivery. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):305. ">Ndoni 2010</a>) and between 28 and 36 weeks' gestation (<a href="./references#CD004947-bbs2-0036" title="SharamiSH , ZahiriZ , ShakibaM , MilaniF . Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: a randomized placebo‐controlled double‐blind trial. International Journal of Fertility and Sterility2010;4(2):45‐50. ">Sharami 2010</a>). The primary outcomes reported included the interval from randomisation to birth in one study (<a href="./references#CD004947-bbs2-0003" title="BornaS , SahabiN . Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2008;48(1):58‐63. BornaS , ShakoieS , BornaH . Progesterone for maintenance tocolytic therapy after threatened preterm labor. Randomized controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:151‐2. ">Borna 2008</a>), transvaginal ultrasound assessment of cervical length in one study (<a href="./references#CD004947-bbs2-0012" title="FacchinettiF , DanteG , VenturiniP , PaganelliS , VolpeA . 17alpha‐hydroxy‐progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery. American Journal of Perinatology2008;25(8):503‐6. FacchinettiF , PaganelliS , ComitinitG , DanteG , VolpeA . Cervical length changes during preterm cervical ripening: effects of 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2007;196:453e1‐453e4. FacchinettiF , PaganelliS , VenturiniP , DanteG . 17 alpha hydroxy‐progesterone caproate (17P) treatment reduced cervical shortening inhibiting cervical interleukin‐1 secretion. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S5. ">Facchinetti 2007</a>), gestational age at birth in one study (<a href="./references#CD004947-bbs2-0004" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. BrieryCM , VeillonEW , KlauserCK , MartinRW , MagannEF , ChauhanSP , et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. American Journal of Obstetrics and Gynecology2011;204(1):54.e1‐5. ">Briery 2011</a>), prolongation of pregnancy and composite neonatal morbidity in one study (<a href="./references#CD004947-bbs2-0009" title="CombsCA , GariteTJ , MaurelK , MalloryK , EdwardsRK , LuG , et al. 17‐Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double‐blind, randomized clinical trial. BMC Research Notes2011;4(1):568. ">Combs 2011a</a>) and time until delivery and birth before 34 or 37 completed weeks in one study (<a href="./references#CD004947-bbs2-0036" title="SharamiSH , ZahiriZ , ShakibaM , MilaniF . Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: a randomized placebo‐controlled double‐blind trial. International Journal of Fertility and Sterility2010;4(2):45‐50. ">Sharami 2010</a>). In one study, reported only in abstract form, data relating to outcomes was not reported (<a href="./references#CD004947-bbs2-0025" title="NdoniE , BimbashiA , DokleA , KallfaE . Treatment with different types of progesterone in prevention of preterm delivery. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):305. ">Ndoni 2010</a>). One study was a multicentre study conducted in the USA (<a href="./references#CD004947-bbs2-0009" title="CombsCA , GariteTJ , MaurelK , MalloryK , EdwardsRK , LuG , et al. 17‐Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double‐blind, randomized clinical trial. BMC Research Notes2011;4(1):568. ">Combs 2011a</a>) and the remaining five studies were single‐centre studies conducted in Iran, the USA, Italy, and Albania (<a href="./references#CD004947-bbs2-0003" title="BornaS , SahabiN . Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2008;48(1):58‐63. BornaS , ShakoieS , BornaH . Progesterone for maintenance tocolytic therapy after threatened preterm labor. Randomized controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:151‐2. ">Borna 2008</a>; <a href="./references#CD004947-bbs2-0004" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. BrieryCM , VeillonEW , KlauserCK , MartinRW , MagannEF , ChauhanSP , et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. American Journal of Obstetrics and Gynecology2011;204(1):54.e1‐5. ">Briery 2011</a>; <a href="./references#CD004947-bbs2-0012" title="FacchinettiF , DanteG , VenturiniP , PaganelliS , VolpeA . 17alpha‐hydroxy‐progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery. American Journal of Perinatology2008;25(8):503‐6. FacchinettiF , PaganelliS , ComitinitG , DanteG , VolpeA . Cervical length changes during preterm cervical ripening: effects of 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2007;196:453e1‐453e4. FacchinettiF , PaganelliS , VenturiniP , DanteG . 17 alpha hydroxy‐progesterone caproate (17P) treatment reduced cervical shortening inhibiting cervical interleukin‐1 secretion. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S5. ">Facchinetti 2007</a>; <a href="./references#CD004947-bbs2-0025" title="NdoniE , BimbashiA , DokleA , KallfaE . Treatment with different types of progesterone in prevention of preterm delivery. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):305. ">Ndoni 2010</a>; <a href="./references#CD004947-bbs2-0036" title="SharamiSH , ZahiriZ , ShakibaM , MilaniF . Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: a randomized placebo‐controlled double‐blind trial. International Journal of Fertility and Sterility2010;4(2):45‐50. ">Sharami 2010</a>). </p> </section> </section> <section id="CD004947-sec-0086"> <h5 class="title">Use of progesterone in women at risk of preterm birth for 'other' reasons</h5> <section id="CD004947-sec-0087"> <h6 class="title">Description of studies</h6> <p><a href="./references#CD004947-bbs2-0028" title="Papiernik‐BerkhauerE . Double blind study of an agent to prevent preterm delivery among women at increased risk [Etude en double aveugle d'un medicament prevenant la survenue prematuree de l'accouchement chez les femmes a risque eleve d'accouchement premature]. Edition Schering Serie IV1970; Vol. 3:65‐8. ">Papiernik 1970</a> recruited 99 women from Paris, France, in a single centred trial, with a 'high preterm risk score'. Women were allocated to receive intramuscular progesterone three times per week or placebo, from 28 to 32 weeks' gestation. </p> <p><a href="./references#CD004947-bbs2-0018" title="HauthJC , GilstrapLC , BrekkenAL , HauthJM . The effect of 17 alpha‐hydroxyprogesterone caproate on pregnancy outcome in an active‐duty military population. American Journal of Obstetrics and Gynecology1983;146(2):187‐90. ">Hauth 1983</a> involved 168 women from the United States of America who were considered to be at risk of preterm birth due to active military service. Women received 1000 mg of progesterone weekly or placebo, from 16 to 20 weeks' gestation, up until 36 weeks' gestation. The primary outcome for the study related to the incidence of preterm birth at less than 37 weeks' gestation. </p> <p><a href="./references#CD004947-bbs2-0024" title="MoghtadaeiP , SardariF , LatifiM . Progesterone for prevention of preterm birth and improvement in pregnancy outcomes among primiparae of advanced maternal age. Archives of Disease in Childhood. Fetal and Neonatal Edition2008; Vol. 93, issue Suppl 1:Fa71. MoghtadeiP , SardariF , LatifiM . Progesterone for prevention of preterm birth and improvement pregnancy outcomes among primiparae of advanced maternal age. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:122. ">Moghtadaei 2008</a> involved 260 women from Iran, in a single centre trial, who were considered to be at risk of preterm birth due to advanced maternal age (greater than 35 years). Women received weekly injections of 17P (250 mg) starting at 16 to 20 weeks' gestation until 34 weeks or matching placebo. The main outcomes for the study included delivery before 37, 35 or 32 weeks' gestation, hypertension, diabetes, intrauterine growth restriction or side effects at the injection site. Data from this study could not be included in a meta‐analysis because the number of women randomised to each group was not reported in the brief abstract report of the study. </p> <p><a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a> recruited 313 women from Egypt who were considered to be at high risk of preterm birth because all the pregnancies were conceived by IVF or ICSI. Women received vaginal progesterone 200 mg twice daily from randomisation until delivery or 37 weeks’ gestation or matching placebo. The primary outcomes included preterm birth of singleton and twin pregnancies before 37 completed weeks and before 34 completed weeks. This study contains a mix of singleton pregnancies (n = 215) and twin pregnancies (n = 91) and presented some outcome data separately, as well as for the whole group.  The results for this study have been analysed separately for the two risk groups: multiple pregnancies and women at risk for 'other' reasons.  </p> </section> </section> </section> <section id="CD004947-sec-0088"> <h4 class="title">Excluded studies</h4> <p>In total, 16 studies were excluded (<a href="./references#CD004947-bbs2-0037" title="AbbottD . Relationship between cervical‐vaginal fluid elafin concentrations and subsequent cervical shortening in women at high risk of spontaneous preterm birth. Reproductive Sciences2012;19(3Suppl):73A. ">Abbott 2012</a>; <a href="./references#CD004947-bbs2-0038" title="ArikanI , BarutA , HarmaM , HarmaIM . Effect of progesterone as a tocolytic and in maintenance therapy during preterm labor. Gynecologic and Obstetric Investigation2011;72(4):269‐73. ">Arikan 2011</a>; <a href="./references#CD004947-bbs2-0039" title="BerghellaV , FigueroaD , SzychowskiJM , OwenJ , HankinsGD , IamsJD , et al. 17‐alpha‐hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. American Journal of Obstetrics and Gynecology2010;202(4):351.e1‐6. ">Berghella 2010</a>; <a href="./references#CD004947-bbs2-0040" title="BreartG , LanfranchiM , ChavignyC , Rumeau‐RouquetteC , SureauC . A comparative study of the efficiency of hydroxyprogesterone caproate and of chlormadinone acetate in the prevention of premature labor. International Journal of Gynecology &amp; Obstetrics1979;16(5):381‐4. ">Breart 1979</a>; <a href="./references#CD004947-bbs2-0041" title="BrennerWE , HendricksCH . Effect of medroxyprogesterone acetate upon the duration and characteristics of human gestation and labor. American Journal of Obstetrics and Gynecology1962;83:1094‐8. ">Brenner 1962</a>; <a href="./references#CD004947-bbs2-0042" title="ChandiramaniM . Serum progesterone concentrations in women with a previous preterm birth treated with vaginal progesterone supplementation. Reproductive Sciences2012;19(3Suppl):189A. ">Chandiramani 2012</a>; <a href="./references#CD004947-bbs2-0043" title="CorradoF , DugoC , CannataM , DiBartoloM , ScilipotiA , StellaN . A randomised trial of progesterone prophylaxis after midtrimester amniocentesis. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2002;100(2):196‐8. ">Corrado 2002</a>; <a href="./references#CD004947-bbs2-0044" title="HobelCJ , BemisRL . West Area Los Angeles prematurity prevention demonstration project. In: PapiernikE , BreartG , SpiraN editor(s). Prevention of Preterm Birth. Paris: INSERM, 1986:205‐22. HobelCJ , BragonierR , RossM , BearM , BemisR , MoriB . West Los Angeles premature prevention program: significant impact. Journal of Perinatal Medicine1987;15:112. HobelCJ , RossMG , BemisRL , BragonierJR , BearM , MoriB . West Los Angeles preterm birth prevention project (LAPPP): program impact. American Journal of Obstetrics and Gynecology1992;166:363. HobelCJ , RossMG , BemisRL , BragonierJR , NessimS , SandhuM , et al. The West Los Angeles preterm birth prevention project: I. program impact on high‐risk women. American Journal of Obstetrics and Gynecology1994;170:54‐62. ">Hobel 1986</a>; <a href="./references#CD004947-bbs2-0045" title="IonescuAC , GheorghiuD , PacuI , DavitoiuB , DimitriuM , HaradjaH . Randomized trial of cerclage and progesterone to prevent spontaneous preterm brith in high‐risk women with a short cervix. Journal of Perinatal Medicine2012;39 Suppl:Abstract no. 008. ">Ionescu 2012</a>; <a href="./references#CD004947-bbs2-0046" title="KeelerSM , KieferD , RochonM , QuinonesJN , NovetskyAP , RustO . A randomized trial of cerclage vs. 17 alpha‐hydroxyprogesterone caproate for treatment of short cervix. Journal of Perinatal Medicine2009;37(5):473‐9. ">Keeler 2009</a>; <a href="./references#CD004947-bbs2-0047" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgical Obstetrics and Gynecology1964;72:30‐6. ">Le Vine 1964</a>; <a href="./references#CD004947-bbs2-0048" title="RustO , LarkinR , RobertsW , QuinonesJ , RochonM , ReedJ , et al. A randomized trial of cerclage versus 17 hydroxyprogesterone for the treatment of short cervix. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S112. ">Rust 2006</a>; <a href="./references#CD004947-bbs2-0049" title="SuvonnakoteT . Prevention of preterm labour with progesterone. Journal of the Medical Association of Thailand1986;69(10):538‐42. ">Suvonnakote 1986</a>; <a href="./references#CD004947-bbs2-0050" title="TurnerSJ , MizockGB , FeldmanGL . Prolonged gynecologic and endocrine manifestations subsequent to administration of medroxyprogesterone acetate during pregnancy. American Journal of Obstetrics and Gynecology1966;95(2):222‐7. ">Turner 1966</a>; <a href="./references#CD004947-bbs2-0051" title="WalchK , HeflerL , NageleF . Oral dydrogesterone treatment during the first trimester of pregnancy: the prevention of miscarriage study. A double blind, prospectively randomised placebo controlled parallel group trial. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(4):265‐9. ">Walch 2005</a>; <a href="./references#CD004947-bbs2-0052" title="YeminiM , BorensteinR , DreazenE , ApelmanZ , MogilnerB , KesslerI , et al. Prevention of premature labor by 17 alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology1985;151(5):574‐7. ">Yemini 1985</a>). Three studies were excluded as they used a quasi‐randomised method of treatment allocation (<a href="./references#CD004947-bbs2-0047" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgical Obstetrics and Gynecology1964;72:30‐6. ">Le Vine 1964</a>; <a href="./references#CD004947-bbs2-0049" title="SuvonnakoteT . Prevention of preterm labour with progesterone. Journal of the Medical Association of Thailand1986;69(10):538‐42. ">Suvonnakote 1986</a>; <a href="./references#CD004947-bbs2-0052" title="YeminiM , BorensteinR , DreazenE , ApelmanZ , MogilnerB , KesslerI , et al. Prevention of premature labor by 17 alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology1985;151(5):574‐7. ">Yemini 1985</a>). One study (<a href="./references#CD004947-bbs2-0044" title="HobelCJ , BemisRL . West Area Los Angeles prematurity prevention demonstration project. In: PapiernikE , BreartG , SpiraN editor(s). Prevention of Preterm Birth. Paris: INSERM, 1986:205‐22. HobelCJ , BragonierR , RossM , BearM , BemisR , MoriB . West Los Angeles premature prevention program: significant impact. Journal of Perinatal Medicine1987;15:112. HobelCJ , RossMG , BemisRL , BragonierJR , BearM , MoriB . West Los Angeles preterm birth prevention project (LAPPP): program impact. American Journal of Obstetrics and Gynecology1992;166:363. HobelCJ , RossMG , BemisRL , BragonierJR , NessimS , SandhuM , et al. The West Los Angeles preterm birth prevention project: I. program impact on high‐risk women. American Journal of Obstetrics and Gynecology1994;170:54‐62. ">Hobel 1986</a>) compared an oral progestogen with placebo, but presented outcomes only as percentages. Five studies were excluded as progesterone was administered in the first trimester to prevent miscarriage (<a href="./references#CD004947-bbs2-0040" title="BreartG , LanfranchiM , ChavignyC , Rumeau‐RouquetteC , SureauC . A comparative study of the efficiency of hydroxyprogesterone caproate and of chlormadinone acetate in the prevention of premature labor. International Journal of Gynecology &amp; Obstetrics1979;16(5):381‐4. ">Breart 1979</a>; <a href="./references#CD004947-bbs2-0041" title="BrennerWE , HendricksCH . Effect of medroxyprogesterone acetate upon the duration and characteristics of human gestation and labor. American Journal of Obstetrics and Gynecology1962;83:1094‐8. ">Brenner 1962</a>; <a href="./references#CD004947-bbs2-0043" title="CorradoF , DugoC , CannataM , DiBartoloM , ScilipotiA , StellaN . A randomised trial of progesterone prophylaxis after midtrimester amniocentesis. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2002;100(2):196‐8. ">Corrado 2002</a>; <a href="./references#CD004947-bbs2-0050" title="TurnerSJ , MizockGB , FeldmanGL . Prolonged gynecologic and endocrine manifestations subsequent to administration of medroxyprogesterone acetate during pregnancy. American Journal of Obstetrics and Gynecology1966;95(2):222‐7. ">Turner 1966</a>; <a href="./references#CD004947-bbs2-0051" title="WalchK , HeflerL , NageleF . Oral dydrogesterone treatment during the first trimester of pregnancy: the prevention of miscarriage study. A double blind, prospectively randomised placebo controlled parallel group trial. Journal of Maternal‐Fetal and Neonatal Medicine2005;18(4):265‐9. ">Walch 2005</a>), and are covered by the Cochrane review relating to the use of progesterone for prevention of miscarriage (<a href="./references#CD004947-bbs2-0082" title="HaasDM , RamseyPS . Progestogen for preventing miscarriage. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.CD003511.pub2] ">Haas 2008</a>). One study was excluded because progesterone was administered as an acute tocolytic medication (<a href="./references#CD004947-bbs2-0038" title="ArikanI , BarutA , HarmaM , HarmaIM . Effect of progesterone as a tocolytic and in maintenance therapy during preterm labor. Gynecologic and Obstetric Investigation2011;72(4):269‐73. ">Arikan 2011</a>). A further six studies were excluded because they compared progesterone with cerclage (<a href="./references#CD004947-bbs2-0037" title="AbbottD . Relationship between cervical‐vaginal fluid elafin concentrations and subsequent cervical shortening in women at high risk of spontaneous preterm birth. Reproductive Sciences2012;19(3Suppl):73A. ">Abbott 2012</a>; <a href="./references#CD004947-bbs2-0042" title="ChandiramaniM . Serum progesterone concentrations in women with a previous preterm birth treated with vaginal progesterone supplementation. Reproductive Sciences2012;19(3Suppl):189A. ">Chandiramani 2012</a>; <a href="./references#CD004947-bbs2-0045" title="IonescuAC , GheorghiuD , PacuI , DavitoiuB , DimitriuM , HaradjaH . Randomized trial of cerclage and progesterone to prevent spontaneous preterm brith in high‐risk women with a short cervix. Journal of Perinatal Medicine2012;39 Suppl:Abstract no. 008. ">Ionescu 2012</a>; <a href="./references#CD004947-bbs2-0046" title="KeelerSM , KieferD , RochonM , QuinonesJN , NovetskyAP , RustO . A randomized trial of cerclage vs. 17 alpha‐hydroxyprogesterone caproate for treatment of short cervix. Journal of Perinatal Medicine2009;37(5):473‐9. ">Keeler 2009</a>; <a href="./references#CD004947-bbs2-0048" title="RustO , LarkinR , RobertsW , QuinonesJ , RochonM , ReedJ , et al. A randomized trial of cerclage versus 17 hydroxyprogesterone for the treatment of short cervix. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S112. ">Rust 2006</a>) or compared cerclage with no cerclage (<a href="./references#CD004947-bbs2-0039" title="BerghellaV , FigueroaD , SzychowskiJM , OwenJ , HankinsGD , IamsJD , et al. 17‐alpha‐hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. American Journal of Obstetrics and Gynecology2010;202(4):351.e1‐6. ">Berghella 2010</a>), and are covered by other Cochrane reviews (<a href="./references#CD004947-bbs2-0067" title="AlfirevicZ , StampalijaT , RobertsD , JorgensenAL . Cervical stitch (cerclage) for preventing preterm birth in singleton pregnancy. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD008991.pub2] ">Alfirevic 2012</a>; <a href="./references#CD004947-bbs2-0104" title="RafaelTJ , BerghellaV , AlfirevicZ . Cervical stitch (cerclage) for preventing preterm birth in multiple pregnancy. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD009166] ">Rafael 2011</a>). </p> <p>Refer to table <a href="./references#CD004947-sec-0175" title="">Characteristics of excluded studies</a> for further details. </p> <section id="CD004947-sec-0089"> <h5 class="title">Studies awaiting assessment</h5> <p>There are 11 ongoing studies awaiting assessment (<a href="./references#CD004947-bbs2-0053" title="CoomarasamyA . First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double‐blind placebo‐controlled multi‐centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). http://www.controlled‐trials.com/ISRCTN92644181/ISRCTN92644181 (accessed 11.01.2012). ">Coomarasamy 2012</a>; <a href="./references#CD004947-bbs2-0054" title="CreasyGW . The effect of vaginal progesterone administration in the prevention of preterm birth in women with a short cervix. ClinicalTrials.gov (http://clinicaltrials.gov/)(accessed 2008). ">Creasy 2008</a>; <a href="./references#CD004947-bbs2-0055" title="ArmsonBA , DoddJ , for the POPPI Collaborative Trial Group. POPPI: prevention of problems of preterm birth with progesterone in women at increased risk: a multicentre randomised controlled trial [abstract]. Journal of Paediatrics and Child Health2007;43:A29. AshwoodP . Progesterone after previous preterm birth for the prevention of neonatal respiratory distress syndrome. WOMBAT Collaboration (www.wombatcollaboration.net/trials) (accessed 4 October 2006). CrowtherCA , DoddJM , McPheeAJ , FlenadyV . Australasian Collaborative Trial of Vaginal Progesterone Therapy (The PROGRESS Trial). http://controlledtrials.com(accessed 2007). DoddJM , CrowtherCA , McPheeAJ , FlenadyV , RobinsonJS . Progesterone after previous preterm birth for prevention of neonatal respiratory distress syndrome (PROGRESS): a randomised controlled trial. BMC Pregnancy and Childbirth2009;9:6. ">Crowther 2007</a>; <a href="./references#CD004947-bbs2-0056" title="Matrinez de TajadaB . Vaginal progesterone to prevent preterm delivery in women with preterm labor. http://controlledtrials.com(accessed 2007). ">Martinez 2007</a>; <a href="./references#CD004947-bbs2-0057" title="NassarA . Prevention of preterm delivery in twin pregnancies by 17 alpha hydroxyprogesterone caproate. http://controlledtrials.com(accessed 2007). NassarA , AwwadJ , SuccarJ , SaassouhW , KhalifeT , HayekS , et al. Incidence of GDM in twin pregnancies of women receiving prophylactic 17‐A OH progesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):307‐8. ">Nassar 2007</a>; <a href="./references#CD004947-bbs2-0058" title="NormanJE , ShennanA , BennettP , ThorntonS , RobsonS , MarlowN , et al. Trial protocol OPPTIMUM‐ Does progesterone prophylaxis for the prevention of preterm labour improve outcome?. BMC pregnancy and childbirth2012;12(1):79. [PUBMED: 22866909] ">Norman 2012</a>; <a href="./references#CD004947-bbs2-0059" title="PerlitzY . Prevention of recurrent preterm delivery by a natural progesterone agent. http://controlledtrials.com(accessed 2007). ">Perlitz 2007</a>; <a href="./references#CD004947-bbs2-0060" title="StarkeyM . Comparing IM vs. vaginal progesterone for pre‐term birth. ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 20 April 2008). ">Starkey 2008</a>; <a href="./references#CD004947-bbs2-0061" title="SwabyC . Pilot randomized controlled trial of vaginal progesterone to prevent preterm birth in multiple pregnancy. JOGC: Journal of Obstetrics and Gynaecology Canada2007; Vol. 29, issue 6 Suppl 1:S47. ">Swaby 2007</a>; <a href="./references#CD004947-bbs2-0062" title="vanOsMA , van derVenJA , KleinrouwelerCE , PajkrtE , deMirandaE , vanWassenaerA , et al. Preventing preterm birth with progesterone: Costs and effects of screening low risk women with a singleton pregnancy for short cervical length, the Triple P study. BMC Pregnancy and Childbirth2011;11:77. ">van Os 2011</a>; <a href="./references#CD004947-bbs2-0063" title="WoodS . Vaginal progesterone versus placebo in multiple pregnancy. http://controlledtrials.com(accessed 2007). ">Wood 2007</a>). </p> </section> </section> </section> <section id="CD004947-sec-0090"> <h3 class="title">Risk of bias in included studies</h3> <p>The overall quality of the included trials varied from good to fair. Refer to table <a href="./references#CD004947-sec-0174" title="">Characteristics of included studies</a> for further details and to <a href="#CD004947-fig-0001">Figure 1</a>; <a href="#CD004947-fig-0002">Figure 2</a>, for a summary of 'Risk of bias' assessments. </p> <div class="figure" id="CD004947-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004947-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD004947-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004947-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD004947-sec-0091"> <h4 class="title">Allocation</h4> <p>While all trials were stated to be randomised and placebo controlled, the method of randomisation was only described in 23 trials (<a href="./references#CD004947-bbs2-0003" title="BornaS , SahabiN . Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2008;48(1):58‐63. BornaS , ShakoieS , BornaH . Progesterone for maintenance tocolytic therapy after threatened preterm labor. Randomized controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:151‐2. ">Borna 2008</a>; <a href="./references#CD004947-bbs2-0004" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. BrieryCM , VeillonEW , KlauserCK , MartinRW , MagannEF , ChauhanSP , et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. American Journal of Obstetrics and Gynecology2011;204(1):54.e1‐5. ">Briery 2011</a>; <a href="./references#CD004947-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>; <a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>; <a href="./references#CD004947-bbs2-0009" title="CombsCA , GariteTJ , MaurelK , MalloryK , EdwardsRK , LuG , et al. 17‐Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double‐blind, randomized clinical trial. BMC Research Notes2011;4(1):568. ">Combs 2011a</a>; <a href="./references#CD004947-bbs2-0010" title="daFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics &amp; Gynecology2003;188(2):419‐24. daFonsecaEB , BittarRE , CarvalhoMHB , MartinelliS , ZugaibM . Uterine contraction monitoring in pregnant women using vaginal natural progesterone. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):525. ">da Fonseca 2003</a>; <a href="./references#CD004947-bbs2-0012" title="FacchinettiF , DanteG , VenturiniP , PaganelliS , VolpeA . 17alpha‐hydroxy‐progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery. American Journal of Perinatology2008;25(8):503‐6. FacchinettiF , PaganelliS , ComitinitG , DanteG , VolpeA . Cervical length changes during preterm cervical ripening: effects of 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2007;196:453e1‐453e4. FacchinettiF , PaganelliS , VenturiniP , DanteG . 17 alpha hydroxy‐progesterone caproate (17P) treatment reduced cervical shortening inhibiting cervical interleukin‐1 secretion. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S5. ">Facchinetti 2007</a>; <a href="./references#CD004947-bbs2-0014" title="GloverM , CroomCS , SonekJD , KovacC , McKennaD . A randomized placebo controlled trial of oral micronized progesterone to prevent recurrent preterm birth. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S172. GloverMM , McKennaDS , DowningCM , SmithDB , CroomCS , SonekJD . A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. American Journal of Perinatology2011;28(5):377‐81. ">Glover 2011</a>; <a href="./references#CD004947-bbs2-0015" title="GrobmanW . RCT of progesterone to prevent preterm birth in nulliparous women with a short cervix. http://controlledtrials.com(accessed 2007). GrobmanW . Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S367. GrobmanWA , ThomEA , SpongCY , IamsJD , SaadeGR , MercerBM , et al. 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;207(5):390.e1‐8. ">Grobman 2012</a>; <a href="./references#CD004947-bbs2-0017" title="HassanSS , RomeroR , VidyadhariD , FuseyS , BaxterJK , KhandelwalM , et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(1):18‐31. ">Hassan 2011</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0022" title="MajhiP , BaggaR , KalraJ , SharmaM . Intravaginal use of natural micronised progesterone to prevent pre‐term birth: a randomised trial in India. Journal of Obstetrics and Gynaecology2009;29(6):493‐8. ">Majhi 2009</a>; <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>; <a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>; <a href="./references#CD004947-bbs2-0029" title="RaiP , RajaramS , GoelN , Ayalur GopalakrishnanR , AgarwalR , MehtaS . Oral micronized progesterone for prevention of preterm birth. International Journal of Gynecology &amp; Obstetrics2009;104(1):40‐3. ">Rai 2009</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>; <a href="./references#CD004947-bbs2-0031" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S197. ManuckT , for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha‐hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S18. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 Alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357:454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD004947-bbs2-0032" title="RozenbergP . Efficacy of 17 alpha‐hydroxyprogesterone caproate for the prevention of preterm delivery. http://controlledtrials.com(accessed 2007). RozenbergP , ChauveaudA , DeruelleP , CapelleM , WinerN ,  DesbriereR , et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. American Journal of Obstetrics &amp; Gynecology2012;206(3):206.e1‐9. RozenbergP , DeruelleP , ChauveaudA , CapelleM , WinerN , PorcherR , et al. Prevention of preterm delivery after successful tocolysis in preterm labour by 17 alpha‐hydroxyprogesterone caproate: a randomised controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S2‐S3. ">Rozenberg 2012</a>; <a href="./references#CD004947-bbs2-0034" title="SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: A randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2012</a>; <a href="./references#CD004947-bbs2-0035" title="SerraV . Natural progesterone and preterm birth in twins. http://controlledtrials.com(accessed 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>). Allocation concealment was assessed as low risk of bias in 23 trials (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD004947-bbs2-0004" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. BrieryCM , VeillonEW , KlauserCK , MartinRW , MagannEF , ChauhanSP , et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. American Journal of Obstetrics and Gynecology2011;204(1):54.e1‐5. ">Briery 2011</a>; <a href="./references#CD004947-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>; <a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>; <a href="./references#CD004947-bbs2-0009" title="CombsCA , GariteTJ , MaurelK , MalloryK , EdwardsRK , LuG , et al. 17‐Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double‐blind, randomized clinical trial. BMC Research Notes2011;4(1):568. ">Combs 2011a</a>; <a href="./references#CD004947-bbs2-0010" title="daFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics &amp; Gynecology2003;188(2):419‐24. daFonsecaEB , BittarRE , CarvalhoMHB , MartinelliS , ZugaibM . Uterine contraction monitoring in pregnant women using vaginal natural progesterone. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):525. ">da Fonseca 2003</a>; <a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>; <a href="./references#CD004947-bbs2-0014" title="GloverM , CroomCS , SonekJD , KovacC , McKennaD . A randomized placebo controlled trial of oral micronized progesterone to prevent recurrent preterm birth. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S172. GloverMM , McKennaDS , DowningCM , SmithDB , CroomCS , SonekJD . A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. American Journal of Perinatology2011;28(5):377‐81. ">Glover 2011</a>; <a href="./references#CD004947-bbs2-0015" title="GrobmanW . RCT of progesterone to prevent preterm birth in nulliparous women with a short cervix. http://controlledtrials.com(accessed 2007). GrobmanW . Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S367. GrobmanWA , ThomEA , SpongCY , IamsJD , SaadeGR , MercerBM , et al. 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;207(5):390.e1‐8. ">Grobman 2012</a>; <a href="./references#CD004947-bbs2-0017" title="HassanSS , RomeroR , VidyadhariD , FuseyS , BaxterJK , KhandelwalM , et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(1):18‐31. ">Hassan 2011</a>; <a href="./references#CD004947-bbs2-0020" title="JohnsonJWC , AustinKL , JonesGS , DavisGH , KingTM . Efficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine1975;293(14):675‐80. KlebanoffM , for the NICHD MFMU Network. Impact of 17alpha hydroxyprogesterone caproate administration on salivary progesterone and estriol [abstract]. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S140. ">Johnson 1975</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0022" title="MajhiP , BaggaR , KalraJ , SharmaM . Intravaginal use of natural micronised progesterone to prevent pre‐term birth: a randomised trial in India. Journal of Obstetrics and Gynaecology2009;29(6):493‐8. ">Majhi 2009</a>; <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>; <a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>; <a href="./references#CD004947-bbs2-0029" title="RaiP , RajaramS , GoelN , Ayalur GopalakrishnanR , AgarwalR , MehtaS . Oral micronized progesterone for prevention of preterm birth. International Journal of Gynecology &amp; Obstetrics2009;104(1):40‐3. ">Rai 2009</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>; <a href="./references#CD004947-bbs2-0031" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S197. ManuckT , for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha‐hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S18. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 Alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357:454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD004947-bbs2-0034" title="SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: A randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2012</a>; <a href="./references#CD004947-bbs2-0035" title="SerraV . Natural progesterone and preterm birth in twins. http://controlledtrials.com(accessed 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>); and unclear in 13 trials (<a href="./references#CD004947-bbs2-0002" title="AkbariS , BirjandiM , MohtashamN . Evaluation of the effect of progesterone on prevention of preterm delivery and its complications. Scientific Journal of Kurdistan University of Medical Sciences2009;14(3):11‐9. ">Akbari 2009</a>; <a href="./references#CD004947-bbs2-0003" title="BornaS , SahabiN . Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2008;48(1):58‐63. BornaS , ShakoieS , BornaH . Progesterone for maintenance tocolytic therapy after threatened preterm labor. Randomized controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:151‐2. ">Borna 2008</a>; <a href="./references#CD004947-bbs2-0011" title="ElsheikhahAZ , DahabS , NegmS , EbrashyA . Effect of prophylactic progesterone on incidence of preterm labour in spontaneous twin pregnancy, randomized controlled study. Ultrasound in Obstetrics and Gynecology2010;36(Suppl 1):108. ">Elsheikhah 2010</a>; <a href="./references#CD004947-bbs2-0012" title="FacchinettiF , DanteG , VenturiniP , PaganelliS , VolpeA . 17alpha‐hydroxy‐progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery. American Journal of Perinatology2008;25(8):503‐6. FacchinettiF , PaganelliS , ComitinitG , DanteG , VolpeA . Cervical length changes during preterm cervical ripening: effects of 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2007;196:453e1‐453e4. FacchinettiF , PaganelliS , VenturiniP , DanteG . 17 alpha hydroxy‐progesterone caproate (17P) treatment reduced cervical shortening inhibiting cervical interleukin‐1 secretion. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S5. ">Facchinetti 2007</a>; <a href="./references#CD004947-bbs2-0016" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56(6):692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen 1980</a>; <a href="./references#CD004947-bbs2-0018" title="HauthJC , GilstrapLC , BrekkenAL , HauthJM . The effect of 17 alpha‐hydroxyprogesterone caproate on pregnancy outcome in an active‐duty military population. American Journal of Obstetrics and Gynecology1983;146(2):187‐90. ">Hauth 1983</a>; <a href="./references#CD004947-bbs2-0019" title="IbrahimM , Mohamed RamyAR , YounisMA‐F . Progesterone supplementation for prevention of preterm labor: a randomized controlled trial. Middle East Fertility Society Journal2010;15(1):39‐41. ">Ibrahim 2010</a>; <a href="./references#CD004947-bbs2-0024" title="MoghtadaeiP , SardariF , LatifiM . Progesterone for prevention of preterm birth and improvement in pregnancy outcomes among primiparae of advanced maternal age. Archives of Disease in Childhood. Fetal and Neonatal Edition2008; Vol. 93, issue Suppl 1:Fa71. MoghtadeiP , SardariF , LatifiM . Progesterone for prevention of preterm birth and improvement pregnancy outcomes among primiparae of advanced maternal age. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:122. ">Moghtadaei 2008</a>; <a href="./references#CD004947-bbs2-0025" title="NdoniE , BimbashiA , DokleA , KallfaE . Treatment with different types of progesterone in prevention of preterm delivery. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):305. ">Ndoni 2010</a>; <a href="./references#CD004947-bbs2-0028" title="Papiernik‐BerkhauerE . Double blind study of an agent to prevent preterm delivery among women at increased risk [Etude en double aveugle d'un medicament prevenant la survenue prematuree de l'accouchement chez les femmes a risque eleve d'accouchement premature]. Edition Schering Serie IV1970; Vol. 3:65‐8. ">Papiernik 1970</a>; <a href="./references#CD004947-bbs2-0032" title="RozenbergP . Efficacy of 17 alpha‐hydroxyprogesterone caproate for the prevention of preterm delivery. http://controlledtrials.com(accessed 2007). RozenbergP , ChauveaudA , DeruelleP , CapelleM , WinerN ,  DesbriereR , et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. American Journal of Obstetrics &amp; Gynecology2012;206(3):206.e1‐9. RozenbergP , DeruelleP , ChauveaudA , CapelleM , WinerN , PorcherR , et al. Prevention of preterm delivery after successful tocolysis in preterm labour by 17 alpha‐hydroxyprogesterone caproate: a randomised controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S2‐S3. ">Rozenberg 2012</a>; <a href="./references#CD004947-bbs2-0033" title="SaghafiN , KhademN , MohajeriT , ShakeriMT . Efficacy of 17alpha‐hydroxyprogesterone caproate in prevention of preterm delivery. Journal of Obstetrics and Gynaecology Research2011;37(10):1342‐5. SaghafiN , KhademN , MohajeriT , ShakeriMT , AminiM . Efficacy of 17alpha‐hydroxyprogesterone caproate in preterm delivery prevention. Iranian Journal of Obstetrics, Gynecology and Infertility2011;14(2):28‐33. ">Saghafi 2011a</a>; <a href="./references#CD004947-bbs2-0036" title="SharamiSH , ZahiriZ , ShakibaM , MilaniF . Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: a randomized placebo‐controlled double‐blind trial. International Journal of Fertility and Sterility2010;4(2):45‐50. ">Sharami 2010</a>). </p> </section> <section id="CD004947-sec-0092"> <h4 class="title">Blinding</h4> <p>Twenty‐five of the 32 included trials were placebo controlled, with blinding of caregivers and participants (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD004947-bbs2-0004" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. BrieryCM , VeillonEW , KlauserCK , MartinRW , MagannEF , ChauhanSP , et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. American Journal of Obstetrics and Gynecology2011;204(1):54.e1‐5. ">Briery 2011</a>; <a href="./references#CD004947-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>; <a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>; <a href="./references#CD004947-bbs2-0009" title="CombsCA , GariteTJ , MaurelK , MalloryK , EdwardsRK , LuG , et al. 17‐Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double‐blind, randomized clinical trial. BMC Research Notes2011;4(1):568. ">Combs 2011a</a>; <a href="./references#CD004947-bbs2-0010" title="daFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics &amp; Gynecology2003;188(2):419‐24. daFonsecaEB , BittarRE , CarvalhoMHB , MartinelliS , ZugaibM . Uterine contraction monitoring in pregnant women using vaginal natural progesterone. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):525. ">da Fonseca 2003</a>; <a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>; <a href="./references#CD004947-bbs2-0014" title="GloverM , CroomCS , SonekJD , KovacC , McKennaD . A randomized placebo controlled trial of oral micronized progesterone to prevent recurrent preterm birth. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S172. GloverMM , McKennaDS , DowningCM , SmithDB , CroomCS , SonekJD . A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. American Journal of Perinatology2011;28(5):377‐81. ">Glover 2011</a>; <a href="./references#CD004947-bbs2-0015" title="GrobmanW . RCT of progesterone to prevent preterm birth in nulliparous women with a short cervix. http://controlledtrials.com(accessed 2007). GrobmanW . Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S367. GrobmanWA , ThomEA , SpongCY , IamsJD , SaadeGR , MercerBM , et al. 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;207(5):390.e1‐8. ">Grobman 2012</a>; <a href="./references#CD004947-bbs2-0016" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56(6):692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen 1980</a>; <a href="./references#CD004947-bbs2-0017" title="HassanSS , RomeroR , VidyadhariD , FuseyS , BaxterJK , KhandelwalM , et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(1):18‐31. ">Hassan 2011</a>; <a href="./references#CD004947-bbs2-0018" title="HauthJC , GilstrapLC , BrekkenAL , HauthJM . The effect of 17 alpha‐hydroxyprogesterone caproate on pregnancy outcome in an active‐duty military population. American Journal of Obstetrics and Gynecology1983;146(2):187‐90. ">Hauth 1983</a>; <a href="./references#CD004947-bbs2-0020" title="JohnsonJWC , AustinKL , JonesGS , DavisGH , KingTM . Efficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine1975;293(14):675‐80. KlebanoffM , for the NICHD MFMU Network. Impact of 17alpha hydroxyprogesterone caproate administration on salivary progesterone and estriol [abstract]. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S140. ">Johnson 1975</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>; <a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>; <a href="./references#CD004947-bbs2-0028" title="Papiernik‐BerkhauerE . Double blind study of an agent to prevent preterm delivery among women at increased risk [Etude en double aveugle d'un medicament prevenant la survenue prematuree de l'accouchement chez les femmes a risque eleve d'accouchement premature]. Edition Schering Serie IV1970; Vol. 3:65‐8. ">Papiernik 1970</a>; <a href="./references#CD004947-bbs2-0029" title="RaiP , RajaramS , GoelN , Ayalur GopalakrishnanR , AgarwalR , MehtaS . Oral micronized progesterone for prevention of preterm birth. International Journal of Gynecology &amp; Obstetrics2009;104(1):40‐3. ">Rai 2009</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>; <a href="./references#CD004947-bbs2-0031" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S197. ManuckT , for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha‐hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S18. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 Alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357:454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD004947-bbs2-0035" title="SerraV . Natural progesterone and preterm birth in twins. http://controlledtrials.com(accessed 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>; <a href="./references#CD004947-bbs2-0036" title="SharamiSH , ZahiriZ , ShakibaM , MilaniF . Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: a randomized placebo‐controlled double‐blind trial. International Journal of Fertility and Sterility2010;4(2):45‐50. ">Sharami 2010</a>). </p> <p>Blinding of outcome assessment was evident in 15 of the trials (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>; <a href="./references#CD004947-bbs2-0010" title="daFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics &amp; Gynecology2003;188(2):419‐24. daFonsecaEB , BittarRE , CarvalhoMHB , MartinelliS , ZugaibM . Uterine contraction monitoring in pregnant women using vaginal natural progesterone. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):525. ">da Fonseca 2003</a>; <a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>; <a href="./references#CD004947-bbs2-0015" title="GrobmanW . RCT of progesterone to prevent preterm birth in nulliparous women with a short cervix. http://controlledtrials.com(accessed 2007). GrobmanW . Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S367. GrobmanWA , ThomEA , SpongCY , IamsJD , SaadeGR , MercerBM , et al. 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;207(5):390.e1‐8. ">Grobman 2012</a>; <a href="./references#CD004947-bbs2-0016" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56(6):692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen 1980</a>; <a href="./references#CD004947-bbs2-0018" title="HauthJC , GilstrapLC , BrekkenAL , HauthJM . The effect of 17 alpha‐hydroxyprogesterone caproate on pregnancy outcome in an active‐duty military population. American Journal of Obstetrics and Gynecology1983;146(2):187‐90. ">Hauth 1983</a>; <a href="./references#CD004947-bbs2-0020" title="JohnsonJWC , AustinKL , JonesGS , DavisGH , KingTM . Efficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine1975;293(14):675‐80. KlebanoffM , for the NICHD MFMU Network. Impact of 17alpha hydroxyprogesterone caproate administration on salivary progesterone and estriol [abstract]. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S140. ">Johnson 1975</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>; <a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>; <a href="./references#CD004947-bbs2-0028" title="Papiernik‐BerkhauerE . Double blind study of an agent to prevent preterm delivery among women at increased risk [Etude en double aveugle d'un medicament prevenant la survenue prematuree de l'accouchement chez les femmes a risque eleve d'accouchement premature]. Edition Schering Serie IV1970; Vol. 3:65‐8. ">Papiernik 1970</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>; <a href="./references#CD004947-bbs2-0031" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S197. ManuckT , for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha‐hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S18. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 Alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357:454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD004947-bbs2-0035" title="SerraV . Natural progesterone and preterm birth in twins. http://controlledtrials.com(accessed 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>). </p> <p>Four trials were assessed as high risk of bias for both blinding of caregivers and participants and outcome assessment as no blinding was attempted (<a href="./references#CD004947-bbs2-0003" title="BornaS , SahabiN . Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2008;48(1):58‐63. BornaS , ShakoieS , BornaH . Progesterone for maintenance tocolytic therapy after threatened preterm labor. Randomized controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:151‐2. ">Borna 2008</a>; <a href="./references#CD004947-bbs2-0012" title="FacchinettiF , DanteG , VenturiniP , PaganelliS , VolpeA . 17alpha‐hydroxy‐progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery. American Journal of Perinatology2008;25(8):503‐6. FacchinettiF , PaganelliS , ComitinitG , DanteG , VolpeA . Cervical length changes during preterm cervical ripening: effects of 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2007;196:453e1‐453e4. FacchinettiF , PaganelliS , VenturiniP , DanteG . 17 alpha hydroxy‐progesterone caproate (17P) treatment reduced cervical shortening inhibiting cervical interleukin‐1 secretion. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S5. ">Facchinetti 2007</a>; <a href="./references#CD004947-bbs2-0032" title="RozenbergP . Efficacy of 17 alpha‐hydroxyprogesterone caproate for the prevention of preterm delivery. http://controlledtrials.com(accessed 2007). RozenbergP , ChauveaudA , DeruelleP , CapelleM , WinerN ,  DesbriereR , et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. American Journal of Obstetrics &amp; Gynecology2012;206(3):206.e1‐9. RozenbergP , DeruelleP , ChauveaudA , CapelleM , WinerN , PorcherR , et al. Prevention of preterm delivery after successful tocolysis in preterm labour by 17 alpha‐hydroxyprogesterone caproate: a randomised controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S2‐S3. ">Rozenberg 2012</a>; <a href="./references#CD004947-bbs2-0034" title="SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: A randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2012</a>). </p> </section> <section id="CD004947-sec-0093"> <h4 class="title">Incomplete outcome data</h4> <p>Thirty‐one studies were assessed as being at low risk of bias for attrition bias. Thirteen studies reported no losses to follow‐up (<a href="./references#CD004947-bbs2-0003" title="BornaS , SahabiN . Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2008;48(1):58‐63. BornaS , ShakoieS , BornaH . Progesterone for maintenance tocolytic therapy after threatened preterm labor. Randomized controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:151‐2. ">Borna 2008</a>; <a href="./references#CD004947-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>; <a href="./references#CD004947-bbs2-0009" title="CombsCA , GariteTJ , MaurelK , MalloryK , EdwardsRK , LuG , et al. 17‐Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double‐blind, randomized clinical trial. BMC Research Notes2011;4(1):568. ">Combs 2011a</a>; <a href="./references#CD004947-bbs2-0012" title="FacchinettiF , DanteG , VenturiniP , PaganelliS , VolpeA . 17alpha‐hydroxy‐progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery. American Journal of Perinatology2008;25(8):503‐6. FacchinettiF , PaganelliS , ComitinitG , DanteG , VolpeA . Cervical length changes during preterm cervical ripening: effects of 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2007;196:453e1‐453e4. FacchinettiF , PaganelliS , VenturiniP , DanteG . 17 alpha hydroxy‐progesterone caproate (17P) treatment reduced cervical shortening inhibiting cervical interleukin‐1 secretion. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S5. ">Facchinetti 2007</a>; <a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>; <a href="./references#CD004947-bbs2-0016" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56(6):692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen 1980</a>; <a href="./references#CD004947-bbs2-0018" title="HauthJC , GilstrapLC , BrekkenAL , HauthJM . The effect of 17 alpha‐hydroxyprogesterone caproate on pregnancy outcome in an active‐duty military population. American Journal of Obstetrics and Gynecology1983;146(2):187‐90. ">Hauth 1983</a>; <a href="./references#CD004947-bbs2-0019" title="IbrahimM , Mohamed RamyAR , YounisMA‐F . Progesterone supplementation for prevention of preterm labor: a randomized controlled trial. Middle East Fertility Society Journal2010;15(1):39‐41. ">Ibrahim 2010</a>; <a href="./references#CD004947-bbs2-0022" title="MajhiP , BaggaR , KalraJ , SharmaM . Intravaginal use of natural micronised progesterone to prevent pre‐term birth: a randomised trial in India. Journal of Obstetrics and Gynaecology2009;29(6):493‐8. ">Majhi 2009</a>; <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>; <a href="./references#CD004947-bbs2-0028" title="Papiernik‐BerkhauerE . Double blind study of an agent to prevent preterm delivery among women at increased risk [Etude en double aveugle d'un medicament prevenant la survenue prematuree de l'accouchement chez les femmes a risque eleve d'accouchement premature]. Edition Schering Serie IV1970; Vol. 3:65‐8. ">Papiernik 1970</a>; <a href="./references#CD004947-bbs2-0033" title="SaghafiN , KhademN , MohajeriT , ShakeriMT . Efficacy of 17alpha‐hydroxyprogesterone caproate in prevention of preterm delivery. Journal of Obstetrics and Gynaecology Research2011;37(10):1342‐5. SaghafiN , KhademN , MohajeriT , ShakeriMT , AminiM . Efficacy of 17alpha‐hydroxyprogesterone caproate in preterm delivery prevention. Iranian Journal of Obstetrics, Gynecology and Infertility2011;14(2):28‐33. ">Saghafi 2011a</a>) and 18 studies reported less than 20% loss to follow‐up (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD004947-bbs2-0004" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. BrieryCM , VeillonEW , KlauserCK , MartinRW , MagannEF , ChauhanSP , et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. American Journal of Obstetrics and Gynecology2011;204(1):54.e1‐5. ">Briery 2011</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>; <a href="./references#CD004947-bbs2-0010" title="daFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics &amp; Gynecology2003;188(2):419‐24. daFonsecaEB , BittarRE , CarvalhoMHB , MartinelliS , ZugaibM . Uterine contraction monitoring in pregnant women using vaginal natural progesterone. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):525. ">da Fonseca 2003</a>; <a href="./references#CD004947-bbs2-0014" title="GloverM , CroomCS , SonekJD , KovacC , McKennaD . A randomized placebo controlled trial of oral micronized progesterone to prevent recurrent preterm birth. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S172. GloverMM , McKennaDS , DowningCM , SmithDB , CroomCS , SonekJD . A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. American Journal of Perinatology2011;28(5):377‐81. ">Glover 2011</a>; <a href="./references#CD004947-bbs2-0015" title="GrobmanW . RCT of progesterone to prevent preterm birth in nulliparous women with a short cervix. http://controlledtrials.com(accessed 2007). GrobmanW . Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S367. GrobmanWA , ThomEA , SpongCY , IamsJD , SaadeGR , MercerBM , et al. 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;207(5):390.e1‐8. ">Grobman 2012</a>; <a href="./references#CD004947-bbs2-0017" title="HassanSS , RomeroR , VidyadhariD , FuseyS , BaxterJK , KhandelwalM , et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(1):18‐31. ">Hassan 2011</a>; <a href="./references#CD004947-bbs2-0020" title="JohnsonJWC , AustinKL , JonesGS , DavisGH , KingTM . Efficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine1975;293(14):675‐80. KlebanoffM , for the NICHD MFMU Network. Impact of 17alpha hydroxyprogesterone caproate administration on salivary progesterone and estriol [abstract]. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S140. ">Johnson 1975</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>; <a href="./references#CD004947-bbs2-0029" title="RaiP , RajaramS , GoelN , Ayalur GopalakrishnanR , AgarwalR , MehtaS . Oral micronized progesterone for prevention of preterm birth. International Journal of Gynecology &amp; Obstetrics2009;104(1):40‐3. ">Rai 2009</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>; <a href="./references#CD004947-bbs2-0031" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S197. ManuckT , for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha‐hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S18. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 Alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357:454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD004947-bbs2-0032" title="RozenbergP . Efficacy of 17 alpha‐hydroxyprogesterone caproate for the prevention of preterm delivery. http://controlledtrials.com(accessed 2007). RozenbergP , ChauveaudA , DeruelleP , CapelleM , WinerN ,  DesbriereR , et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. American Journal of Obstetrics &amp; Gynecology2012;206(3):206.e1‐9. RozenbergP , DeruelleP , ChauveaudA , CapelleM , WinerN , PorcherR , et al. Prevention of preterm delivery after successful tocolysis in preterm labour by 17 alpha‐hydroxyprogesterone caproate: a randomised controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S2‐S3. ">Rozenberg 2012</a>; <a href="./references#CD004947-bbs2-0035" title="SerraV . Natural progesterone and preterm birth in twins. http://controlledtrials.com(accessed 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>; <a href="./references#CD004947-bbs2-0036" title="SharamiSH , ZahiriZ , ShakibaM , MilaniF . Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: a randomized placebo‐controlled double‐blind trial. International Journal of Fertility and Sterility2010;4(2):45‐50. ">Sharami 2010</a>). In five studies reported only in abstract form, it was unclear whether attrition bias was present (<a href="./references#CD004947-bbs2-0011" title="ElsheikhahAZ , DahabS , NegmS , EbrashyA . Effect of prophylactic progesterone on incidence of preterm labour in spontaneous twin pregnancy, randomized controlled study. Ultrasound in Obstetrics and Gynecology2010;36(Suppl 1):108. ">Elsheikhah 2010</a>; <a href="./references#CD004947-bbs2-0015" title="GrobmanW . RCT of progesterone to prevent preterm birth in nulliparous women with a short cervix. http://controlledtrials.com(accessed 2007). GrobmanW . Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S367. GrobmanWA , ThomEA , SpongCY , IamsJD , SaadeGR , MercerBM , et al. 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;207(5):390.e1‐8. ">Grobman 2012</a>; <a href="./references#CD004947-bbs2-0024" title="MoghtadaeiP , SardariF , LatifiM . Progesterone for prevention of preterm birth and improvement in pregnancy outcomes among primiparae of advanced maternal age. Archives of Disease in Childhood. Fetal and Neonatal Edition2008; Vol. 93, issue Suppl 1:Fa71. MoghtadeiP , SardariF , LatifiM . Progesterone for prevention of preterm birth and improvement pregnancy outcomes among primiparae of advanced maternal age. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:122. ">Moghtadaei 2008</a>; <a href="./references#CD004947-bbs2-0025" title="NdoniE , BimbashiA , DokleA , KallfaE . Treatment with different types of progesterone in prevention of preterm delivery. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):305. ">Ndoni 2010</a>; <a href="./references#CD004947-bbs2-0034" title="SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: A randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2012</a>) and in one study details were insufficient to make a judgement (<a href="./references#CD004947-bbs2-0002" title="AkbariS , BirjandiM , MohtashamN . Evaluation of the effect of progesterone on prevention of preterm delivery and its complications. Scientific Journal of Kurdistan University of Medical Sciences2009;14(3):11‐9. ">Akbari 2009</a>). </p> </section> <section id="CD004947-sec-0094"> <h4 class="title">Selective reporting</h4> <p>Twenty‐five studies were assessed as being at low risk of bias for selective reporting (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD004947-bbs2-0002" title="AkbariS , BirjandiM , MohtashamN . Evaluation of the effect of progesterone on prevention of preterm delivery and its complications. Scientific Journal of Kurdistan University of Medical Sciences2009;14(3):11‐9. ">Akbari 2009</a>; <a href="./references#CD004947-bbs2-0003" title="BornaS , SahabiN . Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2008;48(1):58‐63. BornaS , ShakoieS , BornaH . Progesterone for maintenance tocolytic therapy after threatened preterm labor. Randomized controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:151‐2. ">Borna 2008</a>; <a href="./references#CD004947-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>; <a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>; <a href="./references#CD004947-bbs2-0009" title="CombsCA , GariteTJ , MaurelK , MalloryK , EdwardsRK , LuG , et al. 17‐Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double‐blind, randomized clinical trial. BMC Research Notes2011;4(1):568. ">Combs 2011a</a>; <a href="./references#CD004947-bbs2-0010" title="daFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics &amp; Gynecology2003;188(2):419‐24. daFonsecaEB , BittarRE , CarvalhoMHB , MartinelliS , ZugaibM . Uterine contraction monitoring in pregnant women using vaginal natural progesterone. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):525. ">da Fonseca 2003</a>; <a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>; <a href="./references#CD004947-bbs2-0015" title="GrobmanW . RCT of progesterone to prevent preterm birth in nulliparous women with a short cervix. http://controlledtrials.com(accessed 2007). GrobmanW . Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S367. GrobmanWA , ThomEA , SpongCY , IamsJD , SaadeGR , MercerBM , et al. 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;207(5):390.e1‐8. ">Grobman 2012</a>; <a href="./references#CD004947-bbs2-0016" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56(6):692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen 1980</a>; <a href="./references#CD004947-bbs2-0017" title="HassanSS , RomeroR , VidyadhariD , FuseyS , BaxterJK , KhandelwalM , et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(1):18‐31. ">Hassan 2011</a>; <a href="./references#CD004947-bbs2-0018" title="HauthJC , GilstrapLC , BrekkenAL , HauthJM . The effect of 17 alpha‐hydroxyprogesterone caproate on pregnancy outcome in an active‐duty military population. American Journal of Obstetrics and Gynecology1983;146(2):187‐90. ">Hauth 1983</a>; <a href="./references#CD004947-bbs2-0019" title="IbrahimM , Mohamed RamyAR , YounisMA‐F . Progesterone supplementation for prevention of preterm labor: a randomized controlled trial. Middle East Fertility Society Journal2010;15(1):39‐41. ">Ibrahim 2010</a>; <a href="./references#CD004947-bbs2-0020" title="JohnsonJWC , AustinKL , JonesGS , DavisGH , KingTM . Efficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine1975;293(14):675‐80. KlebanoffM , for the NICHD MFMU Network. Impact of 17alpha hydroxyprogesterone caproate administration on salivary progesterone and estriol [abstract]. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S140. ">Johnson 1975</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0022" title="MajhiP , BaggaR , KalraJ , SharmaM . Intravaginal use of natural micronised progesterone to prevent pre‐term birth: a randomised trial in India. Journal of Obstetrics and Gynaecology2009;29(6):493‐8. ">Majhi 2009</a>; <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>; <a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>; <a href="./references#CD004947-bbs2-0029" title="RaiP , RajaramS , GoelN , Ayalur GopalakrishnanR , AgarwalR , MehtaS . Oral micronized progesterone for prevention of preterm birth. International Journal of Gynecology &amp; Obstetrics2009;104(1):40‐3. ">Rai 2009</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>; <a href="./references#CD004947-bbs2-0031" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S197. ManuckT , for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha‐hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S18. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 Alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357:454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD004947-bbs2-0032" title="RozenbergP . Efficacy of 17 alpha‐hydroxyprogesterone caproate for the prevention of preterm delivery. http://controlledtrials.com(accessed 2007). RozenbergP , ChauveaudA , DeruelleP , CapelleM , WinerN ,  DesbriereR , et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. American Journal of Obstetrics &amp; Gynecology2012;206(3):206.e1‐9. RozenbergP , DeruelleP , ChauveaudA , CapelleM , WinerN , PorcherR , et al. Prevention of preterm delivery after successful tocolysis in preterm labour by 17 alpha‐hydroxyprogesterone caproate: a randomised controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S2‐S3. ">Rozenberg 2012</a>) as all expected outcomes were reported. One study was assessed as being at high risk of bias, because one of the outcomes was incompletely reported on (<a href="./references#CD004947-bbs2-0012" title="FacchinettiF , DanteG , VenturiniP , PaganelliS , VolpeA . 17alpha‐hydroxy‐progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery. American Journal of Perinatology2008;25(8):503‐6. FacchinettiF , PaganelliS , ComitinitG , DanteG , VolpeA . Cervical length changes during preterm cervical ripening: effects of 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2007;196:453e1‐453e4. FacchinettiF , PaganelliS , VenturiniP , DanteG . 17 alpha hydroxy‐progesterone caproate (17P) treatment reduced cervical shortening inhibiting cervical interleukin‐1 secretion. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S5. ">Facchinetti 2007</a>) and in one study it was difficult to assess selective reporting based on a translation of the original report (<a href="./references#CD004947-bbs2-0028" title="Papiernik‐BerkhauerE . Double blind study of an agent to prevent preterm delivery among women at increased risk [Etude en double aveugle d'un medicament prevenant la survenue prematuree de l'accouchement chez les femmes a risque eleve d'accouchement premature]. Edition Schering Serie IV1970; Vol. 3:65‐8. ">Papiernik 1970</a>). In all the other study reports, it was not possible to determine whether or not selection bias was present (<a href="./references#CD004947-bbs2-0004" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. BrieryCM , VeillonEW , KlauserCK , MartinRW , MagannEF , ChauhanSP , et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. American Journal of Obstetrics and Gynecology2011;204(1):54.e1‐5. ">Briery 2011</a>; <a href="./references#CD004947-bbs2-0011" title="ElsheikhahAZ , DahabS , NegmS , EbrashyA . Effect of prophylactic progesterone on incidence of preterm labour in spontaneous twin pregnancy, randomized controlled study. Ultrasound in Obstetrics and Gynecology2010;36(Suppl 1):108. ">Elsheikhah 2010</a>; <a href="./references#CD004947-bbs2-0014" title="GloverM , CroomCS , SonekJD , KovacC , McKennaD . A randomized placebo controlled trial of oral micronized progesterone to prevent recurrent preterm birth. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S172. GloverMM , McKennaDS , DowningCM , SmithDB , CroomCS , SonekJD . A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. American Journal of Perinatology2011;28(5):377‐81. ">Glover 2011</a>; <a href="./references#CD004947-bbs2-0024" title="MoghtadaeiP , SardariF , LatifiM . Progesterone for prevention of preterm birth and improvement in pregnancy outcomes among primiparae of advanced maternal age. Archives of Disease in Childhood. Fetal and Neonatal Edition2008; Vol. 93, issue Suppl 1:Fa71. MoghtadeiP , SardariF , LatifiM . Progesterone for prevention of preterm birth and improvement pregnancy outcomes among primiparae of advanced maternal age. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:122. ">Moghtadaei 2008</a>; <a href="./references#CD004947-bbs2-0025" title="NdoniE , BimbashiA , DokleA , KallfaE . Treatment with different types of progesterone in prevention of preterm delivery. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):305. ">Ndoni 2010</a>; <a href="./references#CD004947-bbs2-0032" title="RozenbergP . Efficacy of 17 alpha‐hydroxyprogesterone caproate for the prevention of preterm delivery. http://controlledtrials.com(accessed 2007). RozenbergP , ChauveaudA , DeruelleP , CapelleM , WinerN ,  DesbriereR , et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. American Journal of Obstetrics &amp; Gynecology2012;206(3):206.e1‐9. RozenbergP , DeruelleP , ChauveaudA , CapelleM , WinerN , PorcherR , et al. Prevention of preterm delivery after successful tocolysis in preterm labour by 17 alpha‐hydroxyprogesterone caproate: a randomised controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S2‐S3. ">Rozenberg 2012</a>; <a href="./references#CD004947-bbs2-0033" title="SaghafiN , KhademN , MohajeriT , ShakeriMT . Efficacy of 17alpha‐hydroxyprogesterone caproate in prevention of preterm delivery. Journal of Obstetrics and Gynaecology Research2011;37(10):1342‐5. SaghafiN , KhademN , MohajeriT , ShakeriMT , AminiM . Efficacy of 17alpha‐hydroxyprogesterone caproate in preterm delivery prevention. Iranian Journal of Obstetrics, Gynecology and Infertility2011;14(2):28‐33. ">Saghafi 2011a</a>; <a href="./references#CD004947-bbs2-0034" title="SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: A randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2012</a>; <a href="./references#CD004947-bbs2-0035" title="SerraV . Natural progesterone and preterm birth in twins. http://controlledtrials.com(accessed 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>; <a href="./references#CD004947-bbs2-0036" title="SharamiSH , ZahiriZ , ShakibaM , MilaniF . Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: a randomized placebo‐controlled double‐blind trial. International Journal of Fertility and Sterility2010;4(2):45‐50. ">Sharami 2010</a>). </p> </section> <section id="CD004947-sec-0095"> <h4 class="title">Other potential sources of bias</h4> <p>Twenty‐one studies were assessed as being at low risk of bias for other potential sources of bias based on baseline characteristics being similar between groups and no other bias apparent (<a href="./references#CD004947-bbs2-0003" title="BornaS , SahabiN . Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2008;48(1):58‐63. BornaS , ShakoieS , BornaH . Progesterone for maintenance tocolytic therapy after threatened preterm labor. Randomized controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:151‐2. ">Borna 2008</a>; <a href="./references#CD004947-bbs2-0004" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. BrieryCM , VeillonEW , KlauserCK , MartinRW , MagannEF , ChauhanSP , et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. American Journal of Obstetrics and Gynecology2011;204(1):54.e1‐5. ">Briery 2011</a>; <a href="./references#CD004947-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>; <a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>; <a href="./references#CD004947-bbs2-0010" title="daFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics &amp; Gynecology2003;188(2):419‐24. daFonsecaEB , BittarRE , CarvalhoMHB , MartinelliS , ZugaibM . Uterine contraction monitoring in pregnant women using vaginal natural progesterone. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):525. ">da Fonseca 2003</a>; <a href="./references#CD004947-bbs2-0012" title="FacchinettiF , DanteG , VenturiniP , PaganelliS , VolpeA . 17alpha‐hydroxy‐progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery. American Journal of Perinatology2008;25(8):503‐6. FacchinettiF , PaganelliS , ComitinitG , DanteG , VolpeA . Cervical length changes during preterm cervical ripening: effects of 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2007;196:453e1‐453e4. FacchinettiF , PaganelliS , VenturiniP , DanteG . 17 alpha hydroxy‐progesterone caproate (17P) treatment reduced cervical shortening inhibiting cervical interleukin‐1 secretion. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S5. ">Facchinetti 2007</a>; <a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>; <a href="./references#CD004947-bbs2-0014" title="GloverM , CroomCS , SonekJD , KovacC , McKennaD . A randomized placebo controlled trial of oral micronized progesterone to prevent recurrent preterm birth. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S172. GloverMM , McKennaDS , DowningCM , SmithDB , CroomCS , SonekJD . A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. American Journal of Perinatology2011;28(5):377‐81. ">Glover 2011</a>; <a href="./references#CD004947-bbs2-0017" title="HassanSS , RomeroR , VidyadhariD , FuseyS , BaxterJK , KhandelwalM , et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(1):18‐31. ">Hassan 2011</a>; <a href="./references#CD004947-bbs2-0018" title="HauthJC , GilstrapLC , BrekkenAL , HauthJM . The effect of 17 alpha‐hydroxyprogesterone caproate on pregnancy outcome in an active‐duty military population. American Journal of Obstetrics and Gynecology1983;146(2):187‐90. ">Hauth 1983</a>; <a href="./references#CD004947-bbs2-0020" title="JohnsonJWC , AustinKL , JonesGS , DavisGH , KingTM . Efficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine1975;293(14):675‐80. KlebanoffM , for the NICHD MFMU Network. Impact of 17alpha hydroxyprogesterone caproate administration on salivary progesterone and estriol [abstract]. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S140. ">Johnson 1975</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>; <a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>; <a href="./references#CD004947-bbs2-0028" title="Papiernik‐BerkhauerE . Double blind study of an agent to prevent preterm delivery among women at increased risk [Etude en double aveugle d'un medicament prevenant la survenue prematuree de l'accouchement chez les femmes a risque eleve d'accouchement premature]. Edition Schering Serie IV1970; Vol. 3:65‐8. ">Papiernik 1970</a>; <a href="./references#CD004947-bbs2-0029" title="RaiP , RajaramS , GoelN , Ayalur GopalakrishnanR , AgarwalR , MehtaS . Oral micronized progesterone for prevention of preterm birth. International Journal of Gynecology &amp; Obstetrics2009;104(1):40‐3. ">Rai 2009</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>; <a href="./references#CD004947-bbs2-0033" title="SaghafiN , KhademN , MohajeriT , ShakeriMT . Efficacy of 17alpha‐hydroxyprogesterone caproate in prevention of preterm delivery. Journal of Obstetrics and Gynaecology Research2011;37(10):1342‐5. SaghafiN , KhademN , MohajeriT , ShakeriMT , AminiM . Efficacy of 17alpha‐hydroxyprogesterone caproate in preterm delivery prevention. Iranian Journal of Obstetrics, Gynecology and Infertility2011;14(2):28‐33. ">Saghafi 2011a</a>; <a href="./references#CD004947-bbs2-0036" title="SharamiSH , ZahiriZ , ShakibaM , MilaniF . Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: a randomized placebo‐controlled double‐blind trial. International Journal of Fertility and Sterility2010;4(2):45‐50. ">Sharami 2010</a>). In the remaining studies, it was not possible to determine whether or not other sources of bias were present (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD004947-bbs2-0002" title="AkbariS , BirjandiM , MohtashamN . Evaluation of the effect of progesterone on prevention of preterm delivery and its complications. Scientific Journal of Kurdistan University of Medical Sciences2009;14(3):11‐9. ">Akbari 2009</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0009" title="CombsCA , GariteTJ , MaurelK , MalloryK , EdwardsRK , LuG , et al. 17‐Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double‐blind, randomized clinical trial. BMC Research Notes2011;4(1):568. ">Combs 2011a</a>; <a href="./references#CD004947-bbs2-0011" title="ElsheikhahAZ , DahabS , NegmS , EbrashyA . Effect of prophylactic progesterone on incidence of preterm labour in spontaneous twin pregnancy, randomized controlled study. Ultrasound in Obstetrics and Gynecology2010;36(Suppl 1):108. ">Elsheikhah 2010</a>; <a href="./references#CD004947-bbs2-0015" title="GrobmanW . RCT of progesterone to prevent preterm birth in nulliparous women with a short cervix. http://controlledtrials.com(accessed 2007). GrobmanW . Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S367. GrobmanWA , ThomEA , SpongCY , IamsJD , SaadeGR , MercerBM , et al. 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;207(5):390.e1‐8. ">Grobman 2012</a>; <a href="./references#CD004947-bbs2-0016" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56(6):692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen 1980</a>; <a href="./references#CD004947-bbs2-0019" title="IbrahimM , Mohamed RamyAR , YounisMA‐F . Progesterone supplementation for prevention of preterm labor: a randomized controlled trial. Middle East Fertility Society Journal2010;15(1):39‐41. ">Ibrahim 2010</a>; <a href="./references#CD004947-bbs2-0022" title="MajhiP , BaggaR , KalraJ , SharmaM . Intravaginal use of natural micronised progesterone to prevent pre‐term birth: a randomised trial in India. Journal of Obstetrics and Gynaecology2009;29(6):493‐8. ">Majhi 2009</a>; <a href="./references#CD004947-bbs2-0024" title="MoghtadaeiP , SardariF , LatifiM . Progesterone for prevention of preterm birth and improvement in pregnancy outcomes among primiparae of advanced maternal age. Archives of Disease in Childhood. Fetal and Neonatal Edition2008; Vol. 93, issue Suppl 1:Fa71. MoghtadeiP , SardariF , LatifiM . Progesterone for prevention of preterm birth and improvement pregnancy outcomes among primiparae of advanced maternal age. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:122. ">Moghtadaei 2008</a>; <a href="./references#CD004947-bbs2-0025" title="NdoniE , BimbashiA , DokleA , KallfaE . Treatment with different types of progesterone in prevention of preterm delivery. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):305. ">Ndoni 2010</a>; <a href="./references#CD004947-bbs2-0031" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S197. ManuckT , for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha‐hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S18. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 Alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357:454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD004947-bbs2-0032" title="RozenbergP . Efficacy of 17 alpha‐hydroxyprogesterone caproate for the prevention of preterm delivery. http://controlledtrials.com(accessed 2007). RozenbergP , ChauveaudA , DeruelleP , CapelleM , WinerN ,  DesbriereR , et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. American Journal of Obstetrics &amp; Gynecology2012;206(3):206.e1‐9. RozenbergP , DeruelleP , ChauveaudA , CapelleM , WinerN , PorcherR , et al. Prevention of preterm delivery after successful tocolysis in preterm labour by 17 alpha‐hydroxyprogesterone caproate: a randomised controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S2‐S3. ">Rozenberg 2012</a>; <a href="./references#CD004947-bbs2-0034" title="SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: A randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2012</a>; <a href="./references#CD004947-bbs2-0035" title="SerraV . Natural progesterone and preterm birth in twins. http://controlledtrials.com(accessed 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>). </p> <section id="CD004947-sec-0096"> <h5 class="title">Assessment of studies that included multiple pregnancies</h5> <p>We assessed whether studies that included multiple pregnancies accounted appropriately for non‐independence of babies from the same pregnancy in the analysis. There were 14 studies that included a multiple pregnancy (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD004947-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>; <a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>; <a href="./references#CD004947-bbs2-0011" title="ElsheikhahAZ , DahabS , NegmS , EbrashyA . Effect of prophylactic progesterone on incidence of preterm labour in spontaneous twin pregnancy, randomized controlled study. Ultrasound in Obstetrics and Gynecology2010;36(Suppl 1):108. ">Elsheikhah 2010</a>; <a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>; <a href="./references#CD004947-bbs2-0016" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56(6):692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen 1980</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>; <a href="./references#CD004947-bbs2-0031" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S197. ManuckT , for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha‐hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S18. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 Alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357:454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD004947-bbs2-0034" title="SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: A randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2012</a>; <a href="./references#CD004947-bbs2-0035" title="SerraV . Natural progesterone and preterm birth in twins. http://controlledtrials.com(accessed 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>) and in seven studies adjustment appears to have been made in the analysis (<a href="./references#CD004947-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>; <a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>; <a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>). In the remaining seven studies (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0011" title="ElsheikhahAZ , DahabS , NegmS , EbrashyA . Effect of prophylactic progesterone on incidence of preterm labour in spontaneous twin pregnancy, randomized controlled study. Ultrasound in Obstetrics and Gynecology2010;36(Suppl 1):108. ">Elsheikhah 2010</a>; <a href="./references#CD004947-bbs2-0016" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56(6):692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen 1980</a>; <a href="./references#CD004947-bbs2-0031" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S197. ManuckT , for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha‐hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S18. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 Alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357:454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD004947-bbs2-0034" title="SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: A randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2012</a>; <a href="./references#CD004947-bbs2-0035" title="SerraV . Natural progesterone and preterm birth in twins. http://controlledtrials.com(accessed 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>), it is not clear that any adjustment was made. </p> <p>There were insufficient data presented in the trial reports to allow us to carry out necessary adjustment for cluster design effect ourselves and, although in several trials results had already been adjusted, we were not able to present these data in our data and analyses tables because they were not reported in a consistent way.  </p> </section> </section> </section> <section id="CD004947-sec-0097"> <h3 class="title" id="CD004947-sec-0097">Effects of interventions</h3> <p>Thirty‐six randomised controlled trials (8523 women and 12,515 infants) in total were included in this review. </p> <p>Data were only available in a suitable format from 30 randomised controlled trials involving a total of 7561 women and 10,114 infants. Data from these 30 trials contributed data that were included in meta‐analyses. As the aetiology of preterm birth is multifactorial, results are presented according to the reason considered to be at risk for preterm birth (past history of spontaneous preterm birth (including preterm premature rupture of membranes), ultrasound identified short cervical length, multiple pregnancy, prior presentation with threatened preterm labour, and other reason for risk of preterm birth). </p> <section id="CD004947-sec-0098"> <h4 class="title">Progesterone versus placebo/no treatment for women with a past history of spontaneous preterm birth </h4> <p>Eleven randomised controlled trials involving a total of 1899 women and infants were included in the meta‐analysis. </p> <section id="CD004947-sec-0099"> <h5 class="title">Primary outcomes</h5> <p>For women administered progesterone during pregnancy, there was a statistically significant reduction in perinatal mortality overall (six studies; 1453 women; risk ratio (RR) 0.50, 95% confidence interval (CI) 0.33 to 0.75), <a href="./references#CD004947-fig-0004" title="">Analysis 1.1</a>. For the primary outcome preterm birth less than 34 weeks' gestation, there was also a statistically significant difference between progesterone when compared with placebo (five studies; 602 women; average RR 0.31, 95% CI 0.14 to 0.69), <a href="./references#CD004947-fig-0005" title="">Analysis 1.2</a>. Substantial heterogeneity was evident for <a href="./references#CD004947-fig-0005" title="">Analysis 1.2</a> (heterogeneity: Tau² = 0.45, Chi² = 9.15, df = 4 (P = 0.06), I² = 56%) and so a random‐effects model was used. Major neurodevelopmental handicap in childhood was not reported. </p> </section> <section id="CD004947-sec-0100"> <h5 class="title">Secondary infant outcomes</h5> <p>For women administered progesterone during pregnancy, when compared with placebo, the results showed: </p> <p> <ul id="CD004947-list-0017"> <li> <p>preterm birth less than 37 weeks' gestation (10 studies; 1750 women; average RR 0.55, 95% CI 0.42 to 0.74); considerable heterogeneity was identified, and a random‐effects model was used (heterogeneity: Tau² = 0.11; Chi² = 29.60, df = 9 (P = 0.0005); I² = 70%), <a href="./references#CD004947-fig-0006" title="">Analysis 1.3</a>. This was also evident for the intramuscular subgroup (four studies; 652 women; average RR 0.62, 95% CI 0.52 to 0.75), <a href="./references#CD004947-fig-0006" title="">Analysis 1.3</a>.1. However, for the oral subgroup, no statistically significant differences were observed, <a href="./references#CD004947-fig-0006" title="">Analysis 1.3</a>.3. A funnel plot for this analysis (<a href="#CD004947-fig-0003">Figure 3</a>), including the 10 studies was very asymmetrical. This suggests that there may be some important biases or small‐study effects in the set of studies in this analysis and so these results should be viewed with caution. </p> </li> </ul> </p> <div class="figure" id="CD004947-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth, outcome: 1.3 Preterm birth less than 37 weeks." data-id="CD004947-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth, outcome: 1.3 Preterm birth less than 37 weeks. </p> </div> </div> </div> <p>There was also a statistically significant reduction in the risk of:</p> <p> <ul id="CD004947-list-0018"> <li> <p>infant birthweight less than 2500 g (four studies; 692 infants; RR 0.58, 95% CI 0.42 to 0.79), <a href="./references#CD004947-fig-0012" title="">Analysis 1.9</a>; </p> </li> <li> <p>use of assisted ventilation (three studies; 633 women; RR 0.40, 95% CI 0.18 to 0.90), <a href="./references#CD004947-fig-0014" title="">Analysis 1.11</a>; </p> </li> <li> <p>necrotising enterocolitis (three studies; 1170 infants; RR 0.30, 95% CI 0.10 to 0.89), <a href="./references#CD004947-fig-0019" title="">Analysis 1.16</a>; </p> </li> <li> <p>neonatal death (six studies; 1453 women; RR 0.45, 95% CI 0.27 to 0.76), <a href="./references#CD004947-fig-0023" title="">Analysis 1.20</a>; </p> </li> <li> <p>admission to neonatal intensive care unit (three studies; 389 women; RR 0.24, 95% CI 0.14 to 0.40), <a href="./references#CD004947-fig-0036" title="">Analysis 1.33</a>. </p> </li> </ul> </p> <p>For infant outcomes Apgar score less than seven at five minutes <a href="./references#CD004947-fig-0035" title="">Analysis 1.32</a>, respiratory distress syndrome <a href="./references#CD004947-fig-0013" title="">Analysis 1.10</a>, intrauterine fetal death <a href="./references#CD004947-fig-0022" title="">Analysis 1.19</a>, intraventricular haemorrhage (all grades) <a href="./references#CD004947-fig-0015" title="">Analysis 1.12</a>, intraventricular haemorrhage (grade III or IV) <a href="./references#CD004947-fig-0016" title="">Analysis 1.13</a>, periventricular leucomalacia <a href="./references#CD004947-fig-0017" title="">Analysis 1.14</a>, retinopathy of prematurity <a href="./references#CD004947-fig-0018" title="">Analysis 1.15</a>, neonatal sepsis <a href="./references#CD004947-fig-0020" title="">Analysis 1.17</a>, patent ductus arteriosus <a href="./references#CD004947-fig-0021" title="">Analysis 1.18</a>, intrauterine fetal death <a href="./references#CD004947-fig-0022" title="">Analysis 1.19</a>, or neonatal length of hospital stay <a href="./references#CD004947-fig-0037" title="">Analysis 1.34</a>, there were no statistically significant differences identified. </p> </section> <section id="CD004947-sec-0101"> <h5 class="title">Secondary maternal outcomes</h5> <p>For women administered progesterone during pregnancy, when compared with placebo, there was a statistically significant increase in: </p> <p> <ul id="CD004947-list-0019"> <li> <p>pregnancy prolongation in weeks (one study; 148 women; mean difference (MD) 4.47, 95% CI 2.15 to 6.79), <a href="./references#CD004947-fig-0034" title="">Analysis 1.31</a>. </p> </li> </ul> </p> <p>There were no statistically significant differences for the outcomes threatened preterm labour <a href="./references#CD004947-fig-0007" title="">Analysis 1.4</a>, spontaneous vaginal birth <a href="./references#CD004947-fig-0008" title="">Analysis 1.5</a>, adverse drug reaction <a href="./references#CD004947-fig-0033" title="">Analysis 1.30</a>, caesarean birth <a href="./references#CD004947-fig-0009" title="">Analysis 1.6</a>, use of antenatal corticosteroids <a href="./references#CD004947-fig-0010" title="">Analysis 1.7</a>, or the use of antenatal tocolysis <a href="./references#CD004947-fig-0011" title="">Analysis 1.8</a>. </p> </section> <section id="CD004947-sec-0102"> <h5 class="title">Secondary childhood outcomes</h5> <p>There were no statistically significant differences identified for the outcomes developmental delay <a href="./references#CD004947-fig-0024" title="">Analysis 1.21</a>, intellectual impairment <a href="./references#CD004947-fig-0025" title="">Analysis 1.22</a>, motor impairment <a href="./references#CD004947-fig-0026" title="">Analysis 1.23</a>, visual impairment <a href="./references#CD004947-fig-0027" title="">Analysis 1.24</a>, hearing impairment <a href="./references#CD004947-fig-0028" title="">Analysis 1.25</a>, cerebral palsy <a href="./references#CD004947-fig-0029" title="">Analysis 1.26</a>, learning difficulties <a href="./references#CD004947-fig-0030" title="">Analysis 1.27</a>, height less than fifth centile <a href="./references#CD004947-fig-0031" title="">Analysis 1.28</a> , weight less than the fifth centile <a href="./references#CD004947-fig-0032" title="">Analysis 1.29</a>, infant weight at six, 12 and 24 months' follow‐up <a href="./references#CD004947-fig-0037" title="">Analysis 1.34</a>; <a href="./references#CD004947-fig-0038" title="">Analysis 1.35</a>; <a href="./references#CD004947-fig-0039" title="">Analysis 1.36</a>, infant length (cm) at six, 12 and 24 months' follow‐up <a href="./references#CD004947-fig-0041" title="">Analysis 1.38</a>; <a href="./references#CD004947-fig-0042" title="">Analysis 1.39</a>; <a href="./references#CD004947-fig-0043" title="">Analysis 1.40</a>, and infant head circumference (cm) at six, 12 and 24 months' follow‐up <a href="./references#CD004947-fig-0044" title="">Analysis 1.41</a>; <a href="./references#CD004947-fig-0045" title="">Analysis 1.42</a>; <a href="./references#CD004947-fig-0046" title="">Analysis 1.43</a>. </p> </section> <section id="CD004947-sec-0103"> <h5 class="title">Effect of route of administration, time of commencing therapy, and dose of progesterone</h5> <p>We investigated statistical heterogeneity (I² &gt; 30%) by performing subgroup analyses where possible for all outcomes and found no differential effect on the majority of outcomes examined when considering route of administration of progesterone (intramuscular versus vaginal versus oral). However, for respiratory distress syndrome, the subgroup analysis indicated a differential effect between the different routes of administration (test for subgroup differences: P = 0.001, I² = 84.8%, <a href="./references#CD004947-fig-0013" title="">Analysis 1.10</a>), although only one trial was included in each subgroup of intramuscular versus vaginal versus oral, <a href="./references#CD004947-fig-0013" title="">Analysis 1.10</a>. </p> <p>We performed subgroup analysis to investigate the differential effect of time of commencement of supplementation (prior to 20 weeks' gestation versus after 20 weeks' gestation) where outcome data allowed, and found no subgroup differences (test for subgroup differences: P = 0.28, I² = 15.9%, <a href="./references#CD004947-fig-0047" title="">Analysis 2.1</a>). </p> <p>We also performed subgroup analysis by total weekly cumulative dose of progesterone (less than 500 mg versus greater than 500 mg) and found no differential effect for the majority of outcomes examined: <a href="./references#CD004947-fig-0048" title="">Analysis 3.1</a>; <a href="./references#CD004947-fig-0049" title="">Analysis 3.2</a>; <a href="./references#CD004947-fig-0050" title="">Analysis 3.3</a>; <a href="./references#CD004947-fig-0051" title="">Analysis 3.4</a>; <a href="./references#CD004947-fig-0052" title="">Analysis 3.5</a>; <a href="./references#CD004947-fig-0053" title="">Analysis 3.6</a>; <a href="./references#CD004947-fig-0054" title="">Analysis 3.7</a>; <a href="./references#CD004947-fig-0056" title="">Analysis 3.9</a>; <a href="./references#CD004947-fig-0057" title="">Analysis 3.10</a>; <a href="./references#CD004947-fig-0058" title="">Analysis 3.11</a>; <a href="./references#CD004947-fig-0059" title="">Analysis 3.12</a>. However, for intraventricular haemorrhage (all grades), the subgroup analysis indicated a differential effect between the different doses of progesterone (test for subgroup differences: P = 0.04, I² = 76.2%, <a href="./references#CD004947-fig-0041" title="">Analysis 1.38</a>), although only one trial was included in each subgroup of intramuscular versus vaginal versus oral, <a href="./references#CD004947-fig-0013" title="">Analysis 1.10</a>. </p> </section> </section> <section id="CD004947-sec-0104"> <h4 class="title">Progesterone versus placebo for women with a short cervix identified on ultrasound</h4> <p>Four randomised controlled trials involving a total of 1556 women and infants were included in the meta‐analysis. </p> <section id="CD004947-sec-0105"> <h5 class="title">Primary outcomes</h5> <p>For women administered progesterone during pregnancy, for the primary outcome perinatal death, there were no statistically significant differences identified when compared with placebo, <a href="./references#CD004947-fig-0060" title="">Analysis 4.1</a>. Women administered progesterone were significantly less likely to have a preterm birth at less than 34 weeks' gestation (two studies; 438 women; RR 0.64, 95% CI 0.45 to 0.90), <a href="./references#CD004947-fig-0061" title="">Analysis 4.2</a>. Major neurodevelopmental handicap in childhood was not reported. </p> </section> <section id="CD004947-sec-0106"> <h5 class="title">Secondary infant outcomes</h5> <p>For women administered progesterone during pregnancy, for the outcome preterm birth at less than 37 weeks' gestation, there were no statistically significant differences identified when compared with placebo, <a href="./references#CD004947-fig-0071" title="">Analysis 4.12</a>. However, women administered progesterone were significantly less likely to have a preterm birth at less than 28 weeks' gestation (two studies; 1115 women; RR 0.59, 95% CI 0.37 to 0.93), <a href="./references#CD004947-fig-0072" title="">Analysis 4.13</a>. </p> <p>For infant outcomes infant birthweight less than 2500 g <a href="./references#CD004947-fig-0073" title="">Analysis 4.14</a>, respiratory distress syndrome <a href="./references#CD004947-fig-0074" title="">Analysis 4.15</a>, Apgar score less than seven at five minutes <a href="./references#CD004947-fig-0075" title="">Analysis 4.16</a>, need for assisted ventilation <a href="./references#CD004947-fig-0076" title="">Analysis 4.17</a>, intraventricular haemorrhage (all grades) <a href="./references#CD004947-fig-0077" title="">Analysis 4.18</a>, intraventricular haemorrhage (grades III or IV) <a href="./references#CD004947-fig-0078" title="">Analysis 4.19</a>, periventricular leucomalacia <a href="./references#CD004947-fig-0079" title="">Analysis 4.20</a>, retinopathy of prematurity <a href="./references#CD004947-fig-0080" title="">Analysis 4.21</a>, necrotising enterocolitis <a href="./references#CD004947-fig-0081" title="">Analysis 4.22</a>, neonatal sepsis <a href="./references#CD004947-fig-0082" title="">Analysis 4.23</a>, intrauterine fetal death <a href="./references#CD004947-fig-0083" title="">Analysis 4.24</a>, neonatal death <a href="./references#CD004947-fig-0084" title="">Analysis 4.25</a> or admission to neonatal intensive care unit <a href="./references#CD004947-fig-0085" title="">Analysis 4.26</a>, there were no statistically significant differences identified. </p> </section> <section id="CD004947-sec-0107"> <h5 class="title">Secondary maternal outcomes</h5> <p>Women administered progesterone were significantly more likely to experience the adverse drug reaction urticaria (one study; 654 women; RR 5.03, 95% CI 1.11 to 22.78), <a href="./references#CD004947-fig-0066" title="">Analysis 4.7</a>. For all other maternal outcomes, threatened preterm labour <a href="./references#CD004947-fig-0062" title="">Analysis 4.3</a>, prelabour spontaneous rupture of membranes <a href="./references#CD004947-fig-0063" title="">Analysis 4.4</a>, adverse drug reactions (any, injection site, nausea) <a href="./references#CD004947-fig-0064" title="">Analysis 4.5</a>; <a href="./references#CD004947-fig-0065" title="">Analysis 4.6</a>; <a href="./references#CD004947-fig-0067" title="">Analysis 4.8</a>, pregnancy prolongation <a href="./references#CD004947-fig-0068" title="">Analysis 4.9</a>, caesarean section <a href="./references#CD004947-fig-0069" title="">Analysis 4.10</a>, or antenatal tocolysis <a href="./references#CD004947-fig-0070" title="">Analysis 4.11</a>, there were no statistically significant differences identified. </p> </section> <section id="CD004947-sec-0108"> <h5 class="title">Secondary childhood outcomes</h5> <p>None of the secondary childhood outcomes were reported.</p> </section> <section id="CD004947-sec-0109"> <h5 class="title">Effect of route of administration, time of commencing therapy, and dose of progesterone</h5> <p>We investigated statistical heterogeneity (I² &gt; 30%) by performing subgroup analyses where possible for all outcomes and found no differential effect on the outcomes examined when considering route of administration of progesterone (intramuscular versus vaginal), <a href="./references#CD004947-fig-0079" title="">Analysis 4.20</a>; <a href="./references#CD004947-fig-0080" title="">Analysis 4.21</a>; <a href="./references#CD004947-fig-0082" title="">Analysis 4.23</a>. It was not possible to assess the effect of gestational age at commencing therapy. </p> <p>We also performed subgroup analysis by total weekly cumulative dose of progesterone (less than 500 mg versus greater than 500 mg) and found no differential effect for the two outcomes examined: <a href="./references#CD004947-fig-0086" title="">Analysis 5.1</a>; <a href="./references#CD004947-fig-0087" title="">Analysis 5.2</a>. </p> </section> </section> <section id="CD004947-sec-0110"> <h4 class="title">Progesterone versus placebo for women with a multiple pregnancy</h4> <p>Ten randomised controlled trials involving a total of 3395 women and 6178 infants were included in the meta‐analysis. </p> <p>One trial (<a href="./references#CD004947-bbs2-0035" title="SerraV . Natural progesterone and preterm birth in twins. http://controlledtrials.com(accessed 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>) consisted of three groups: progesterone 200 mg versus progesterone 400 mg versus placebo. This trial has been analysed as separate pair‐wise comparisons, with separate analyses for progesterone 200 mg versus placebo (<a href="./references#CD004947-fig-0088" title="">Analysis 6.1</a>; <a href="./references#CD004947-fig-0089" title="">Analysis 6.2</a>; <a href="./references#CD004947-fig-0090" title="">Analysis 6.3</a>; <a href="./references#CD004947-fig-0092" title="">Analysis 6.5</a>; <a href="./references#CD004947-fig-0096" title="">Analysis 6.9</a>; <a href="./references#CD004947-fig-0097" title="">Analysis 6.10</a>; <a href="./references#CD004947-fig-0098" title="">Analysis 6.11</a>; <a href="./references#CD004947-fig-0099" title="">Analysis 6.12</a>; <a href="./references#CD004947-fig-0100" title="">Analysis 6.13</a>; <a href="./references#CD004947-fig-0101" title="">Analysis 6.14</a>; <a href="./references#CD004947-fig-0108" title="">Analysis 6.21</a>; <a href="./references#CD004947-fig-0111" title="">Analysis 6.24</a>; <a href="./references#CD004947-fig-0112" title="">Analysis 6.25</a>; <a href="./references#CD004947-fig-0113" title="">Analysis 6.26</a>) and progesterone 400 mg versus placebo (<a href="./references#CD004947-fig-0114" title="">Analysis 6.27</a>; <a href="./references#CD004947-fig-0115" title="">Analysis 6.28</a>; <a href="./references#CD004947-fig-0116" title="">Analysis 6.29</a>; <a href="./references#CD004947-fig-0117" title="">Analysis 6.30</a>; <a href="./references#CD004947-fig-0118" title="">Analysis 6.31</a>; <a href="./references#CD004947-fig-0119" title="">Analysis 6.32</a>; <a href="./references#CD004947-fig-0120" title="">Analysis 6.33</a>; <a href="./references#CD004947-fig-0121" title="">Analysis 6.34</a>; <a href="./references#CD004947-fig-0122" title="">Analysis 6.35</a>; <a href="./references#CD004947-fig-0123" title="">Analysis 6.36</a>; <a href="./references#CD004947-fig-0124" title="">Analysis 6.37</a>; <a href="./references#CD004947-fig-0125" title="">Analysis 6.38</a>; <a href="./references#CD004947-fig-0126" title="">Analysis 6.39</a>; <a href="./references#CD004947-fig-0127" title="">Analysis 6.40</a>; <a href="./references#CD004947-fig-0128" title="">Analysis 6.41</a>; <a href="./references#CD004947-fig-0129" title="">Analysis 6.42</a>; ; <a href="./references#CD004947-fig-0130" title="">Analysis 7.1</a>; <a href="./references#CD004947-fig-0131" title="">Analysis 7.2</a>; <a href="./references#CD004947-fig-0132" title="">Analysis 7.3</a>). </p> <section id="CD004947-sec-0111"> <h5 class="title">Primary outcomes</h5> <p>For women administered progesterone during pregnancy, for the primary outcomes perinatal death <a href="./references#CD004947-fig-0088" title="">Analysis 6.1</a>, <a href="./references#CD004947-fig-0114" title="">Analysis 6.27</a>, and preterm birth less than 34 weeks' gestation <a href="./references#CD004947-fig-0089" title="">Analysis 6.2</a>; <a href="./references#CD004947-fig-0115" title="">Analysis 6.28</a>, there were no statistically significant differences identified when compared with placebo. Major neurodevelopmental handicap in childhood was not reported. </p> </section> <section id="CD004947-sec-0112"> <h5 class="title">Secondary infant outcomes</h5> <p>For women administered progesterone during pregnancy, when compared with placebo, there were no statistically significant differences identified in the risk of birth before 37 <a href="./references#CD004947-fig-0098" title="">Analysis 6.11</a>; <a href="./references#CD004947-fig-0120" title="">Analysis 6.33</a> or 28 weeks <a href="./references#CD004947-fig-0099" title="">Analysis 6.12</a>; <a href="./references#CD004947-fig-0121" title="">Analysis 6.34</a>, infant birthweight less than 2500 g <a href="./references#CD004947-fig-0100" title="">Analysis 6.13</a>; <a href="./references#CD004947-fig-0122" title="">Analysis 6.35</a>, Apgar score less than seven at five minutes <a href="./references#CD004947-fig-0101" title="">Analysis 6.14</a>; <a href="./references#CD004947-fig-0123" title="">Analysis 6.36</a>, respiratory distress syndrome <a href="./references#CD004947-fig-0102" title="">Analysis 6.15</a>, need for ventilation <a href="./references#CD004947-fig-0103" title="">Analysis 6.16</a>; <a href="./references#CD004947-fig-0124" title="">Analysis 6.37</a>, intraventricular haemorrhage <a href="./references#CD004947-fig-0104" title="">Analysis 6.17</a>; <a href="./references#CD004947-fig-0105" title="">Analysis 6.18</a>, periventricular leucomalacia <a href="./references#CD004947-fig-0106" title="">Analysis 6.19</a>, retinopathy of prematurity <a href="./references#CD004947-fig-0107" title="">Analysis 6.20</a>, chronic lung disease <a href="./references#CD004947-fig-0108" title="">Analysis 6.21</a>, necrotising enterocolitis <a href="./references#CD004947-fig-0109" title="">Analysis 6.22</a>, neonatal sepsis <a href="./references#CD004947-fig-0110" title="">Analysis 6.23</a>, fetal death <a href="./references#CD004947-fig-0111" title="">Analysis 6.24</a>; <a href="./references#CD004947-fig-0125" title="">Analysis 6.38</a>, neonatal death <a href="./references#CD004947-fig-0112" title="">Analysis 6.25</a>; <a href="./references#CD004947-fig-0126" title="">Analysis 6.39</a>, or admission to neonatal intensive care unit (NICU) <a href="./references#CD004947-fig-0113" title="">Analysis 6.26</a>; <a href="./references#CD004947-fig-0127" title="">Analysis 6.40</a>. Due to extreme heterogeneity, we did not combine data from trials for the outcomes neonatal length of hospital stay or patent ductus arteriosus. </p> </section> <section id="CD004947-sec-0113"> <h5 class="title">Secondary maternal outcomes</h5> <p>For women administered progesterone during pregnancy, when compared with placebo, there were no statistically significant differences identified in any of the following maternal outcomes: prelabour spontaneous rupture of membranes <a href="./references#CD004947-fig-0090" title="">Analysis 6.3</a>, adverse drug reaction <a href="./references#CD004947-fig-0091" title="">Analysis 6.4</a>, caesarean section <a href="./references#CD004947-fig-0092" title="">Analysis 6.5</a>, spontaneous birth <a href="./references#CD004947-fig-0093" title="">Analysis 6.6</a>, assisted birth <a href="./references#CD004947-fig-0094" title="">Analysis 6.7</a>, satisfaction with the therapy <a href="./references#CD004947-fig-0095" title="">Analysis 6.8</a>, antenatal tocolysis <a href="./references#CD004947-fig-0096" title="">Analysis 6.9</a>, or antenatal corticosteroids <a href="./references#CD004947-fig-0097" title="">Analysis 6.10</a>. </p> </section> <section id="CD004947-sec-0114"> <h5 class="title">Secondary childhood outcomes</h5> <p>None of the secondary childhood outcomes were reported.</p> </section> <section id="CD004947-sec-0115"> <h5 class="title">Sensitivity analyses to account for multiple pregnancies</h5> <p>For multiple pregnancies we had planned to analyse neonatal data as 'clusters' to account for dependency between twins and triplets. We anticipated that the degree of dependence between twins would vary at the outcome level i.e. in the case of preterm birth the dependency (ICC) is likely to be high, whereas in some outcomes, such as perinatal death or morbidity, the ICC may be much lower. However, there were insufficient data presented in the trial reports to allow us to carry out necessary adjustment for cluster design effect ourselves and, although in several trials results had already been adjusted, we were not able to present these data in our data and analyses tables because they were not reported in a consistent way. </p> <p>For the primary outcome perinatal death, we therefore carried out a sensitivity analysis assuming two extremes. In the first we assumed complete dependence between infants in multiple pregnancies, i.e. we assumed outcomes were the same for all infants within that pregnancy; in this case the effective sample size for twin pregnancies would be the total number of women rather than infants, and for infant outcomes all event rates and sample sizes were therefore divided by two. In the second sensitivity analyses we assumed very limited dependence (1%) and in this case event rates and sample sizes were divided by 1.01. Results from sensitivity analyses were very similar to those from the unadjusted analyses although the effect estimates changed slightly due to rounding up of event rates and sample sizes, and the 95% CIs were generally slightly wider. Adjusted analyses showed that for women administered progesterone during pregnancy, for the primary outcome perinatal death, there were no statistically significant differences identified when compared with placebo. (Data not shown, available from the authors on request). </p> </section> <section id="CD004947-sec-0116"> <h5 class="title">Effect of route of administration, time of commencing therapy, and dose of progesterone</h5> <p>We investigated statistical heterogeneity (I² &gt; 30%) by performing subgroup analyses and found no differential effect on the majority of outcomes examined when considering route of administration of progesterone (intramuscular versus vaginal). However, for spontaneous birth, infant birthweight less than 2500 g and admission to NICU, the subgroup analyses indicated a differential effect between the different routes of administration (test for subgroup differences: P = 0.0008, I² = 91.1%, <a href="./references#CD004947-fig-0093" title="">Analysis 6.6</a>; P = 0.02, I² = 80.8% <a href="./references#CD004947-fig-0100" title="">Analysis 6.13</a>; P = 0.009, I² = 85.5%, <a href="./references#CD004947-fig-0113" title="">Analysis 6.26</a>) although it must be noted that in <a href="./references#CD004947-fig-0093" title="">Analysis 6.6</a>; <a href="./references#CD004947-fig-0113" title="">Analysis 6.26</a>, some of the subgroups contained only one trial. </p> <p>We performed subgroup analysis to investigate the differential effect of time of commencement of supplementation (prior to 20 weeks' gestation versus after 20 weeks' gestation) where outcome data allowed, and found no subgroup differences for the outcomes examined, <a href="./references#CD004947-fig-0130" title="">Analysis 7.1</a>; <a href="./references#CD004947-fig-0131" title="">Analysis 7.2</a>; <a href="./references#CD004947-fig-0132" title="">Analysis 7.3</a>. </p> <p>We also performed subgroup analysis by total weekly cumulative dose of progesterone (less than 500 per week mg versus greater than 500 mg per week) and found no differential effect for the majority of outcomes examined, <a href="./references#CD004947-fig-0133" title="">Analysis 8.1</a>; <a href="./references#CD004947-fig-0134" title="">Analysis 8.2</a>; <a href="./references#CD004947-fig-0135" title="">Analysis 8.3</a>; <a href="./references#CD004947-fig-0136" title="">Analysis 8.4</a>; <a href="./references#CD004947-fig-0137" title="">Analysis 8.5</a>; <a href="./references#CD004947-fig-0138" title="">Analysis 8.6</a>; <a href="./references#CD004947-fig-0139" title="">Analysis 8.7</a>. However, for infant birthweight less than 2500 g and admission to NICU, the subgroup analyses indicated a differential effect between the cumulative doses of progesterone (test for subgroup difference: P = 0.02, I² = 80.8%, <a href="./references#CD004947-fig-0137" title="">Analysis 8.5</a>; P = 0.009, I² = 85.5%, <a href="./references#CD004947-fig-0140" title="">Analysis 8.8</a>). </p> </section> </section> <section id="CD004947-sec-0117"> <h4 class="title">Progesterone versus placebo/no treatment for women following presentation with threatened preterm labour </h4> <p>Five randomised controlled trials involving a total of 384 women and infants were included in the meta‐analysis. </p> <section id="CD004947-sec-0118"> <h5 class="title">Primary outcomes</h5> <p>For women administered progesterone during pregnancy, for the primary outcomes perinatal death <a href="./references#CD004947-fig-0141" title="">Analysis 9.1</a>, and preterm birth less than 34 weeks' gestation <a href="./references#CD004947-fig-0142" title="">Analysis 9.2</a>, there were no statistically significant differences identified when compared with placebo. Major neurodevelopmental handicap in childhood was not reported. </p> </section> <section id="CD004947-sec-0119"> <h5 class="title">Secondary infant outcomes</h5> <p>For women administered progesterone during pregnancy, when compared with placebo, there was a statistically significant reduction in the risk of: </p> <p> <ul id="CD004947-list-0020"> <li> <p>infant birthweight less than 2500 g (one study; 70 infants; RR 0.52, 95% CI 0.28 to 0.98), <a href="./references#CD004947-fig-0151" title="">Analysis 9.11</a>. </p> </li> </ul> </p> <p>There were no statistically significant differences for any of the other outcomes analysed: preterm birth less than 37 weeks' gestation <a href="./references#CD004947-fig-0150" title="">Analysis 9.10</a>, respiratory distress syndrome <a href="./references#CD004947-fig-0152" title="">Analysis 9.12</a>, intraventricular haemorrhage grade III or IV <a href="./references#CD004947-fig-0153" title="">Analysis 9.13</a>, periventricular leucomalacia <a href="./references#CD004947-fig-0154" title="">Analysis 9.14</a>, needed for mechanical ventilation <a href="./references#CD004947-fig-0155" title="">Analysis 9.15</a>, necrotising enterocolitis <a href="./references#CD004947-fig-0156" title="">Analysis 9.16</a>, neonatal sepsis <a href="./references#CD004947-fig-0157" title="">Analysis 9.17</a>, fetal death <a href="./references#CD004947-fig-0158" title="">Analysis 9.18</a>, neonatal death <a href="./references#CD004947-fig-0159" title="">Analysis 9.19</a>, or neonatal length of hospital stay <a href="./references#CD004947-fig-0160" title="">Analysis 9.20</a>. </p> </section> <section id="CD004947-sec-0120"> <h5 class="title">Secondary maternal outcomes</h5> <p>For women administered progesterone during pregnancy, when compared with placebo, there were no statistically significant differences for any of the outcomes analysed: pregnancy prolongation <a href="./references#CD004947-fig-0143" title="">Analysis 9.3</a>; <a href="./references#CD004947-fig-0144" title="">Analysis 9.4</a>; <a href="./references#CD004947-fig-0145" title="">Analysis 9.5</a>; <a href="./references#CD004947-fig-0146" title="">Analysis 9.6</a>, spontaneous vaginal birth <a href="./references#CD004947-fig-0147" title="">Analysis 9.7</a>, caesarean section <a href="./references#CD004947-fig-0148" title="">Analysis 9.8</a>, or use of tocolysis <a href="./references#CD004947-fig-0149" title="">Analysis 9.9</a>. </p> </section> <section id="CD004947-sec-0121"> <h5 class="title">Secondary childhood outcomes</h5> <p>There were no secondary childhood outcomes reported.</p> </section> <section id="CD004947-sec-0122"> <h5 class="title">Effect of route of administration, time of commencing therapy, and dose of progesterone</h5> <p>We investigated statistical heterogeneity (I² &gt; 30%) by performing subgroup analyses where possible for all outcomes and found no differential effect on some of the outcomes examined when considering route of administration of progesterone (intramuscular versus vaginal), <a href="./references#CD004947-fig-0142" title="">Analysis 9.2</a>; <a href="./references#CD004947-fig-0149" title="">Analysis 9.9</a>; <a href="./references#CD004947-fig-0152" title="">Analysis 9.12</a>; <a href="./references#CD004947-fig-0157" title="">Analysis 9.17</a>; <a href="./references#CD004947-fig-0159" title="">Analysis 9.19</a>. However, for pregnancy prolongation and preterm birth less than 37 weeks' gestation, the subgroup analyses indicated a differential effect between the different routes of administration (test for subgroup differences: P = 0.001, I² = 90.5%, <a href="./references#CD004947-fig-0143" title="">Analysis 9.3</a>; P = 0.04, I² = 75.6%, <a href="./references#CD004947-fig-0150" title="">Analysis 9.10</a>), although it must be noted that in both analyses the subgroups contained only one trial. </p> <p>It was not possible to assess the effect of gestational age at commencing therapy.</p> <p>We also performed subgroup analysis by total weekly cumulative dose of progesterone (less than 500 mg versus greater than 500 mg) and found no differential effect for three outcomes examined: <a href="./references#CD004947-fig-0168" title="">Analysis 10.3</a>; <a href="./references#CD004947-fig-0169" title="">Analysis 10.4</a>; <a href="./references#CD004947-fig-0170" title="">Analysis 10.5</a>. However, for the two outcomes, pregnancy prolongation and preterm birth less than 37 weeks' gestation, the subgroup analyses indicated a differential effect between the different drug doses (test for subgroup differences: P = 0.001, I² = 90.5%, <a href="./references#CD004947-fig-0166" title="">Analysis 10.1</a>; P = 0.04, I² = 75.6% , <a href="./references#CD004947-fig-0167" title="">Analysis 10.2</a>). </p> </section> </section> <section id="CD004947-sec-0123"> <h4 class="title">Progesterone versus placebo for women with 'other' risk factors for preterm birth</h4> <p>Three randomised controlled trials involving a total of 482 women and infants were included in the meta‐analysis. Data from a fourth study (<a href="./references#CD004947-bbs2-0024" title="MoghtadaeiP , SardariF , LatifiM . Progesterone for prevention of preterm birth and improvement in pregnancy outcomes among primiparae of advanced maternal age. Archives of Disease in Childhood. Fetal and Neonatal Edition2008; Vol. 93, issue Suppl 1:Fa71. MoghtadeiP , SardariF , LatifiM . Progesterone for prevention of preterm birth and improvement pregnancy outcomes among primiparae of advanced maternal age. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:122. ">Moghtadaei 2008</a>), could not be included in the meta‐analysis because the number of women randomised to each group was not reported in the brief abstract report of the study. </p> <section id="CD004947-sec-0124"> <h5 class="title">Primary outcomes</h5> <p>For women administered progesterone during pregnancy, for the primary outcomes perinatal death <a href="./references#CD004947-fig-0171" title="">Analysis 11.1</a> and preterm birth less than 34 weeks' gestation <a href="./references#CD004947-fig-0172" title="">Analysis 11.2</a>, there were no statistically significant differences identified when compared with placebo. The outcome major neurodevelopmental handicap in childhood were not reported. </p> </section> <section id="CD004947-sec-0125"> <h5 class="title">Secondary infant outcomes</h5> <p>For women administered progesterone during pregnancy, when compared with placebo, there was a statistically significant reduction in the risk of: </p> <p> <ul id="CD004947-list-0021"> <li> <p>infant birthweight less than 2500 g (three studies; 482 infants; RR 0.48, 95% CI 0.25 to 0.91) <a href="./references#CD004947-fig-0174" title="">Analysis 11.4</a>. </p> </li> </ul> </p> <p>In addition, for women administered progesterone who were considered to be at risk of preterm birth for 'other' reasons, when compared with placebo, there were no statistically significant differences for the outcomes preterm birth less than 37 weeks' gestation <a href="./references#CD004947-fig-0173" title="">Analysis 11.3</a>., perinatal death <a href="./references#CD004947-fig-0171" title="">Analysis 11.1</a>, intrauterine fetal death <a href="./references#CD004947-fig-0175" title="">Analysis 11.5</a> or neonatal death <a href="./references#CD004947-fig-0176" title="">Analysis 11.6</a>. </p> </section> <section id="CD004947-sec-0126"> <h5 class="title">Secondary childhood outcomes</h5> <p>There were no secondary childhood outcomes reported.</p> </section> <section id="CD004947-sec-0127"> <h5 class="title">Effect of route of administration, time of commencing therapy, and dose of progesterone</h5> <p>We investigated statistical heterogeneity (I² &gt; 30%) by performing subgroup analysis for perinatal death <a href="./references#CD004947-fig-0178" title="">Analysis 12.1</a>, preterm birth less than 37 weeks <a href="./references#CD004947-fig-0179" title="">Analysis 12.2</a>, and infant birthweight less than 2500 g, <a href="./references#CD004947-fig-0180" title="">Analysis 12.3</a>, and no differential effect was observed related for gestational age at commencing therapy, (test for subgroup differences: P = 0.10, I² = 63.9%, <a href="./references#CD004947-fig-0179" title="">Analysis 12.2</a>; P = 0.19, I² = 42.2%, <a href="./references#CD004947-fig-0180" title="">Analysis 12.3</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004947-sec-0128" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004947-sec-0128"></div> <p>The randomised trials identified assessed the use of progesterone in women considered to be at increased risk of preterm birth by virtue of history of spontaneous preterm birth, ultrasonographic evaluation of cervical length, presentation in threatened preterm labour, multiple pregnancy, or other reasons (including 'high preterm risk score' and active military duty). </p> <section id="CD004947-sec-0129"> <h3 class="title" id="CD004947-sec-0129">Summary of main results</h3> <section id="CD004947-sec-0130"> <h4 class="title">Progesterone for women with a past history of spontaneous preterm birth</h4> <p>For women with a past history of spontaneous preterm birth, there was a statistically significant reduction in the risk of the primary outcomes, perinatal death and in the risk of preterm birth less than 34 weeks' gestation. The reduction in risk of perinatal death is confined to the subgroup of women receiving intramuscular progesterone. There was significant heterogeneity identified for the outcomes preterm birth before 34 and 37 weeks’ gestation, with evidence of funnel plot asymmetry, raising questions about potential bias and therefore caution in interpretation. For the secondary infant and maternal outcomes, the use of progesterone was associated with a reduction in the risk of infant birthweight less than 2500 g, use of assisted ventilation, necrotising enterocolitis, neonatal death, admission to neonatal intensive care unit, preterm birth less than 37 weeks' gestation and a significant increase in prolongation in pregnancy prolongation. There were no significant differences identified for other secondary infant and maternal health outcomes with the use of progesterone. Information related to childhood health and well being is limited, with only two trials reporting two‐year follow‐up results to date (<a href="./references#CD004947-bbs2-0099" title="NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. ">Northen 2007</a>; <a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>), in which there were no documented differences in growth or developmental outcomes between those infants exposed in utero to progesterone and those to placebo. There was no differential effect on outcomes in terms of time of commencing therapy and dose of progesterone from the available evidence. </p> <p>Further information is required about the optimal route of administration of progesterone, with the largest study to date using vaginal progesterone gel suggesting no benefit in this group of women (<a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>). </p> </section> <section id="CD004947-sec-0131"> <h4 class="title">Progesterone for women with a short cervix identified on ultrasound</h4> <p>In the trials to date assessing the role of progesterone in women with a short cervix identified on ultrasound (<a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>; <a href="./references#CD004947-bbs2-0015" title="GrobmanW . RCT of progesterone to prevent preterm birth in nulliparous women with a short cervix. http://controlledtrials.com(accessed 2007). GrobmanW . Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S367. GrobmanWA , ThomEA , SpongCY , IamsJD , SaadeGR , MercerBM , et al. 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;207(5):390.e1‐8. ">Grobman 2012</a>; <a href="./references#CD004947-bbs2-0017" title="HassanSS , RomeroR , VidyadhariD , FuseyS , BaxterJK , KhandelwalM , et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(1):18‐31. ">Hassan 2011</a>; <a href="./references#CD004947-bbs2-0032" title="RozenbergP . Efficacy of 17 alpha‐hydroxyprogesterone caproate for the prevention of preterm delivery. http://controlledtrials.com(accessed 2007). RozenbergP , ChauveaudA , DeruelleP , CapelleM , WinerN ,  DesbriereR , et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. American Journal of Obstetrics &amp; Gynecology2012;206(3):206.e1‐9. RozenbergP , DeruelleP , ChauveaudA , CapelleM , WinerN , PorcherR , et al. Prevention of preterm delivery after successful tocolysis in preterm labour by 17 alpha‐hydroxyprogesterone caproate: a randomised controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S2‐S3. ">Rozenberg 2012</a>), there were no statistically significant differences identified for the primary outcome perinatal death. Women administered progesterone were significantly less likely to have preterm birth less than 34 weeks' gestation. For the secondary infant outcomes, the use of progesterone was associated with a reduction in risk of preterm birth at less than 28 weeks' gestation. There was also a significant increase in the risk urticaria in women receiving progesterone. Further information is required about the risk of other infant health outcomes, and maternal health outcomes in this group of women. Reporting of childhood outcomes is lacking, with no trials reporting this information to date. The relative efficacy of progesterone compared with cerclage for women with a short cervix remains uncertain, as does the use of progesterone as an adjunct therapy following cerclage placement (<a href="./references#CD004947-bbs2-0075" title="Conde‐AgudeloA , RomeroR , NicolaidesK , ChaiworapongsaT , O'BrienJM , CetingozE , et al. Vaginal progesterone vs. cervical cerclage for the prevention of preterm birth in women with a sonographic short cervix, previous preterm birth, and singleton gestation: a systematic review and indirect comparison metaanalysis. American Journal of Obstetrics and Gynecology2013;208(1):42.e1‐42.e18. ">Conde‐Agudelo 2013</a>). </p> </section> <section id="CD004947-sec-0132"> <h4 class="title">Progesterone for women with a multiple pregnancy</h4> <p>The role of progesterone in women with a multiple pregnancy is less clear, with no identified differences in the primary outcomes perinatal death, and preterm birth less than 34 weeks' gestation. There were also no differences identified for the other secondary infant and maternal health outcomes. Information relating to long‐term childhood health outcomes is unavailable to date. There are several ongoing randomised trials assessing the role of intramuscular (<a href="./references#CD004947-bbs2-0057" title="NassarA . Prevention of preterm delivery in twin pregnancies by 17 alpha hydroxyprogesterone caproate. http://controlledtrials.com(accessed 2007). NassarA , AwwadJ , SuccarJ , SaassouhW , KhalifeT , HayekS , et al. Incidence of GDM in twin pregnancies of women receiving prophylactic 17‐A OH progesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):307‐8. ">Nassar 2007</a>) and vaginal (<a href="./references#CD004947-bbs2-0063" title="WoodS . Vaginal progesterone versus placebo in multiple pregnancy. http://controlledtrials.com(accessed 2007). ">Wood 2007</a>) progesterone in women with a multiple pregnancy which will contribute information about the role of progesterone in this group of women. </p> <p>For multiple pregnancies, we had planned to analyse neonatal data as 'clusters' to account for dependency between twins and triplets. We anticipated that the degree of dependence between twins would vary at the outcome level i.e. in the case of preterm birth the dependency (ICC) is likely to be high, whereas in some outcomes such as perinatal death or morbidity, the ICC may be much lower. However, there were insufficient data presented in the trial reports to allow us to carry out necessary adjustment for cluster design effect ourselves and, although in several trials results had already been adjusted, we were not able to present these data in our data and analyses tables because they were not reported in a consistent way. In future updates, we will contact trial authors for additional information to allow us to carry out necessary adjustments in the analysis of the neonatal data. </p> </section> <section id="CD004947-sec-0133"> <h4 class="title">Progesterone for women following presentation with threatened preterm labour</h4> <p>The role of progesterone for women following presentation with threatened preterm labour remains uncertain. The identified randomised trials indicate a reduction in only the risk of infant birthweight less than 2500 g. However, the outcomes have been reported in only five small trials (332 women), with only four contributing data to meta‐analysis (211 women) and are underpowered to detect differences in both maternal and infant health outcomes. There is an ongoing randomised trial assessing the role of vaginal progesterone in women presenting with symptoms or signs of threatened preterm labour which will contribute information about the role of progesterone in this group of women (<a href="./references#CD004947-bbs2-0056" title="Matrinez de TajadaB . Vaginal progesterone to prevent preterm delivery in women with preterm labor. http://controlledtrials.com(accessed 2007). ">Martinez 2007</a>). </p> </section> <section id="CD004947-sec-0134"> <h4 class="title">Progesterone versus placebo for women with 'other' risk factors for preterm birth</h4> <p>The role of progesterone in women considered to be at risk of preterm birth for 'other reasons' is uncertain, with the three randomised trials that contributed data to the meta‐analysis to date indicating no benefit in terms of perinatal death or preterm birth less than 37 weeks' gestation. However, the combined sample size of these trials is significantly underpowered to detect all but large differences in these outcomes. </p> <p>There is evidence that progesterone for women with a history of previous preterm birth is associated with a reduction in preterm birth before 34 and 37 weeks gestation. As indicated earlier, there was considerable heterogeneity identified, in addition to evidence of funnel plot asymmetry, raising concern about potential bias. The observed reduction in perinatal mortality appears confined to the use of intramuscular progesterone. </p> <p>However, information relating to longer‐term infant and childhood outcomes is currently insufficient, with only two randomised trials reporting to date. Ongoing follow‐up of children exposed to progesterone in utero remains a priority. Maternal outcomes following antenatal progesterone therapy were poorly reported in the available literature, including treatment side‐effects, preferences of mode of administration and satisfaction of care. Further information is required on these important issues (<a href="./references#CD004947-bbs2-0081" title="GreeneMF . Progesterone and preterm delivery ‐ deja vu all over again. New England Medical Journal2003;348:2453‐5. ">Greene 2003</a>; <a href="./references#CD004947-bbs2-0090" title="IamsJD . Supplemental progesterone to prevent preterm birth. American Journal Obstetrics and Gynecology2003;188(2):303. ">Iams 2003</a>). In addition, there remains uncertainty as to the optimal dose of progesterone to be administered, the optimal route of administration, and the optimal gestational age at which to commence therapy. The American College of Obstetricians and Gynecologists have issued a committee opinion relating to the use of progesterone for the prevention of preterm birth, indicating the need for further information about the optimal mode of administration (<a href="./references#CD004947-bbs2-0064" title="American College of Obstetrics and Gynecology. Committee opinion: use of progesterone to reduce preterm birth. Obstetrics &amp; Gynecology2003;102:1115‐6. ">ACOG 2003</a>), including studies directly comparing the relative efficacy of vaginal and intramuscular preparations. </p> </section> </section> <section id="CD004947-sec-0135"> <h3 class="title" id="CD004947-sec-0135">Overall completeness and applicability of evidence</h3> <p>The majority of studies to date have reported short‐term maternal and infant outcomes, with only two studies reporting longer‐term childhood outcomes (<a href="./references#CD004947-bbs2-0099" title="NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. ">Northen 2007</a>; <a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>). </p> <p>As outlined above, there are a number of ongoing studies which will contribute to the evidence relating to the use of progesterone for women considered at risk of preterm birth. The trials by Crowther (<a href="./references#CD004947-bbs2-0055" title="ArmsonBA , DoddJ , for the POPPI Collaborative Trial Group. POPPI: prevention of problems of preterm birth with progesterone in women at increased risk: a multicentre randomised controlled trial [abstract]. Journal of Paediatrics and Child Health2007;43:A29. AshwoodP . Progesterone after previous preterm birth for the prevention of neonatal respiratory distress syndrome. WOMBAT Collaboration (www.wombatcollaboration.net/trials) (accessed 4 October 2006). CrowtherCA , DoddJM , McPheeAJ , FlenadyV . Australasian Collaborative Trial of Vaginal Progesterone Therapy (The PROGRESS Trial). http://controlledtrials.com(accessed 2007). DoddJM , CrowtherCA , McPheeAJ , FlenadyV , RobinsonJS . Progesterone after previous preterm birth for prevention of neonatal respiratory distress syndrome (PROGRESS): a randomised controlled trial. BMC Pregnancy and Childbirth2009;9:6. ">Crowther 2007</a>), Norman (<a href="./references#CD004947-bbs2-0058" title="NormanJE , ShennanA , BennettP , ThorntonS , RobsonS , MarlowN , et al. Trial protocol OPPTIMUM‐ Does progesterone prophylaxis for the prevention of preterm labour improve outcome?. BMC pregnancy and childbirth2012;12(1):79. [PUBMED: 22866909] ">Norman 2012</a>), and Perlitz (<a href="./references#CD004947-bbs2-0059" title="PerlitzY . Prevention of recurrent preterm delivery by a natural progesterone agent. http://controlledtrials.com(accessed 2007). ">Perlitz 2007</a>) will contribute data from women with a prior preterm birth; van Os (<a href="./references#CD004947-bbs2-0062" title="vanOsMA , van derVenJA , KleinrouwelerCE , PajkrtE , deMirandaE , vanWassenaerA , et al. Preventing preterm birth with progesterone: Costs and effects of screening low risk women with a singleton pregnancy for short cervical length, the Triple P study. BMC Pregnancy and Childbirth2011;11:77. ">van Os 2011</a>) will contribute data from women with a short cervix identified by ultrasound; Nassar (<a href="./references#CD004947-bbs2-0057" title="NassarA . Prevention of preterm delivery in twin pregnancies by 17 alpha hydroxyprogesterone caproate. http://controlledtrials.com(accessed 2007). NassarA , AwwadJ , SuccarJ , SaassouhW , KhalifeT , HayekS , et al. Incidence of GDM in twin pregnancies of women receiving prophylactic 17‐A OH progesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):307‐8. ">Nassar 2007</a>), and Wood (<a href="./references#CD004947-bbs2-0063" title="WoodS . Vaginal progesterone versus placebo in multiple pregnancy. http://controlledtrials.com(accessed 2007). ">Wood 2007</a>) will contribute data from women with a multiple pregnancy; and Martinez (<a href="./references#CD004947-bbs2-0056" title="Matrinez de TajadaB . Vaginal progesterone to prevent preterm delivery in women with preterm labor. http://controlledtrials.com(accessed 2007). ">Martinez 2007</a>) will contribute data from women who present with symptoms or signs of threatened preterm labour. </p> </section> <section id="CD004947-sec-0136"> <h3 class="title" id="CD004947-sec-0136">Quality of the evidence</h3> <p>Overall, the trials included in this review were considered to be of good to fair quality. Of the 36 included trials, adequate randomisation methods were described in 23 (<a href="./references#CD004947-bbs2-0003" title="BornaS , SahabiN . Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2008;48(1):58‐63. BornaS , ShakoieS , BornaH . Progesterone for maintenance tocolytic therapy after threatened preterm labor. Randomized controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:151‐2. ">Borna 2008</a>; <a href="./references#CD004947-bbs2-0004" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. BrieryCM , VeillonEW , KlauserCK , MartinRW , MagannEF , ChauhanSP , et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. American Journal of Obstetrics and Gynecology2011;204(1):54.e1‐5. ">Briery 2011</a>; <a href="./references#CD004947-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>; <a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>; <a href="./references#CD004947-bbs2-0009" title="CombsCA , GariteTJ , MaurelK , MalloryK , EdwardsRK , LuG , et al. 17‐Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double‐blind, randomized clinical trial. BMC Research Notes2011;4(1):568. ">Combs 2011a</a>; <a href="./references#CD004947-bbs2-0010" title="daFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics &amp; Gynecology2003;188(2):419‐24. daFonsecaEB , BittarRE , CarvalhoMHB , MartinelliS , ZugaibM . Uterine contraction monitoring in pregnant women using vaginal natural progesterone. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):525. ">da Fonseca 2003</a>; <a href="./references#CD004947-bbs2-0012" title="FacchinettiF , DanteG , VenturiniP , PaganelliS , VolpeA . 17alpha‐hydroxy‐progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery. American Journal of Perinatology2008;25(8):503‐6. FacchinettiF , PaganelliS , ComitinitG , DanteG , VolpeA . Cervical length changes during preterm cervical ripening: effects of 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2007;196:453e1‐453e4. FacchinettiF , PaganelliS , VenturiniP , DanteG . 17 alpha hydroxy‐progesterone caproate (17P) treatment reduced cervical shortening inhibiting cervical interleukin‐1 secretion. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S5. ">Facchinetti 2007</a>; <a href="./references#CD004947-bbs2-0014" title="GloverM , CroomCS , SonekJD , KovacC , McKennaD . A randomized placebo controlled trial of oral micronized progesterone to prevent recurrent preterm birth. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S172. GloverMM , McKennaDS , DowningCM , SmithDB , CroomCS , SonekJD . A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. American Journal of Perinatology2011;28(5):377‐81. ">Glover 2011</a>; <a href="./references#CD004947-bbs2-0015" title="GrobmanW . RCT of progesterone to prevent preterm birth in nulliparous women with a short cervix. http://controlledtrials.com(accessed 2007). GrobmanW . Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S367. GrobmanWA , ThomEA , SpongCY , IamsJD , SaadeGR , MercerBM , et al. 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;207(5):390.e1‐8. ">Grobman 2012</a>; <a href="./references#CD004947-bbs2-0017" title="HassanSS , RomeroR , VidyadhariD , FuseyS , BaxterJK , KhandelwalM , et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(1):18‐31. ">Hassan 2011</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0022" title="MajhiP , BaggaR , KalraJ , SharmaM . Intravaginal use of natural micronised progesterone to prevent pre‐term birth: a randomised trial in India. Journal of Obstetrics and Gynaecology2009;29(6):493‐8. ">Majhi 2009</a>; <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>; <a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>; <a href="./references#CD004947-bbs2-0029" title="RaiP , RajaramS , GoelN , Ayalur GopalakrishnanR , AgarwalR , MehtaS . Oral micronized progesterone for prevention of preterm birth. International Journal of Gynecology &amp; Obstetrics2009;104(1):40‐3. ">Rai 2009</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>; <a href="./references#CD004947-bbs2-0031" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S197. ManuckT , for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha‐hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S18. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 Alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357:454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD004947-bbs2-0032" title="RozenbergP . Efficacy of 17 alpha‐hydroxyprogesterone caproate for the prevention of preterm delivery. http://controlledtrials.com(accessed 2007). RozenbergP , ChauveaudA , DeruelleP , CapelleM , WinerN ,  DesbriereR , et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. American Journal of Obstetrics &amp; Gynecology2012;206(3):206.e1‐9. RozenbergP , DeruelleP , ChauveaudA , CapelleM , WinerN , PorcherR , et al. Prevention of preterm delivery after successful tocolysis in preterm labour by 17 alpha‐hydroxyprogesterone caproate: a randomised controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S2‐S3. ">Rozenberg 2012</a>; <a href="./references#CD004947-bbs2-0034" title="SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: A randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2012</a>; <a href="./references#CD004947-bbs2-0035" title="SerraV . Natural progesterone and preterm birth in twins. http://controlledtrials.com(accessed 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>), allocation concealment was assessed to be at low risk of bias in 23 (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD004947-bbs2-0004" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. BrieryCM , VeillonEW , KlauserCK , MartinRW , MagannEF , ChauhanSP , et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. American Journal of Obstetrics and Gynecology2011;204(1):54.e1‐5. ">Briery 2011</a>; <a href="./references#CD004947-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>; <a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>; <a href="./references#CD004947-bbs2-0009" title="CombsCA , GariteTJ , MaurelK , MalloryK , EdwardsRK , LuG , et al. 17‐Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double‐blind, randomized clinical trial. BMC Research Notes2011;4(1):568. ">Combs 2011a</a>; <a href="./references#CD004947-bbs2-0010" title="daFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics &amp; Gynecology2003;188(2):419‐24. daFonsecaEB , BittarRE , CarvalhoMHB , MartinelliS , ZugaibM . Uterine contraction monitoring in pregnant women using vaginal natural progesterone. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):525. ">da Fonseca 2003</a>; <a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>; <a href="./references#CD004947-bbs2-0014" title="GloverM , CroomCS , SonekJD , KovacC , McKennaD . A randomized placebo controlled trial of oral micronized progesterone to prevent recurrent preterm birth. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S172. GloverMM , McKennaDS , DowningCM , SmithDB , CroomCS , SonekJD . A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. American Journal of Perinatology2011;28(5):377‐81. ">Glover 2011</a>; <a href="./references#CD004947-bbs2-0015" title="GrobmanW . RCT of progesterone to prevent preterm birth in nulliparous women with a short cervix. http://controlledtrials.com(accessed 2007). GrobmanW . Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S367. GrobmanWA , ThomEA , SpongCY , IamsJD , SaadeGR , MercerBM , et al. 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;207(5):390.e1‐8. ">Grobman 2012</a>; <a href="./references#CD004947-bbs2-0017" title="HassanSS , RomeroR , VidyadhariD , FuseyS , BaxterJK , KhandelwalM , et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(1):18‐31. ">Hassan 2011</a>; <a href="./references#CD004947-bbs2-0020" title="JohnsonJWC , AustinKL , JonesGS , DavisGH , KingTM . Efficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine1975;293(14):675‐80. KlebanoffM , for the NICHD MFMU Network. Impact of 17alpha hydroxyprogesterone caproate administration on salivary progesterone and estriol [abstract]. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S140. ">Johnson 1975</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0022" title="MajhiP , BaggaR , KalraJ , SharmaM . Intravaginal use of natural micronised progesterone to prevent pre‐term birth: a randomised trial in India. Journal of Obstetrics and Gynaecology2009;29(6):493‐8. ">Majhi 2009</a>; <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>; <a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>; <a href="./references#CD004947-bbs2-0029" title="RaiP , RajaramS , GoelN , Ayalur GopalakrishnanR , AgarwalR , MehtaS . Oral micronized progesterone for prevention of preterm birth. International Journal of Gynecology &amp; Obstetrics2009;104(1):40‐3. ">Rai 2009</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>; <a href="./references#CD004947-bbs2-0031" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S197. ManuckT , for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha‐hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S18. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 Alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357:454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD004947-bbs2-0034" title="SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: A randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2012</a>; <a href="./references#CD004947-bbs2-0035" title="SerraV . Natural progesterone and preterm birth in twins. http://controlledtrials.com(accessed 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>), and blinding was achieved with the use of a placebo agent in 25 (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD004947-bbs2-0004" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. BrieryCM , VeillonEW , KlauserCK , MartinRW , MagannEF , ChauhanSP , et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. American Journal of Obstetrics and Gynecology2011;204(1):54.e1‐5. ">Briery 2011</a>; <a href="./references#CD004947-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>; <a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>; <a href="./references#CD004947-bbs2-0009" title="CombsCA , GariteTJ , MaurelK , MalloryK , EdwardsRK , LuG , et al. 17‐Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double‐blind, randomized clinical trial. BMC Research Notes2011;4(1):568. ">Combs 2011a</a>; <a href="./references#CD004947-bbs2-0010" title="daFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics &amp; Gynecology2003;188(2):419‐24. daFonsecaEB , BittarRE , CarvalhoMHB , MartinelliS , ZugaibM . Uterine contraction monitoring in pregnant women using vaginal natural progesterone. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):525. ">da Fonseca 2003</a>; <a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>; <a href="./references#CD004947-bbs2-0014" title="GloverM , CroomCS , SonekJD , KovacC , McKennaD . A randomized placebo controlled trial of oral micronized progesterone to prevent recurrent preterm birth. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S172. GloverMM , McKennaDS , DowningCM , SmithDB , CroomCS , SonekJD . A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. American Journal of Perinatology2011;28(5):377‐81. ">Glover 2011</a>; <a href="./references#CD004947-bbs2-0015" title="GrobmanW . RCT of progesterone to prevent preterm birth in nulliparous women with a short cervix. http://controlledtrials.com(accessed 2007). GrobmanW . Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S367. GrobmanWA , ThomEA , SpongCY , IamsJD , SaadeGR , MercerBM , et al. 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. American Journal of Obstetrics and Gynecology2012;207(5):390.e1‐8. ">Grobman 2012</a>; <a href="./references#CD004947-bbs2-0016" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56(6):692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen 1980</a>; <a href="./references#CD004947-bbs2-0017" title="HassanSS , RomeroR , VidyadhariD , FuseyS , BaxterJK , KhandelwalM , et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(1):18‐31. ">Hassan 2011</a>; <a href="./references#CD004947-bbs2-0018" title="HauthJC , GilstrapLC , BrekkenAL , HauthJM . The effect of 17 alpha‐hydroxyprogesterone caproate on pregnancy outcome in an active‐duty military population. American Journal of Obstetrics and Gynecology1983;146(2):187‐90. ">Hauth 1983</a>; <a href="./references#CD004947-bbs2-0020" title="JohnsonJWC , AustinKL , JonesGS , DavisGH , KingTM . Efficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine1975;293(14):675‐80. KlebanoffM , for the NICHD MFMU Network. Impact of 17alpha hydroxyprogesterone caproate administration on salivary progesterone and estriol [abstract]. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S140. ">Johnson 1975</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>; <a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>; <a href="./references#CD004947-bbs2-0028" title="Papiernik‐BerkhauerE . Double blind study of an agent to prevent preterm delivery among women at increased risk [Etude en double aveugle d'un medicament prevenant la survenue prematuree de l'accouchement chez les femmes a risque eleve d'accouchement premature]. Edition Schering Serie IV1970; Vol. 3:65‐8. ">Papiernik 1970</a>; <a href="./references#CD004947-bbs2-0029" title="RaiP , RajaramS , GoelN , Ayalur GopalakrishnanR , AgarwalR , MehtaS . Oral micronized progesterone for prevention of preterm birth. International Journal of Gynecology &amp; Obstetrics2009;104(1):40‐3. ">Rai 2009</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>; <a href="./references#CD004947-bbs2-0031" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S197. ManuckT , for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha‐hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S18. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 Alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357:454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD004947-bbs2-0035" title="SerraV . Natural progesterone and preterm birth in twins. http://controlledtrials.com(accessed 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>; <a href="./references#CD004947-bbs2-0036" title="SharamiSH , ZahiriZ , ShakibaM , MilaniF . Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: a randomized placebo‐controlled double‐blind trial. International Journal of Fertility and Sterility2010;4(2):45‐50. ">Sharami 2010</a>).Twenty‐one of the 36 included studies were assessed as being at low risk of bias for other potential sources of bias (<a href="./references#CD004947-bbs2-0003" title="BornaS , SahabiN . Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology2008;48(1):58‐63. BornaS , ShakoieS , BornaH . Progesterone for maintenance tocolytic therapy after threatened preterm labor. Randomized controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2008; Vol. 21, issue Suppl 1:151‐2. ">Borna 2008</a>; <a href="./references#CD004947-bbs2-0004" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. BrieryCM , VeillonEW , KlauserCK , MartinRW , MagannEF , ChauhanSP , et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. American Journal of Obstetrics and Gynecology2011;204(1):54.e1‐5. ">Briery 2011</a>; <a href="./references#CD004947-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>; <a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>; <a href="./references#CD004947-bbs2-0010" title="daFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics &amp; Gynecology2003;188(2):419‐24. daFonsecaEB , BittarRE , CarvalhoMHB , MartinelliS , ZugaibM . Uterine contraction monitoring in pregnant women using vaginal natural progesterone. Journal of Perinatal Medicine2001;29 Suppl 1(Pt 2):525. ">da Fonseca 2003</a>; <a href="./references#CD004947-bbs2-0012" title="FacchinettiF , DanteG , VenturiniP , PaganelliS , VolpeA . 17alpha‐hydroxy‐progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery. American Journal of Perinatology2008;25(8):503‐6. FacchinettiF , PaganelliS , ComitinitG , DanteG , VolpeA . Cervical length changes during preterm cervical ripening: effects of 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2007;196:453e1‐453e4. FacchinettiF , PaganelliS , VenturiniP , DanteG . 17 alpha hydroxy‐progesterone caproate (17P) treatment reduced cervical shortening inhibiting cervical interleukin‐1 secretion. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S5. ">Facchinetti 2007</a>; <a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>; <a href="./references#CD004947-bbs2-0014" title="GloverM , CroomCS , SonekJD , KovacC , McKennaD . A randomized placebo controlled trial of oral micronized progesterone to prevent recurrent preterm birth. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S172. GloverMM , McKennaDS , DowningCM , SmithDB , CroomCS , SonekJD . A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. American Journal of Perinatology2011;28(5):377‐81. ">Glover 2011</a>; <a href="./references#CD004947-bbs2-0017" title="HassanSS , RomeroR , VidyadhariD , FuseyS , BaxterJK , KhandelwalM , et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(1):18‐31. ">Hassan 2011</a>; <a href="./references#CD004947-bbs2-0018" title="HauthJC , GilstrapLC , BrekkenAL , HauthJM . The effect of 17 alpha‐hydroxyprogesterone caproate on pregnancy outcome in an active‐duty military population. American Journal of Obstetrics and Gynecology1983;146(2):187‐90. ">Hauth 1983</a>; <a href="./references#CD004947-bbs2-0020" title="JohnsonJWC , AustinKL , JonesGS , DavisGH , KingTM . Efficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine1975;293(14):675‐80. KlebanoffM , for the NICHD MFMU Network. Impact of 17alpha hydroxyprogesterone caproate administration on salivary progesterone and estriol [abstract]. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S140. ">Johnson 1975</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0023" title="GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. KlebanoffMA , MeisPJ , DombrowskiMP , ZhaoY , MoawadAH , NorthenA , et al. Salivary progesterone and estriol among pregnant women treated with 17‐alpha‐hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology2008;199(5):506.e1‐7. KoontzG . Does gestational age at randomization affect the efficacy of alpha hydroxyprogesterone caproate (17‐OHCP) in preventing recurrent preterm delivery? [abstract]. American Journal of Obstetrics and Gynecology2005;193(6 Suppl 1):S55. ManuckTA , LaiY , MeisPJ , DombrowskiMP , SibaiB , SpongCY , et al. Progesterone receptor polymorphisms and clinical response to 17‐alpha‐hydroxyprogesterone caproate. American Journal of Obstetrics &amp; Gynecology2011;205(2):135.e1‐9. MeisP , NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha‐hydroxyprogesterone (17P) [abstract]. American Journal of Obstetrics and Gynecology2003;189(6):S168. MeisPJ , KlebanoffM , DombrowskiMP , SibaiBM , LeindeckerS , MoawadAH , et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstetrics &amp; Gynecology2005;106(3):557‐61. MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. MeisPJ , NICHD MFMU Network. 17 alphahydroxyprogesterone caproate prevents recurrent preterm birth [abstract]. American Journal of Obstetrics and Gynecology2002;187(6 Pt 2):S54. NorthenA . 4‐year follow‐up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S6. NorthenAT , NormanGS , AndersonK , Moseley , L , DivitoM , CotroneoM , et al. Follow‐up of children exposed in utero to 17 alpha‐hydroxyprogesterone caproate compared with placebo. Obstetrics &amp; Gynecology2007;110(4):864‐72. SibaiB . Plasma CRH levels at 16‐20 weeks do not predict preterm delivery in women at high‐risk for preterm delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S114. SibaiB , MeisPJ , KlebanoffM , DombrowskiMP , WeinerSJ , MoawadAH , et al. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high‐risk for preterm delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1181‐6. SpongCY . Progesterone for prevention of recurrent preterm birth: impact of gestational age at prior delivery [abstract]. American Journal of Obstetrics and Gynecology2004;191(6 Suppl 1):S11. SpongCY , MeisPJ , ThomEA , SibaiB , DombrowskiMP , MoawadAH , et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology2005;193(3 Pt 2):1127‐31. ">Meis 2003</a>; <a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD004947-bbs2-0027" title="DeFrancoEA , O'BrienJM , AdairCD , LewisDF , HallDR , FuseyS , et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics and Gynecology2007; Vol. 30, issue 5:697‐705. DefrancoE , O'BrienJ , AdairJ , LewisDF , HallD , PhillipsJ , et al. Is there a racial disparity of progesterone to prevent preterm birth. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S200, Abstract no: 702. O'BrienJ , DefrancoE , AdairD , LewisDF , HallD , BsharatM , et al. Progesterone reduces the rate of cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2007; Vol. 197, issue 6 Suppl 1:S7, Abstract no: 15. O'BrienJ , DefrancoE , HallD , CreasyG . Natural progesterone administration and the risk of medical complications of pregnancy: secondary analysis from a multinational, randomized, double blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S139. O'BrienJ , DefrancoE , HallD , PhillipsJ , CreasyG . Do other elements of the obstetrical history provide a possible indication for progesterone supplementation? Secondary analysis from the progesterone vaginal gel trial. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S42. O'BrienJM , AdairCD , LewisDF , HallDR , DefrancoEA , FuseyS , et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized double blind placebo controlled trial. Ultrasound in Obstetrics and Gynecology2007;30(5):687‐96. O'BrienJM , DefrancoEA , AdairCD , LewisDF , HallDR , HowH , et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double‐blind, placebo‐controlled trial. Ultrasound in Obstetrics &amp; Gynecology2010;34(6):653‐9. O'BrienJM , SteichenJJ , PhillipsJA , CreasyGW . Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S223. ">O'Brien 2007</a>; <a href="./references#CD004947-bbs2-0028" title="Papiernik‐BerkhauerE . Double blind study of an agent to prevent preterm delivery among women at increased risk [Etude en double aveugle d'un medicament prevenant la survenue prematuree de l'accouchement chez les femmes a risque eleve d'accouchement premature]. Edition Schering Serie IV1970; Vol. 3:65‐8. ">Papiernik 1970</a>; <a href="./references#CD004947-bbs2-0029" title="RaiP , RajaramS , GoelN , Ayalur GopalakrishnanR , AgarwalR , MehtaS . Oral micronized progesterone for prevention of preterm birth. International Journal of Gynecology &amp; Obstetrics2009;104(1):40‐3. ">Rai 2009</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>; <a href="./references#CD004947-bbs2-0033" title="SaghafiN , KhademN , MohajeriT , ShakeriMT . Efficacy of 17alpha‐hydroxyprogesterone caproate in prevention of preterm delivery. Journal of Obstetrics and Gynaecology Research2011;37(10):1342‐5. SaghafiN , KhademN , MohajeriT , ShakeriMT , AminiM . Efficacy of 17alpha‐hydroxyprogesterone caproate in preterm delivery prevention. Iranian Journal of Obstetrics, Gynecology and Infertility2011;14(2):28‐33. ">Saghafi 2011a</a>; <a href="./references#CD004947-bbs2-0036" title="SharamiSH , ZahiriZ , ShakibaM , MilaniF . Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: a randomized placebo‐controlled double‐blind trial. International Journal of Fertility and Sterility2010;4(2):45‐50. ">Sharami 2010</a>). </p> <p>We assessed whether studies that included multiple pregnancies accounted appropriately for non‐independence of babies from the same pregnancy in the analysis. There were 14 studies that included a multiple pregnancy (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD004947-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>; <a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>; <a href="./references#CD004947-bbs2-0011" title="ElsheikhahAZ , DahabS , NegmS , EbrashyA . Effect of prophylactic progesterone on incidence of preterm labour in spontaneous twin pregnancy, randomized controlled study. Ultrasound in Obstetrics and Gynecology2010;36(Suppl 1):108. ">Elsheikhah 2010</a>; <a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>; <a href="./references#CD004947-bbs2-0016" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56(6):692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen 1980</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>; <a href="./references#CD004947-bbs2-0031" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S197. ManuckT , for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha‐hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S18. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 Alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357:454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD004947-bbs2-0034" title="SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: A randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2012</a>; <a href="./references#CD004947-bbs2-0035" title="SerraV . Natural progesterone and preterm birth in twins. http://controlledtrials.com(accessed 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>) and in seven studies adjustment appears to have been made in the analysis (<a href="./references#CD004947-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD004947-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2010</a>; <a href="./references#CD004947-bbs2-0008" title="CombsCA , GariteT , MaurelK , DasA , PortoM , fortheOCRN . 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , fortheOCRN . 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S7. MaurelK , CombsA . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. http://controlledtrials.com(accessed 2007). ">Combs 2011</a>; <a href="./references#CD004947-bbs2-0013" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH . Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357:462‐9. ">Fonseca 2007</a>; <a href="./references#CD004947-bbs2-0021" title="BruinseHW . 17 alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants (The AMPHIA Study). http://www.controlledtrials.com(accessed 2007). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007; Vol. 7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , for theASG . Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl 1):S54. ">Lim 2011</a>; <a href="./references#CD004947-bbs2-0026" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. NormanJ . Double blind randomised placebo controlled trial of progesterone for the prevention of preterm birth. http://controlledtrials.com(accessed 2007). NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD004947-bbs2-0030" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL . The PREDICT study. http://controlledtrials.com(accessed 2007). RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICTG . Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. ">Rode 2011</a>). In the remaining seven studies (<a href="./references#CD004947-bbs2-0001" title="AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD004947-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD004947-bbs2-0011" title="ElsheikhahAZ , DahabS , NegmS , EbrashyA . Effect of prophylactic progesterone on incidence of preterm labour in spontaneous twin pregnancy, randomized controlled study. Ultrasound in Obstetrics and Gynecology2010;36(Suppl 1):108. ">Elsheikhah 2010</a>; <a href="./references#CD004947-bbs2-0016" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17 alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56(6):692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen 1980</a>; <a href="./references#CD004947-bbs2-0031" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S197. ManuckT , for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The relationship between polymorphisms in the human progesterone receptor and clinical response to 17 alpha‐hydroxyprogesterone caproate for the prevention of recurrent spontaneous preterm birth. American Journal of Obstetrics and Gynecology2008; Vol. 199, issue 6 Suppl 1:S18. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 Alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357:454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007;</a><a href="./references#CD004947-bbs2-0034" title="SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: A randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2012</a>; <a href="./references#CD004947-bbs2-0035" title="SerraV . Natural progesterone and preterm birth in twins. http://controlledtrials.com(accessed 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>), it is not clear that any adjustment was made. There was not enough information in the trial reports for us to carry out the necessary adjustments ourselves in the analysis of neonatal outcomes. This information will be sought for future updates. </p> </section> <section id="CD004947-sec-0137"> <h3 class="title" id="CD004947-sec-0137">Potential biases in the review process</h3> <p>The possibility of introducing bias was present at every stage of the reviewing process. We attempted to minimise bias in a number of ways: two review authors assessed eligibility for inclusion, carried out data extraction and assessed risk of bias. Each worked independently. Nevertheless, the process of assessing risk of bias is not an exact science and includes many personal judgements. </p> </section> <section id="CD004947-sec-0138"> <h3 class="title" id="CD004947-sec-0138">Agreements and disagreements with other studies or reviews</h3> <p>Despite the differences in methodology and included studies, our findings of a reduction in preterm birth before 34 weeks' and 28 weeks' gestation for women with a short cervix identified on ultrasound examination, and a reduction in infant respiratory distress syndrome are consistent with those reported in an individual patient data meta‐analysis by Romero and colleagues (<a href="./references#CD004947-bbs2-0108" title="RomeroR , NicolaidesK , Conde‐AgudeloA , TaborA , O'BrienJM , CetingozE , et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. American Journal of Obstetrics and Gynecology2012;206(2):124: 1‐19. ">Romero 2012</a>). Similarly, the findings of a proposed individual patient data meta‐analysis for women with a multiple pregnancy are awaited to evaluate if there are specific subgroups of women with a multiple pregnancy who may receive benefit from progesterone therapy (<a href="./references#CD004947-bbs2-0109" title="SchuitE , StockS , GroenwoldRH , MaurelK , CombsCA , GariteT , et al. Progestogens to prevent preterm birth in twin pregnancies: an individual participant data meta‐analysis of randomized trials. BMC Pregnancy Childbirth2012;15(12):13. ">Schuit 2012</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004947-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004947-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/full#CD004947-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004947-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/full#CD004947-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth, outcome: 1.3 Preterm birth less than 37 weeks." data-id="CD004947-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth, outcome: 1.3 Preterm birth less than 37 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/full#CD004947-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 1 Perinatal mortality." data-id="CD004947-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 1 Perinatal mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 2 Preterm birth less than 34 weeks." data-id="CD004947-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 2 Preterm birth less than 34 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 3 Preterm birth less than 37 weeks." data-id="CD004947-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 3 Preterm birth less than 37 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 4 Threatened preterm labour." data-id="CD004947-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 4 Threatened preterm labour. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 5 Spontaneous vaginal delivery." data-id="CD004947-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 5 Spontaneous vaginal delivery. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 6 Caesarean section." data-id="CD004947-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 6 Caesarean section. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 7 Antenatal corticosteroids." data-id="CD004947-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 7 Antenatal corticosteroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 8 Antenatal tocolysis." data-id="CD004947-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 8 Antenatal tocolysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 9 Infant birthweight less than 2500 g." data-id="CD004947-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 9 Infant birthweight less than 2500 g. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 10 Respiratory distress syndrome." data-id="CD004947-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 10 Respiratory distress syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 11 Use of assisted ventilation." data-id="CD004947-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 11 Use of assisted ventilation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 12 Intraventricular haemorrhage ‐ all grades." data-id="CD004947-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 12 Intraventricular haemorrhage ‐ all grades. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 13 Intraventricular haemorrhage ‐ grade III or IV." data-id="CD004947-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 13 Intraventricular haemorrhage ‐ grade III or IV. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 14 Periventricular leucomalacia." data-id="CD004947-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 14 Periventricular leucomalacia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 15 Retinopathy of prematurity." data-id="CD004947-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 15 Retinopathy of prematurity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 16 Necrotising enterocolitis." data-id="CD004947-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 16 Necrotising enterocolitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 17 Neonatal sepsis." data-id="CD004947-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 17 Neonatal sepsis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 18 Patent ductus arteriosus." data-id="CD004947-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 18 Patent ductus arteriosus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 19 Intrauterine fetal death." data-id="CD004947-fig-0022" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 19 Intrauterine fetal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 20 Neonatal death." data-id="CD004947-fig-0023" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 20 Neonatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 21 Developmental delay." data-id="CD004947-fig-0024" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 21 Developmental delay. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 22 Intellectual impairment." data-id="CD004947-fig-0025" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 22 Intellectual impairment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 23 Motor Impairment." data-id="CD004947-fig-0026" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 23 Motor Impairment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 24 Visual Impairment." data-id="CD004947-fig-0027" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 24 Visual Impairment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 25 Hearing Impairment." data-id="CD004947-fig-0028" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 25 Hearing Impairment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 26 Cerebral palsy." data-id="CD004947-fig-0029" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 26 Cerebral palsy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 27 Learning difficulties." data-id="CD004947-fig-0030" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 27 Learning difficulties. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 28 Height less than 5th centile." data-id="CD004947-fig-0031" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 28 Height less than 5th centile. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 29 Weight less than 5th centile." data-id="CD004947-fig-0032" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 29 Weight less than 5th centile. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 30 Adverse drug reaction." data-id="CD004947-fig-0033" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 30 Adverse drug reaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 31 Pregnancy prolongation (weeks)." data-id="CD004947-fig-0034" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 31 Pregnancy prolongation (weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 32 Apgar score &lt; 7." data-id="CD004947-fig-0035" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 32 Apgar score &lt; 7. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 33 Admission to neonatal intensive care unit." data-id="CD004947-fig-0036" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 33 Admission to neonatal intensive care unit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 34 Neonatal length of hospital stay (days)." data-id="CD004947-fig-0037" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 34 Neonatal length of hospital stay (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 35 Infant weight at 6 months follow‐up (g)." data-id="CD004947-fig-0038" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 35 Infant weight at 6 months follow‐up (g). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 36 Infant weight at 12 months follow‐up (g)." data-id="CD004947-fig-0039" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.36</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 36 Infant weight at 12 months follow‐up (g). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 37 Infant weight at 24 months follow‐up (g)." data-id="CD004947-fig-0040" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.37</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 37 Infant weight at 24 months follow‐up (g). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 38 Infant length at 6 months follow‐up (cm)." data-id="CD004947-fig-0041" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.38</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 38 Infant length at 6 months follow‐up (cm). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 39 Infant length at 12 months follow‐up (cm)." data-id="CD004947-fig-0042" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.39</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 39 Infant length at 12 months follow‐up (cm). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-40.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 40 Infant length at 24 months follow‐up (cm)." data-id="CD004947-fig-0043" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.40</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 40 Infant length at 24 months follow‐up (cm). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 41 Infant head circumference at 6 months follow‐up (cm)." data-id="CD004947-fig-0044" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.41</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 41 Infant head circumference at 6 months follow‐up (cm). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-41.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-42" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-42.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 42 Infant head circumference at 12 months follow‐up (cm)." data-id="CD004947-fig-0045" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-42.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.42</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 42 Infant head circumference at 12 months follow‐up (cm). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-42.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-001-43" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-001-43.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 43 Infant head circumference at 24 months follow‐up (cm)." data-id="CD004947-fig-0046" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-43.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.43</div> <div class="figure-caption"> <p>Comparison 1 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons), Outcome 43 Infant head circumference at 24 months follow‐up (cm). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-001-43.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth, by timing of commencement (&lt; 20 wk v &gt; 20 wk, singletons), Outcome 1 Preterm birth less than 37 weeks." data-id="CD004947-fig-0047" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth, by timing of commencement (&lt; 20 wk v &gt; 20 wk, singletons), Outcome 1 Preterm birth less than 37 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 1 Perinatal death." data-id="CD004947-fig-0048" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 1 Perinatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 2 Preterm birth less than 37 weeks." data-id="CD004947-fig-0049" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 2 Preterm birth less than 37 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 3 Threatened preterm labour." data-id="CD004947-fig-0050" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 3 Threatened preterm labour. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 4 Caesarean section." data-id="CD004947-fig-0051" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 4 Caesarean section. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 5 Antenatal corticosteroids." data-id="CD004947-fig-0052" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 5 Antenatal corticosteroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 6 Need for tocolysis." data-id="CD004947-fig-0053" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 6 Need for tocolysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 7 Respiratory distress syndrome." data-id="CD004947-fig-0054" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 7 Respiratory distress syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 8 Intraventricular haemorrhage ‐ all grades." data-id="CD004947-fig-0055" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 8 Intraventricular haemorrhage ‐ all grades. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 9 Intraventricular haemorrhage ‐ grade III or IV." data-id="CD004947-fig-0056" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 9 Intraventricular haemorrhage ‐ grade III or IV. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 10 Necrotising enterocolitis." data-id="CD004947-fig-0057" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 10 Necrotising enterocolitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 11 Intrauterine fetal death." data-id="CD004947-fig-0058" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 11 Intrauterine fetal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 12 Neonatal death." data-id="CD004947-fig-0059" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons), Outcome 12 Neonatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 1 Perinatal death." data-id="CD004947-fig-0060" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 1 Perinatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 2 Preterm birth less than 34 weeks." data-id="CD004947-fig-0061" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 2 Preterm birth less than 34 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 3 Preterm labour." data-id="CD004947-fig-0062" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 3 Preterm labour. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 4 Prelabour spontaneous rupture of membranes." data-id="CD004947-fig-0063" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 4 Prelabour spontaneous rupture of membranes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 5 Side effects (any)." data-id="CD004947-fig-0064" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 5 Side effects (any). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 6 Side effects (injection site)." data-id="CD004947-fig-0065" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 6 Side effects (injection site). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 7 Side effects (urticaria)." data-id="CD004947-fig-0066" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 7 Side effects (urticaria). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 8 Side effects (nausea)." data-id="CD004947-fig-0067" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 8 Side effects (nausea). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 9 Pregnancy prolongation (days)." data-id="CD004947-fig-0068" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 9 Pregnancy prolongation (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 10 Caesarean section." data-id="CD004947-fig-0069" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 10 Caesarean section. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 11 Antenatal tocolysis." data-id="CD004947-fig-0070" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 11 Antenatal tocolysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 12 Preterm birth less than 37 weeks." data-id="CD004947-fig-0071" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 12 Preterm birth less than 37 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 13 Preterm birth less than 28 weeks." data-id="CD004947-fig-0072" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 13 Preterm birth less than 28 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 14 Infant birthweight less than 2500 g." data-id="CD004947-fig-0073" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 14 Infant birthweight less than 2500 g. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 15 Respiratory distress syndrome." data-id="CD004947-fig-0074" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 15 Respiratory distress syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 16 Apgar score &lt; 7." data-id="CD004947-fig-0075" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 16 Apgar score &lt; 7. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 17 Need for assisted ventilation." data-id="CD004947-fig-0076" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.17</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 17 Need for assisted ventilation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 18 Intraventricular haemorrhage ‐ all grades." data-id="CD004947-fig-0077" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.18</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 18 Intraventricular haemorrhage ‐ all grades. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 19 Intraventricular haemorrhage ‐ grades III or IV." data-id="CD004947-fig-0078" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.19</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 19 Intraventricular haemorrhage ‐ grades III or IV. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 20 Periventricular leucomalacia." data-id="CD004947-fig-0079" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.20</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 20 Periventricular leucomalacia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 21 Retinopathy of prematurity." data-id="CD004947-fig-0080" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.21</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 21 Retinopathy of prematurity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 22 Necrotising enterocolitis." data-id="CD004947-fig-0081" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.22</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 22 Necrotising enterocolitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 23 Neonatal sepsis." data-id="CD004947-fig-0082" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.23</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 23 Neonatal sepsis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 24 Intrauterine fetal death." data-id="CD004947-fig-0083" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.24</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 24 Intrauterine fetal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 25 Neonatal death." data-id="CD004947-fig-0084" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.25</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 25 Neonatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-004-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-004-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 26 Admission to neonatal intensive care unit." data-id="CD004947-fig-0085" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.26</div> <div class="figure-caption"> <p>Comparison 4 Progesterone versus placebo: ultrasound identified short cervix, singletons, Outcome 26 Admission to neonatal intensive care unit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-004-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Progesterone versus placebo: ultrasound identified short cervix, singletons by cumulative weekly dose (&lt;500 mg v &gt;=500 mg), Outcome 1 Periventricular leucomalacia." data-id="CD004947-fig-0086" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Progesterone versus placebo: ultrasound identified short cervix, singletons by cumulative weekly dose (&lt;500 mg v &gt;=500 mg), Outcome 1 Periventricular leucomalacia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Progesterone versus placebo: ultrasound identified short cervix, singletons by cumulative weekly dose (&lt;500 mg v &gt;=500 mg), Outcome 2 Admission to neonatal intensive care unit." data-id="CD004947-fig-0087" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Progesterone versus placebo: ultrasound identified short cervix, singletons by cumulative weekly dose (&lt;500 mg v &gt;=500 mg), Outcome 2 Admission to neonatal intensive care unit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 1 Perinatal death." data-id="CD004947-fig-0088" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 1 Perinatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 2 Preterm birth less than 34 weeks." data-id="CD004947-fig-0089" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 2 Preterm birth less than 34 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 3 Preterm PROM." data-id="CD004947-fig-0090" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 3 Preterm PROM.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 4 Adverse drug reaction." data-id="CD004947-fig-0091" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 4 Adverse drug reaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 5 Caesarean section." data-id="CD004947-fig-0092" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 5 Caesarean section. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 6 Spontaneous birth." data-id="CD004947-fig-0093" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 6 Spontaneous birth. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 7 Assisted birth." data-id="CD004947-fig-0094" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 7 Assisted birth.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 8 Satisfaction with therapy." data-id="CD004947-fig-0095" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 8 Satisfaction with therapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 9 Antenatal tocolysis." data-id="CD004947-fig-0096" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 9 Antenatal tocolysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 10 Antenatal corticosteroids." data-id="CD004947-fig-0097" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 10 Antenatal corticosteroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 11 Preterm birth less than 37 weeks." data-id="CD004947-fig-0098" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 11 Preterm birth less than 37 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 12 Preterm birth less than 28 weeks." data-id="CD004947-fig-0099" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 12 Preterm birth less than 28 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 13 Infant birthweight less than 2500 g." data-id="CD004947-fig-0100" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.13</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 13 Infant birthweight less than 2500 g. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 14 Apgar score &lt; 7 at 5 minutes." data-id="CD004947-fig-0101" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.14</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 14 Apgar score &lt; 7 at 5 minutes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 15 Respiratory distress syndrome." data-id="CD004947-fig-0102" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.15</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 15 Respiratory distress syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 16 Use of assisted ventilation." data-id="CD004947-fig-0103" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.16</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 16 Use of assisted ventilation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 17 Intraventricular haemorrhage ‐ grades III or IV." data-id="CD004947-fig-0104" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.17</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 17 Intraventricular haemorrhage ‐ grades III or IV. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 18 Intraventricular haemorrhage ‐ all grades." data-id="CD004947-fig-0105" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.18</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 18 Intraventricular haemorrhage ‐ all grades. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 19 Periventricular leucomalacia." data-id="CD004947-fig-0106" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.19</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 19 Periventricular leucomalacia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 20 Retinopathy of prematurity." data-id="CD004947-fig-0107" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.20</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 20 Retinopathy of prematurity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 21 Chronic lung disease." data-id="CD004947-fig-0108" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.21</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 21 Chronic lung disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 22 Necrotising enterocolitis." data-id="CD004947-fig-0109" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.22</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 22 Necrotising enterocolitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 23 Neonatal sepsis." data-id="CD004947-fig-0110" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.23</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 23 Neonatal sepsis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 24 Fetal death." data-id="CD004947-fig-0111" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.24</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 24 Fetal death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 25 Neonatal death." data-id="CD004947-fig-0112" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.25</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 25 Neonatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 26 Admission to NICU." data-id="CD004947-fig-0113" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.26</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 26 Admission to NICU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 27 Perinatal death." data-id="CD004947-fig-0114" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.27</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 27 Perinatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 28 Preterm birth less than 34 weeks." data-id="CD004947-fig-0115" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.28</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 28 Preterm birth less than 34 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 29 Preterm PROM." data-id="CD004947-fig-0116" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.29</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 29 Preterm PROM.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 30 Caesarean section." data-id="CD004947-fig-0117" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.30</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 30 Caesarean section. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 31 Antenatal tocolysis." data-id="CD004947-fig-0118" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.31</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 31 Antenatal tocolysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 32 Antenatal corticosteroids." data-id="CD004947-fig-0119" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.32</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 32 Antenatal corticosteroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 33 Preterm birth less than 37 weeks." data-id="CD004947-fig-0120" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.33</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 33 Preterm birth less than 37 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 34 Preterm birth less than 28 weeks." data-id="CD004947-fig-0121" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.34</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 34 Preterm birth less than 28 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 35 Infant birthweight less than 2500 g." data-id="CD004947-fig-0122" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.35</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 35 Infant birthweight less than 2500 g. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 36 Apgar score &lt; 7 at 5 minutes." data-id="CD004947-fig-0123" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.36</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 36 Apgar score &lt; 7 at 5 minutes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 37 Use of assisted ventilation." data-id="CD004947-fig-0124" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.37</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 37 Use of assisted ventilation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 38 Fetal death." data-id="CD004947-fig-0125" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.38</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 38 Fetal death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 39 Neonatal death." data-id="CD004947-fig-0126" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.39</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 39 Neonatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-40.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 40 Admission to NICU." data-id="CD004947-fig-0127" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.40</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 40 Admission to NICU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 41 Sensitivity analysis for perinatal death (assuming total non‐independence)." data-id="CD004947-fig-0128" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.41</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 41 Sensitivity analysis for perinatal death (assuming total non‐independence). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-41.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-006-42" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-006-42.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 42 Sensitivity analysis for perinatal death (assuming 1% non‐independence)." data-id="CD004947-fig-0129" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-42.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.42</div> <div class="figure-caption"> <p>Comparison 6 Progesterone versus placebo: multiple pregnancy, Outcome 42 Sensitivity analysis for perinatal death (assuming 1% non‐independence). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-006-42.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Progesterone versus placebo: multiple pregnancy, by timing of commencement (&lt; 20 wk v &gt; 20 wk), Outcome 1 Preterm birth &lt; 37 weeks." data-id="CD004947-fig-0130" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Progesterone versus placebo: multiple pregnancy, by timing of commencement (&lt; 20 wk v &gt; 20 wk), Outcome 1 Preterm birth &lt; 37 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Progesterone versus placebo: multiple pregnancy, by timing of commencement (&lt; 20 wk v &gt; 20 wk), Outcome 2 Neonatal death." data-id="CD004947-fig-0131" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Progesterone versus placebo: multiple pregnancy, by timing of commencement (&lt; 20 wk v &gt; 20 wk), Outcome 2 Neonatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Progesterone versus placebo: multiple pregnancy, by timing of commencement (&lt; 20 wk v &gt; 20 wk), Outcome 3 Admission to NICU." data-id="CD004947-fig-0132" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Progesterone versus placebo: multiple pregnancy, by timing of commencement (&lt; 20 wk v &gt; 20 wk), Outcome 3 Admission to NICU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Progesterone versus placebo: multiple pregnancy by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 1 Perinatal death." data-id="CD004947-fig-0133" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Progesterone versus placebo: multiple pregnancy by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 1 Perinatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Progesterone versus placebo: multiple pregnancy by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 2 Preterm birth less than 34 weeks." data-id="CD004947-fig-0134" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Progesterone versus placebo: multiple pregnancy by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 2 Preterm birth less than 34 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Progesterone versus placebo: multiple pregnancy by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 3 Antenatal tocolysis." data-id="CD004947-fig-0135" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Progesterone versus placebo: multiple pregnancy by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 3 Antenatal tocolysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Progesterone versus placebo: multiple pregnancy by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 4 Preterm birth less than 37 weeks." data-id="CD004947-fig-0136" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Progesterone versus placebo: multiple pregnancy by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 4 Preterm birth less than 37 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Progesterone versus placebo: multiple pregnancy by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 5 Infant birthweight less than 2500 g." data-id="CD004947-fig-0137" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Progesterone versus placebo: multiple pregnancy by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 5 Infant birthweight less than 2500 g. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Progesterone versus placebo: multiple pregnancy by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 6 Respiratory distress syndrome." data-id="CD004947-fig-0138" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 Progesterone versus placebo: multiple pregnancy by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 6 Respiratory distress syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Progesterone versus placebo: multiple pregnancy by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 7 Fetal death." data-id="CD004947-fig-0139" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 Progesterone versus placebo: multiple pregnancy by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 7 Fetal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-008-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-008-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Progesterone versus placebo: multiple pregnancy by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 8 Admission to NICU." data-id="CD004947-fig-0140" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-008-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8 Progesterone versus placebo: multiple pregnancy by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 8 Admission to NICU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-008-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 1 Perinatal death." data-id="CD004947-fig-0141" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 1 Perinatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 2 Preterm birth less than 34 weeks' gestation." data-id="CD004947-fig-0142" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 2 Preterm birth less than 34 weeks' gestation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 3 Pregnancy prolongation (days)." data-id="CD004947-fig-0143" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 3 Pregnancy prolongation (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 4 Pregnancy prolongation ‐ less than 1 week." data-id="CD004947-fig-0144" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 4 Pregnancy prolongation ‐ less than 1 week. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 5 Pregnancy prolongation ‐ 1.0 to 1.9 weeks." data-id="CD004947-fig-0145" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 5 Pregnancy prolongation ‐ 1.0 to 1.9 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 6 Pregnancy prolongation ‐ 2 weeks or more." data-id="CD004947-fig-0146" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 6 Pregnancy prolongation ‐ 2 weeks or more. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 7 Spontaneous birth." data-id="CD004947-fig-0147" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 7 Spontaneous birth. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 8 Caesarean section." data-id="CD004947-fig-0148" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.8</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 8 Caesarean section. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 9 Use of tocolysis." data-id="CD004947-fig-0149" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.9</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 9 Use of tocolysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0150"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 10 Preterm birth less than 37 weeks' gestation." data-id="CD004947-fig-0150" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.10</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 10 Preterm birth less than 37 weeks' gestation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0150">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0151"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 11 Infant birthweight less than 2500 g." data-id="CD004947-fig-0151" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.11</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 11 Infant birthweight less than 2500 g. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0151">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0152"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 12 Respiratory distress syndrome." data-id="CD004947-fig-0152" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.12</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 12 Respiratory distress syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0152">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0153"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 13 Intraventricular haemorrhage grade III or IV." data-id="CD004947-fig-0153" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.13</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 13 Intraventricular haemorrhage grade III or IV. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0153">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0154"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 14 Periventricular leucomalacia." data-id="CD004947-fig-0154" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.14</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 14 Periventricular leucomalacia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0154">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0155"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 15 Use of assisted ventilation." data-id="CD004947-fig-0155" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.15</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 15 Use of assisted ventilation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0155">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0156"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 16 Necrotizing enterocolitis." data-id="CD004947-fig-0156" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.16</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 16 Necrotizing enterocolitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0156">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0157"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 17 Neonatal sepsis." data-id="CD004947-fig-0157" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.17</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 17 Neonatal sepsis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0157">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0158"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 18 Fetal death." data-id="CD004947-fig-0158" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.18</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 18 Fetal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0158">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0159"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 19 Neonatal death." data-id="CD004947-fig-0159" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.19</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 19 Neonatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0159">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0160"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 20 Neonatal length of hospital stay (days)." data-id="CD004947-fig-0160" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.20</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 20 Neonatal length of hospital stay (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0160">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0161"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 21 Apgar score less than seven at five minutes." data-id="CD004947-fig-0161" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.21</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 21 Apgar score less than seven at five minutes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0161">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0162"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 22 Prelabour spontaneous rupture of membranes." data-id="CD004947-fig-0162" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.22</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 22 Prelabour spontaneous rupture of membranes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0162">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0163"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 23 Preterm birth less than 28 weeks' gestation." data-id="CD004947-fig-0163" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.23</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 23 Preterm birth less than 28 weeks' gestation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0163">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0164"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 24 Apgar score less than seven at five minutes." data-id="CD004947-fig-0164" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.24</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 24 Apgar score less than seven at five minutes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0164">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0165"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-009-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-009-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 25 Admission to neonatal intensive care unit." data-id="CD004947-fig-0165" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.25</div> <div class="figure-caption"> <p>Comparison 9 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, Outcome 25 Admission to neonatal intensive care unit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0165">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-009-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0166"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 1 Pregnancy prolongation (days)." data-id="CD004947-fig-0166" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 1 Pregnancy prolongation (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0166">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0167"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 2 Preterm birth less than 37 weeks' gestation." data-id="CD004947-fig-0167" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 2 Preterm birth less than 37 weeks' gestation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0167">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0168"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 3 Respiratory distress syndrome." data-id="CD004947-fig-0168" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 3 Respiratory distress syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0168">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0169"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-010-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-010-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 4 Neonatal sepsis." data-id="CD004947-fig-0169" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-010-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 4 Neonatal sepsis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0169">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-010-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0170"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-010-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-010-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 5 Neonatal death." data-id="CD004947-fig-0170" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-010-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10 Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg), Outcome 5 Neonatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0170">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-010-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0171"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Progesterone versus placebo: other reason at risk of preterm birth, singletons, Outcome 1 Perinatal death." data-id="CD004947-fig-0171" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Progesterone versus placebo: other reason at risk of preterm birth, singletons, Outcome 1 Perinatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0171">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0172"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Progesterone versus placebo: other reason at risk of preterm birth, singletons, Outcome 2 Preterm birth less than 34 weeks." data-id="CD004947-fig-0172" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Progesterone versus placebo: other reason at risk of preterm birth, singletons, Outcome 2 Preterm birth less than 34 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0172">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0173"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-011-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-011-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Progesterone versus placebo: other reason at risk of preterm birth, singletons, Outcome 3 Preterm birth less than 37 weeks." data-id="CD004947-fig-0173" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-011-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11 Progesterone versus placebo: other reason at risk of preterm birth, singletons, Outcome 3 Preterm birth less than 37 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0173">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-011-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0174"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-011-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-011-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Progesterone versus placebo: other reason at risk of preterm birth, singletons, Outcome 4 Infant birthweight less than 2500 g." data-id="CD004947-fig-0174" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-011-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11 Progesterone versus placebo: other reason at risk of preterm birth, singletons, Outcome 4 Infant birthweight less than 2500 g. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0174">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-011-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0175"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-011-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-011-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Progesterone versus placebo: other reason at risk of preterm birth, singletons, Outcome 5 Intrauterine fetal death." data-id="CD004947-fig-0175" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-011-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11 Progesterone versus placebo: other reason at risk of preterm birth, singletons, Outcome 5 Intrauterine fetal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0175">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-011-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0176"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-011-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-011-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Progesterone versus placebo: other reason at risk of preterm birth, singletons, Outcome 6 Neonatal death." data-id="CD004947-fig-0176" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-011-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.6</div> <div class="figure-caption"> <p>Comparison 11 Progesterone versus placebo: other reason at risk of preterm birth, singletons, Outcome 6 Neonatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0176">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-011-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0177"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-011-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-011-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Progesterone versus placebo: other reason at risk of preterm birth, singletons, Outcome 7 Admission to neonatal intensive care unit." data-id="CD004947-fig-0177" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-011-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.7</div> <div class="figure-caption"> <p>Comparison 11 Progesterone versus placebo: other reason at risk of preterm birth, singletons, Outcome 7 Admission to neonatal intensive care unit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0177">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-011-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0178"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Progesterone versus placebo: other reason at risk of preterm birth, by timing of commencement (&lt; 20 wk v &gt; 20 wk, singletons), Outcome 1 Perinatal death." data-id="CD004947-fig-0178" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Progesterone versus placebo: other reason at risk of preterm birth, by timing of commencement (&lt; 20 wk v &gt; 20 wk, singletons), Outcome 1 Perinatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0178">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0179"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-012-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-012-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Progesterone versus placebo: other reason at risk of preterm birth, by timing of commencement (&lt; 20 wk v &gt; 20 wk, singletons), Outcome 2 Preterm birth less than 37 weeks." data-id="CD004947-fig-0179" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-012-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 Progesterone versus placebo: other reason at risk of preterm birth, by timing of commencement (&lt; 20 wk v &gt; 20 wk, singletons), Outcome 2 Preterm birth less than 37 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0179">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-012-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004947-fig-0180"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/urn:x-wiley:14651858:media:CD004947:CD004947-CMP-012-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_t/tCD004947-CMP-012-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Progesterone versus placebo: other reason at risk of preterm birth, by timing of commencement (&lt; 20 wk v &gt; 20 wk, singletons), Outcome 3 Infant birthweight less than 2500 g." data-id="CD004947-fig-0180" src="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-012-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12 Progesterone versus placebo: other reason at risk of preterm birth, by timing of commencement (&lt; 20 wk v &gt; 20 wk, singletons), Outcome 3 Infant birthweight less than 2500 g. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-fig-0180">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/media/CDSR/CD004947/image_n/nCD004947-CMP-012-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="comparison" data-id="CD004947-tbl-0001"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Perinatal mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.33, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.23, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.34, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.12, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Preterm birth less than 34 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.14, 0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.10, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.39, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Preterm birth less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.42, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.52, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1065</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.29, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.19, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Threatened preterm labour <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.47, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.73, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.35, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Spontaneous vaginal delivery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.97, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.97, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.81, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.68, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>711</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.79, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Antenatal corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.73, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.58, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.72, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Antenatal tocolysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.78, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.73, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.70, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.42, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Infant birthweight less than 2500 g <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>692</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.42, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.49, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.07, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.17, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.38, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.59, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.03, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Use of assisted ventilation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.18, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.35, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.07, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Intraventricular haemorrhage ‐ all grades <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.20, 2.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.08, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.46, 3.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Intraventricular haemorrhage ‐ grade III or IV <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1069</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.21, 11.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.52 [0.12, 52.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.06, 15.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Periventricular leucomalacia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [0.13, 75.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [0.13, 75.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Retinopathy of prematurity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.15, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.15, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Necrotising enterocolitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.10, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.00, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>711</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.15, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Neonatal sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.08, 2.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.35, 3.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.02, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Patent ductus arteriosus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.16, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.16, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Intrauterine fetal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.26, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.14, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.33, 4.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.27, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.17, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.24, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.12, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Developmental delay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.36, 2.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.36, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Intellectual impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.05, 31.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.05, 31.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Motor Impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.11, 3.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.11, 3.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Visual Impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.16, 4.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.16, 4.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Hearing Impairment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.09, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.09, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Cerebral palsy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 3.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 3.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Learning difficulties <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.38, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.38, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Height less than 5th centile <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.23, 2.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.23, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Weight less than 5th centile <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.30, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.30, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Adverse drug reaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.24, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.24, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Pregnancy prolongation (weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.47 [2.15, 6.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.47 [2.15, 6.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Apgar score &lt; 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.24, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.24, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Admission to neonatal intensive care unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.14, 0.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.14, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.09, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 Neonatal length of hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐7.67, 5.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐7.67, 5.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 Infant weight at 6 months follow‐up (g) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>29.0 [‐209.62, 267.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>29.0 [‐209.62, 267.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 Infant weight at 12 months follow‐up (g) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐88.0 [‐381.48, 205.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐88.0 [‐381.48, 205.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 Infant weight at 24 months follow‐up (g) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐40.0 [‐482.41, 402.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐40.0 [‐482.41, 402.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 Infant length at 6 months follow‐up (cm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.59, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.59, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 Infant length at 12 months follow‐up (cm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.80, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.80, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 Infant length at 24 months follow‐up (cm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐1.23, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐1.23, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 Infant head circumference at 6 months follow‐up (cm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.23, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.23, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42 Infant head circumference at 12 months follow‐up (cm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.26, 0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.26, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43 Infant head circumference at 24 months follow‐up (cm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.21, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.21, 0.61]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Progesterone versus placebo/no treatment: previous history spontaneous preterm birth (singletons)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004947-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Progesterone versus placebo/no treatment: previous history spontaneous preterm birth, by timing of commencement (&lt; 20 wk v &gt; 20 wk, singletons)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Preterm birth less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.44, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Therapy commences before 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.46, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Therapy commences after 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.30, 0.78]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Progesterone versus placebo/no treatment: previous history spontaneous preterm birth, by timing of commencement (&lt; 20 wk v &gt; 20 wk, singletons)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004947-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Perinatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.35, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.07, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.29, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Preterm birth less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.40, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.44, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1098</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.31, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Threatened preterm labour <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.47, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.73, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.35, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.72, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.58, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>711</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.70, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Antenatal corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.73, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.58, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.72, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Need for tocolysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.81, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.73, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.70, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.16, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.38, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.07, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Intraventricular haemorrhage ‐ all grades <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.20, 2.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.08, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.46, 3.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Intraventricular haemorrhage ‐ grade III or IV <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.21, 11.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.51 [0.12, 51.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.06, 15.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Necrotising enterocolitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.10, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.00, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>711</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.15, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Intrauterine fetal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.32, 2.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.05, 6.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.33, 4.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.28, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.17, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.26, 0.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Progesterone versus placebo/no treatment: previous history spontaneous preterm birth by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg, singletons)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004947-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Progesterone versus placebo: ultrasound identified short cervix, singletons</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Perinatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.42, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.27, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.46, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Preterm birth less than 34 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.45, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.38, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.43, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Preterm labour <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.63, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.63, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Prelabour spontaneous rupture of membranes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>845</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.68, 2.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>845</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.68, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Side effects (any) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.92, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.92, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Side effects (injection site) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.93, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.93, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Side effects (urticaria) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.03 [1.11, 22.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.03 [1.11, 22.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Side effects (nausea) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.27, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.27, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Pregnancy prolongation (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.0 [‐10.29, 6.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.0 [‐10.29, 6.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.79, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.79, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Antenatal tocolysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.60, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.60, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Preterm birth less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.82, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>845</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.83, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Preterm birth less than 28 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.37, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.25, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.36, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Infant birthweight less than 2500 g <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.78, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>728</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.73, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.73, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.48, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.29, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>824</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.58, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Apgar score &lt; 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.41, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.41, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Need for assisted ventilation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.36, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.36, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Intraventricular haemorrhage ‐ all grades <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.05, 5.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.05, 5.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Intraventricular haemorrhage ‐ grades III or IV <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.17, 5.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [0.18, 22.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Periventricular leucomalacia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.38, 8.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>824</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.38, 8.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Retinopathy of prematurity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.23, 4.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.07 [0.25, 104.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.04, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Necrotising enterocolitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.27, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.30, 3.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.08, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Neonatal sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.18, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.15, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.08, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Intrauterine fetal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.48, 3.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.28, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.04 [0.45, 35.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.26, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.15, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>839</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.27, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Admission to neonatal intensive care unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>834</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.79, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>834</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.79, 1.35]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Progesterone versus placebo: ultrasound identified short cervix, singletons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004947-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Progesterone versus placebo: ultrasound identified short cervix, singletons by cumulative weekly dose (&lt;500 mg v &gt;=500 mg)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Periventricular leucomalacia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>824</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.13, 16.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.03 [0.45, 35.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Admission to neonatal intensive care unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>834</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.72, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.69, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.83, 2.55]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Progesterone versus placebo: ultrasound identified short cervix, singletons by cumulative weekly dose (&lt;500 mg v &gt;=500 mg)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004947-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Progesterone versus placebo: multiple pregnancy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Perinatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.45, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.30, 3.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.24, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Preterm birth less than 34 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.74, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.69, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.73, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Preterm PROM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.74, 1.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>802</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.72, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.30, 5.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse drug reaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.64, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.54, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.91, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.94, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.84, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Spontaneous birth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.62, 2.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.75, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.21, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Assisted birth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.57, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.86, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.44, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Satisfaction with therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.35, 0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.35, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Antenatal tocolysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.80, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.82, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.55, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Antenatal corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>847</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.77, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.70, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.81, 3.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Preterm birth less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.95, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1638</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.96, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.85, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Preterm birth less than 28 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.75, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.68, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>868</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.51, 3.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Infant birthweight less than 2500 g <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.91, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1902</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.80, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Apgar score &lt; 7 at 5 minutes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.66, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.70, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.28, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5065</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.94, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.91, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.79, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Use of assisted ventilation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.78, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.80, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.45, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Intraventricular haemorrhage ‐ grades III or IV <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.45, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.45, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Intraventricular haemorrhage ‐ all grades <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.75, 4.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.36, 10.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.62, 4.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Periventricular leucomalacia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1091</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.05, 3.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1091</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.05, 3.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Retinopathy of prematurity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.32, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.20, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.26, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Chronic lung disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [0.13, 27.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [0.13, 27.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Necrotising enterocolitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5059</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.50, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.52, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.05, 5.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Neonatal sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5065</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.89, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.87, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.61, 2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Fetal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.71, 2.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2074</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.77, 3.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2714</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.35, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.48, 2.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.31, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2714</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.36, 4.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Admission to NICU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.76, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2896</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.71, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.05, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Perinatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.61, 2.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.30, 3.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.67, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Preterm birth less than 34 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.71, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.65, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.73, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Preterm PROM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.69, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>802</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.72, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.03, 3.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.91, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.94, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.84, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Antenatal tocolysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.80, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.82, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.56, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Antenatal corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>847</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.76, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.70, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [0.76, 3.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Preterm birth less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.95, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1638</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.96, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.84, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 Preterm birth less than 28 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.80, 2.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.68, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>868</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.63, 3.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 Infant birthweight less than 2500 g <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.89, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.91, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.82, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 Apgar score &lt; 7 at 5 minutes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.70, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.70, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.41, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 Use of assisted ventilation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.81, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.80, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1714</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.55, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 Fetal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.79, 2.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2074</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.77, 3.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2711</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.49, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 Neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.62, 2.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.31, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2711</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.84, 3.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 Admission to NICU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.75, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2893</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.70, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.2 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.05, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 Sensitivity analysis for perinatal death (assuming total non‐independence) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2068</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.43, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.29, 3.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>954</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.28, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42 Sensitivity analysis for perinatal death (assuming 1% non‐independence) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4091</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.44, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.29, 3.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.24, 2.41]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Progesterone versus placebo: multiple pregnancy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004947-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Progesterone versus placebo: multiple pregnancy, by timing of commencement (&lt; 20 wk v &gt; 20 wk)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Preterm birth &lt; 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.82, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Supplementation commenced prior to 20 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.92, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Supplementation commenced after 20 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.38, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2738</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.47, 1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Supplementation commenced prior to 20 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.29, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Supplementation commenced after 20 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.47, 3.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Admission to NICU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.95, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Supplementation commenced prior to 20 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.88, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Supplementation commenced after 20 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.05, 1.62]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Progesterone versus placebo: multiple pregnancy, by timing of commencement (&lt; 20 wk v &gt; 20 wk)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004947-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Progesterone versus placebo: multiple pregnancy by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Perinatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.45, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.30, 3.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.24, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Preterm birth less than 34 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.74, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.73, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Dose &gt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.69, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Antenatal tocolysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.80, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.82, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.55, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Preterm birth less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.88, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.88, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.80, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Infant birthweight less than 2500 g <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.91, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1902</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.80, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5065</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.94, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.91, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.79, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Fetal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.51, 2.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2074</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.52 [0.19, 33.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2714</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.36, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Admission to NICU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.76, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.05, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2896</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.71, 1.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Progesterone versus placebo: multiple pregnancy by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004947-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Perinatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.16, 24.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.16, 24.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Preterm birth less than 34 weeks' gestation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.55, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.72, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.37, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Pregnancy prolongation (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [‐8.42, 12.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.30 [‐7.41, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.21 [2.39, 12.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Pregnancy prolongation ‐ less than 1 week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.4 [0.07, 2.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.4 [0.07, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Pregnancy prolongation ‐ 1.0 to 1.9 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.16, 24.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.16, 24.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Pregnancy prolongation ‐ 2 weeks or more <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.42, 9.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.42, 9.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Spontaneous birth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.80, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.80, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.51, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.51, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Use of tocolysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.58, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.2 [0.55, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.50, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Preterm birth less than 37 weeks' gestation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.20, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.55, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.12, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Infant birthweight less than 2500 g <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.28, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.28, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.49, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.20, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.66, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Intraventricular haemorrhage grade III or IV <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.0 [0.53, 152.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.0 [0.53, 152.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Periventricular leucomalacia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Use of assisted ventilation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.06, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.06, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Necrotizing enterocolitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.06 [0.50, 18.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.06 [0.50, 18.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Neonatal sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.17, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.07, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.39, 3.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Fetal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.07, 16.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.07, 16.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.05, 6.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.16, 24.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.02, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Neonatal length of hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.16 [‐15.84, 11.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.16 [‐15.84, 11.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Apgar score less than seven at five minutes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.03, 2.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.03, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Prelabour spontaneous rupture of membranes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.19, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.19, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Preterm birth less than 28 weeks' gestation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.06, 15.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.06, 15.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Apgar score less than seven at five minutes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.03, 2.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.03, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Admission to neonatal intensive care unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.27, 9.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.27, 9.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004947-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pregnancy prolongation (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [‐8.42, 12.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Dose &lt; 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.30 [‐7.41, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Dose &gt;= 500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.21 [2.39, 12.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Preterm birth less than 37 weeks' gestation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.20, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Dose &gt;=500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.55, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Dose &lt;500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.12, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.49, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Dose &gt;=500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.20, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Dose &lt;500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.66, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Neonatal sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.17, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Dose &gt;=500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.07, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Dose &lt;500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.39, 3.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.05, 6.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Dose &lt;500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.16, 24.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Dose &gt;=500 mg per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.02, 1.40]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Progesterone versus placebo/no treatment: prior threatened preterm labour, singletons, by cumulative weekly dose (&lt; 500 mg v &gt;= 500 mg)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004947-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Progesterone versus placebo: other reason at risk of preterm birth, singletons</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Perinatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.09, 3.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.1 [0.23, 5.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.02, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Preterm birth less than 34 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.16, 3.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.16, 3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Preterm birth less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.32, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.11, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.40, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Infant birthweight less than 2500 g <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.25, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.23, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.15, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Intrauterine fetal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.04, 3.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.04, 3.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.49 [0.27, 112.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Intramuscular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.49 [0.27, 112.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Admission to neonatal intensive care unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.71, 4.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.71, 4.11]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Progesterone versus placebo: other reason at risk of preterm birth, singletons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004947-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Progesterone versus placebo: other reason at risk of preterm birth, by timing of commencement (&lt; 20 wk v &gt; 20 wk, singletons)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Perinatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.1 [0.23, 5.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Supplementation commenced prior to 20 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.1 [0.23, 5.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Supplementation commenced after 20 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Preterm birth less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.11, 2.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Supplementation commenced prior to 20 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.1 [0.33, 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Supplementation commenced after 20 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.05, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Infant birthweight less than 2500 g <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.16, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Supplementation commenced prior to 20 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.30, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Supplementation commenced after 20 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.05, 1.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Progesterone versus placebo: other reason at risk of preterm birth, by timing of commencement (&lt; 20 wk v &gt; 20 wk, singletons)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004947.pub3/references#CD004947-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004947.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004947-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004947-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004947-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="pt#CD004947-note-0001">Português</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004947\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004947\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004947\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004947\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004947\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004947\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004947\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004947\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004947\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004947\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004947\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004947\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004947\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004947\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004947\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004947\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004947\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004947\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZDBB8PHY&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004947.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004947.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004947.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004947.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004947.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714222039"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004947.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714222043"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004947.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d695e7fb8f3cd',t:'MTc0MDcxNDIyMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 